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Abstract 
 
 
 Type 1 diabetes (T1D) is a T cell-mediated autoimmune disease in which the immune 
system specifically targets and destroys the pancreatic insulin-producing beta-cells. We are 
interested in defining whether adipose tissue-derived cytokines (adipokines) such as 
adiponectin (anti-inflammatory) and leptin (pro-inflammatory) could influence T1D 
progression.  
 We first demonstrate the expression of the leptin receptor (LEPR) on peripheral blood 
mononuclear cells (PBMC) and observed higher expression of LEPR on PBMC from patients 
with T1D. However, we found no significant functional relevance for this observation. On the 
other hand, we show lower expression of the adiponectin receptors on lymphocytes from 
patients with T1D. This was associated with a reduced capacity of adiponectin to inhibit 
lymphocyte trans-endothelial migration in T1D. Remarkably, we show that adiponectin 
strongly inhibited lymphocyte migration either by action on the endothelium or directly on the 
lymphocytes. We have now established that this effect on lymphocytes is mediated by a 
newly identified B cell-secreted agent following adiponectin stimulation. The agent stimulates 
endothelial production of sphingosine-1-phosphate, which in turn is responsible for the 
inhibition of lymphocyte trans-endothelial migration. These observations were confirmed in 
vivo using a peritoneal model of inflammation in a B cell knock-out mouse strain. In these 
animals, T cell recruitment in the peritoneum is increased compared to the wild-type and 
restored when the agent was administrated. 
 These observations underline the importance of adiponectin in the control of 
lymphocyte transmigration during an inflammatory response and offer a potential therapeutic 
agent for T1D as well as other T cell-mediated diseases. 
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1. Type 1 diabetes (T1D) disease 
 
 Diabetes mellitus is a group of diseases characterised by high circulating blood 
glucose. T1D is a chronic autoimmune disease in which the immune system specifically 
targets and destroys the insulin-producing beta-cells, located in the pancreatic islets of 
Langherhans. This results in loss of insulin secretion (Daneman et al., 2006). Insulin is an 
important metabolic hormone that regulates glucose uptake, and insulin deficiency resulting 
from the autoimmune process leads to high blood glucose. 
1.1. Clinical aspects of T1D 
 Studies in relatives of patients at high risk of developing T1D have shown that the 
beta-cell loss resulting in T1D can last from months to years before the disease is clinically 
detected (DCCTRG, 1998; Achenbach et al., 2006) (Figure 1-1). At clinical diagnosis, 50 to 
80% of the beta-cell function has been lost. After initial insulin treatment, a few patients can 
exhibit an insulin-independent phase (honeymoon) where insulin injections are drastically 
reduced or even stopped (Abdul-Rasoul et al., 2006). The occurrence of honeymoon relies on 
factors associated with preservation of beta-cell function, such as the age at diagnosis, number 
of different auto-antibodies present, body mass index (BMI), genetic risks factors, glycated 
haemoglobin (HbA1c), C-peptide and immune parameters (level of interleukin-1 (IL-1) 
receptor, IL-1 beta for example) (reviewed in Ali et al., 2009). When beta-cell function falls 
below a threshold required for maintaining euglycaemia, patients exhibit symptoms caused by 
hyperglycaemia such as polyuria, polydipsia, tiredness and weight loss, sometimes with 
polyphagia and blurred vision (ADA, 2004; Roche et al., 2005).  
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Figure 1-1: Natural history of T1D 
T1D has both genetic predispositions and environmental factors. An as yet unidentified 
trigger elicits islet autoimmunity in individuals at genetic risk for T1D. Islet autoimmunity 
manifests as the appearance of autoantibodies against islets antigens such as insulin (IAA), 
glutamic acid decarboxylase (GAD65) and the tyrosine phosphatase-like protein (IA-2). There 
is a subsequent infiltration of immune cells into the islets. This initiates a gradual loss of beta-
cell function that can take years before clinical symptoms appear. After beta-cell function has 
fallen below a threshold, classic symptoms of diabetes caused by hyperglycaemia are 
detectable, leading to the diagnosis of T1D. Some patients experience a remission referred as 
the honeymoon phase after initial insulin treatment. This phase can last months or even a year, 
but beta-cell function is rapidly degraded as the islet autoimmunity progresses.  
 
 
 If not rapidly treated, these symptoms will quickly result in dangerous acute 
complications such as ketoacidosis (Neu et al., 2003). Long-term complications include 
retinopathy leading to blindness; peripheral neuropathy with risk of foot ulcers, amputations 
and Charcot joints; neuropathy causing gastrointestinal, genitourinary and sexual dysfunction; 
nephropathy resulting in renal failure; cardiovascular disease and high risk of mortality 
(ADA, 2004; Soedamah-Muthu et al., 2006). More than 80% of the subjects have residual 
beta-cell function in the first year following diagnosis (Greenbaum et al., 2009). This falls to 
10-20% within five years of disease and to 1% after five years (Scholin et al., 2004), though 
there appears to be considerable variability in these figures. Residual beta-cell function 
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improves HbA1c, lowers risk of hypoglycaemia, reduces long-term complications, decrease 
risks of ketoacidosis and improves the response to immunotherapy (reviewed in Ali et al., 
2009). This indicates the importance of preserving beta-cell function, even at low levels, for 
as long as possible (Torn et al., 2000).  
1.2. Prevalence of T1D 
 Despite a better understanding of the natural history of T1D, its incidence continues to 
increase in the United Kingdom (UK) and worldwide, especially among children under the 
age of 5 years (Figure 1-2) (Gardner et al., 1997; Moore et al., 2003; Zipris et al., 2009). 
Northern Europe, North America, New Zealand and Australia exhibit the highest rates, whilst 
much lower incidence is observed in Asia, Africa and South America (DIAMOND project 
group, 2006). 2.6 million people have currently been diagnosed with diabetes in the UK, and 
by 2025 this number is predicted to increase to 4 million (Figure 1-2c) (DUK, 2010). These 
figures include both T1D and type 2 diabetes (T2D). Including both children and adults, it is 
estimated that 15% have T1D.  
 Alarmingly, on average 400 people per day are diagnosed with diabetes (including 
T1D and T2D) in the UK. This impacts the national health system (NHS) budget. The latest 
report states that about £9 billion per year is spent on diabetes, which represents about 10% of 
the NHS annual expenditure (NHS, 2011). 
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Figure 1-2: Global prevalence of T1D 
(a) Numbers of cases of T1D have significantly increased in European countries such as 
Germany, Czech Republic and France (Zipris et al., 2009; copyright license number: 
2814281274788) (b) but also in other develop countries such as Australia, New Zealand and 
North America (Zipris et al., 2009; copyright license number: 2814281274788). (c) In the 
UK, the prevalence of diabetes in 2009 was a total of 2.6 million people. However, these 
statistics include both type 1 and type 2 diabetes. Within the 2.6 million of people with 
diabetes, it is estimated that 15% have type 1 diabetes (DUK, 2010). 
 
 
Country Prevalence (%) Number of people
England 5.1 2,213,138
Northern Ireland 4.5 65,066
Wales 4.6 146,173
Scotland 3.9 209,886
a) c)
b)
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1.3. Immunity and pathogenesis of T1D 
1.3.1. Autoimmunity in T1D 
 T1D is characterised by the auto-immune destruction of insulin-producing pancreatic 
beta-cells, a process referred to as insulitis (Cnop et al., 2005).  
1.3.1.1. Humoral autoimmunity in T1D 
 The autoimmune destruction of beta-cells is associated with the appearance of islet 
auto-antibodies early in life (Kimpimäki et al., 2001). 
Auto-antibody production can be detected up to five years before clinical diagnosis of T1D, 
making them an attractive marker of diabetes risk and a tool for diagnosis (Lindberg et al., 
1999). The most common auto-antibodies are directed against the glutamic acid 
decarboxylase (GAD65), the tyrosine phosphatase-like protein (IA-2) and insulin itself (IAA) 
(Velloso et al., 1993; Lan et al., 1996; Palmer et al., 1983). Studies have shown that high risk 
of developing T1D is associated with subjects carrying auto-antibodies to two or three of 
these antigens (Verge et al., 1998). Combination of GAD65 and IA-2 is linked to a 50% risk, 
GAD65, IA-2 and IAA to at least 70% of developing diabetes (Leslie et al., 1999; Verge et 
al., 1996). This risk is increased when combining the detection of these antibodies with 
detection of the recently discovered beta-cell antigen ZnT8, a zinc transporter (Wenzlau et al., 
2007).  
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Figure 1-3: Insulitis in the pancreatic islet resulting in auto-immune destruction of beta-
cells 
Section of the pancreatic islets stained for insulin (red) and CD3 (cluster of differentiation 3), 
a marker of T cells (green). This shows infiltration of T cells in the pancreas from a patient 
with T1D (left) compared to a healthy subject without infiltration (right) (Imagawa et al., 
1999; copyright license number: 2814290215519). 
 
1.3.1.2. Cellular autoimmunity in T1D 
 The destruction of beta-cells is predominantly mediated by T cells. This is evidenced 
by the presence of T cells in the insulitic lesions (Figure 1-3) (Imagawa et al., 1999), and by 
the presence of autoreactive circulating T cells (Hanafusa et al., 2008). Studies in humans and 
murine models have demonstrated that both CD4+ and CD8+ T cells subsets, but also 
macrophages, monocytes, dendritic cells (DCs) and B lymphocytes are required to trigger 
insulitis (Xiu et al., 2008; Lee et al., 1998; Papaccio et al., 1999; Miyazaki et al., 1985). A 
still unknown trigger promotes the activation of these cells leading to a cascade of events 
resulting in the autoimmune destruction of beta-cells.  
 DCs are the most efficient antigen presenting cells (APCs). Immature DCs (imDCs) 
circulate in the periphery as sentinels. They have a low co-stimulatory capacity and low 
ability to present antigens, but they are very well equipped to capture antigens. They are able 
Patient with T1D Healthy control
Green: T cells
Red:  beta- cells
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to engulf pathogens by endocytosis, phagocytosis or pinocytosis (Svensson et al., 1997; 
Sallusto et al., 1995). This results in their maturation and migration to the lymphoid organs, 
spleen and lymph nodes where they will activate naive T cells. Once mature, DCs redistribute 
major histocompatibility complex (MHC) molecules to the surface and express high levels of 
co-stimulatory molecules (CD80/86) at their surface, which are essential for T cell stimulation 
(Jensen PE, 2007). Intracellular pathogens are cut into peptides in the cytosol and presented at 
the surface on MHC class I molecules which activates cytotoxic T cells (CD8+ T cells) 
(Banchereau et al., 1998). Extracellular pathogens that are engulfed via the endocytic 
pathway, are processed and presented on MHC class II molecules resulting in T helper 
stimulation (CD4+ T cells) (Banchereau et al., 1998). It has been shown that in certain 
circumstances, extracellular pathogens are presented on MHC class I to stimulate cytotoxic 
CD8+ T cells. This is a phenomenon called cross-presentation (Rock et al., 2005). DCs are 
also important in the induction of tolerance (Banchereau et al., 1998). 
 B cells develop and differentiate in the bone marrow. They are characterised by the 
expression of the B cell receptor (BCR) that recognises antigens presented by APCs (Delves, 
Roitt, 2000a). Upon antigen stimulation, B cells are clonally expanded and differentiated into 
antibody secreting plasma cells or memory B cells (Depoil et al., 2008; Pierce, Liu, 2010). 
Antibodies released by the plasma cells are a soluble immunoglobulin copy of the B cell 
receptor that will help neutralise pathogens. B cells can be divided into different subsets 
depending in their degree of maturity (Figure 1-4) (LeBien, Tedder, 2008; Engel et al., 2011). 
The lymphoid progenitor firstly differentiates into pro-B cells in the bone marrow. It is during 
the development into pro-B cells that immunoglobulin locus genetic rearrangements starts, 
but is not complete. Pro-B cells express only the Igα, Igβ and calnexin that forms the pro-
BCR. After differentiation, the pre-BCR is composed of the Igµ chain that characterises the 
IgM molecule and the surrogate light chains. Once differentiation is accomplished, immature 
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B cells express a mature and functional BCR composed of assembled heavy and light chains, 
the IgM molecule (Delves, Roitt, 2000a). At this phase of development, B cells will undergo 
negative selection to avoid expansion of auto-reactive B cells. Cells that have successfully 
passed this checkpoint will then migrate to the periphery as transitional and intermediate B 
cells (Carsetti et al., 2004). When they enter the SLOs, they are differentiated into mature 
follicular B cells, which results in expression of IgD at the cell surface (LeBien, 2000). B cell 
responses to antigen require the participation of T cells. When B cells have recognised an 
antigen, they migrate to the edges of the follicles in the SLOs; up-regulate expressions of 
CD40 and MHC class II and present antigens to T cells (Engel et al., 2011). This step is 
crucial to trigger B cell proliferation and differentiation. At this stage, germinal centres (GC) 
are generated within the follicles. During the GC reaction, the B cell clones first differentiate 
into plasmablasts, which continue proliferating and start secreting low quantities of 
antibodies. Plasmablasts then differentiate into long-lived plasma cells and memory B cells. B 
cells can recognise other types of antigens i.e. lipids and nuclear acids without T cell help 
(Engel et al., 2011). They can differentiate into short life plasma cells but are not capable of 
class switching or memory cell generation (Fagarasan, Honjo, 2000). However, they are 
essential for quick responses to pathogens.  
 Natural Killer cells (NKs) represent 10 to 15 % of the immune cell pool in the 
circulation. They share the same lymphoid precursor as other lymphocytes. NKs were first 
identified as “natural occurring killer lymphocytes with specificity for tumour cells” 
(Kiessling et al., 1975). Detection of pathogenic antigens or stressed cells results in their 
activation, with the release of granules containing the perforin/granzyme machinery. Upon 
degranulation, perforin inserts itself in the membrane of the target cell forming a pore. This 
allows the entrance of granzyme, which will induce apoptosis of the target cell (Trapani, 
Smyth, 2002).  
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Figure 1-4: B cell development in humans 
B cells develop in the bone marrow and enter the circulation as immature B cells to travel to 
SLOs where they differentiate into mature B cells. In SLOs, B cells meet with their antigen 
and become activated, leading to germinal centre formation. Activated mature B cells can 
differentiate into plasmablast, which begin to produce antibodies but are still dividing and 
then become antibody-secreting plasma cells. Some antigen-stimulated B cells become 
memory B cells. Differential expression of the numerous cell surface markers allow dissection 
of B cell development and recognition of the different subsets circulating in the blood. 
 
 NK cells can distinguish between a normal cell expressing MHC class I molecules and 
a stressed cell which has lost MHC class I, using receptors such as the natural killer cell 
immunoglobulin like receptor (KIMs). These inhibitory receptors allow the NK cells to 
inhibit NK activation if interacting with a healthy MHC class I baring cell, and to specifically 
target stressed cells having no MHC class I, i.e. those that are a potential danger for the body. 
This mechanism is called “missing self recognition” (Vivier, 2006). NK cells are recognised 
by the expression of the CD56 marker. In humans, they can be divided into two populations, 
CD56low (which also express CD16) and CD56high NK cells subsets. These two populations 
differ in their trafficking properties. The most abundant type, CD56low, is predominant in the 
blood, whereas CD56high have greater capacity to migrate into lymphoid organs (Vivier, 
2006). The latter do not have strong cytolytic activity, as they lack perforin. However, they do 
secrete high levels of IFN-γ in response to IL-12, IL-15 and IL-18 stimulation. 
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 Finally, NK T cells are lymphocytes with characteristics close to cells from the 
adaptive immune system. They also have NK like properties, as they co-express a TCR/CD3 
complex and CD56. They are able to rapidly kill target cells by using the perforin/granzyme 
machinery, and can also secrete cytokines such as IFN-γ, TNF-α and IL-4 in response to 
antigen stimulation. NK T cells do not recognise peptides presented by MHC molecules; 
instead they identify lipids presented on invariant CD1 molecules (Tupin et al., 2007). There 
are different types of NK T cells. The most common are the invariant NK T cells that are 
CD1d-restricted. A lot of work has been conducted showing their capacity to aid in the 
clearance of bacteria, viruses and protozoan parasites. 
 
  In T1D, DCs can directly take up beta-cells’ auto-antigens in the islets and migrate to 
the pancreatic lymph nodes where autoreactive CD8+ T cells and CD4+ effector T cells are 
stimulated upon recognition of the auto-antigens presented by the DCs (Yoon et al., 2001; 
Morran et al., 2008). These autoreactive T cells will then traffic to the islets where they will 
cause damage and recruit other cytotoxic cells (Yoon et al., 2001; Morran et al., 2008). CD8+ 
cytotoxic T cells can also directly recognise antigens presented on the up-regulated MHC 
class I on beta-cells (Notkins et al., 2002). This results in up-regulation of the FasL/Fas 
apoptotic signal and perforin/ granzyme mediated cytotoxicity (Pirot et al., 2008). Antigen 
presentation to CD4+ T cells is mediated by APCs presenting on MHC class II, thus resulting 
in production of cytokines (Mathis et al., 2001). These cytokines can directly act on beta-cells 
or on the APCs that will in turn secrete more cytokines, nitric oxide or oxygen derived free 
radicals that induce cell death (Notkins et al., 2001). The CD4+ effector T cells are also 
responsible for initiation of the activation of other cells such as B cells, resulting in the 
production of auto-antibodies (Morran et al., 2008). Pro-inflammatory mediators such as IL-
1, interferon-gamma (IFN-γ), tumor necrosis-alpha (TNF-α) (Induction of FasL/Fas pathway), 
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IL-2, IL-21, IL-18 and IL-17 produced by effector T cells can contribute to the suppression of 
beta-cells function and their subsequent apoptosis (Rabinovitch et al., 2003; Emamaullee et 
al., 2009). However, most of the current knowledge in this area comes from studies in murine 
models of T1D (Notkins et al., 2001; Rabinovitch et al., 2003). Indeed, the hazard in 
performing pancreatic biopsies is too high, therefore, what is known about the pathogenesis of 
human T1D comes from autopsy specimens, assays involving peripheral blood or isolated 
islets (Notkins et al., 2001).    
 It is clear that inflammation can cause harm, in this case through the destruction of 
beta-cells. However, the immune system also has built into it, a system for self-regulation. 
Regulatory T cells (Treg) are key regulators of the immune function. Treg play a critical role 
in maintaining self-tolerance and controlling the extent of immune responses. They were first 
identified by the expression of the IL-2 receptor α chain, CD25 (Sakagushi et al., 1995). 
However, CD25 is also a marker of activated T cells. Accurate definition of Treg came with 
the identification of the forkhead family transcription factor, FoxP3 specific to Treg (Hori et 
al., 2003).  Two types of Treg have been identified: natural Treg (nTreg) and induced Treg 
(iTreg). nTreg develop in the thymus and express a similar repertoire to naive T cells but are 
skewed to self-antigens, indicating their important role in tolerance (Pacholczyk et al., 2008). 
iTreg conversely develop in the periphery upon conventional CD4+ CD25- T cells activation. 
Consequently, they express a similar antigen repertoire to conventional T cells. Both Treg 
subsets exert their suppressor function upon antigen recognition (Pacholczyk et al., 2008). 
However, once activated, Treg exhibit a T cell receptor (TCR)-independent bystander 
suppression of other T cells (Tang et al., 2008). 
 Various mechanisms of Treg suppression have been determined, mainly using in vitro 
experiments. Treg can act either directly on effector T cells or indirectly as shown by APC 
absence or presence assays respectively. Direct mechanisms involve the consumption of IL-2 
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by Treg, secretion of anti-inflammatory cytokines such as IL-10 and TGF-β, induction of 
apoptosis through contact by granzymeB/perforin or galectin-1 action (Shevach et al., 2009; 
Sojka et al., 2008). Indirect action involves the action of Treg on APC by suppressing antigen 
presentation or modulation of co-stimulation involving CTLA-4, LAG-3, CD39 or Nrp1 
(Shevach et al., 2009; Misra et al., 2004; Liang et al., 2008; Borsellino et al., 2007; Sarris et 
al., 2008). 
 It was first believed that Treg number was decreased in patients with T1D (Kukreja et 
al., 2002). Subsequent studies have failed to demonstrate a Treg deficit, either in human T1D 
or in the Non Obese Diabetic (NOD) mice model of T1D (Brusko et al., 2005; Lindley et al., 
2005; Putnam et al., 2005; Brusko et al., 2007).  
Presence of Treg at sites of inflammation such as the pancreas of T1D patients (Bottazo et al., 
1985) suggests that their capacity to sense responses is not affected. Another possible 
mechanism to explain autoimmunity was shown to be caused by defect in Treg suppressive 
function (Lindley et al., 2005). However this was not confirmed by other groups (Liu et al., 
2006). Finally, it is now believed that the deficit in Treg regulation is caused by a resistance 
of effector T cells to Treg suppression. This is mediated by alteration of sensitivity to 
transforming growth factor-beta (TGF-β) (Gregori et al., 2003; You et al., 2005; Lawson et 
al., 2008; D’Alise et al., 2008).  
Defects in other regulatory mechanisms can potentially also contribute to the establishment of 
insulitis. These relate to the control of T cell migration, or involvement of adipokines, both of 
which will be elaborated below. 
1.3.2. Trafficking and recruitment of lymphocytes during inflammation 
 Inflammation is referred to the rapid and protective cascade of responses occurring in 
response to a local tissue injury, infection or occurrence of a local immune response (Goldsby 
et al., 2001). It triggers the recruitment of leukocytes and humoral proteins required for 
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clearance of a pathogen or trauma (Ryan et al., 1977). If successful, acute inflammation is 
resolved by restoring normal tissue homeostasis or formation of a connective tissue scar 
(Pober et al., 2007; Springer, 1994). If the stimulus is not eliminated, the inflammation 
persists and evolves to become chronic inflammation that results in disease such as asthma, 
atherosclerosis, multiple sclerosis, rheumatoid arthritis and T1D (Pober et al., 2007; 
Koulmanda et al., 2007). Inflammation is characterised by four signs: pain, redness, swelling 
and heat (Springer, 1994). These result from the vasodilatation of blood vessels causing 
increased local blood flow and leakage of proteins into the tissues. This also acts on the local 
endothelium that adopts an inflammatory phenotype contributing to the recruitment of 
leukocytes (Pober et al., 2007; Springer, 1994). 
 
 This thesis is primarily interested in understanding the modulation of inflammatory 
processes taking place in T1D. This includes the study of immune cell stimulation as well as 
their trafficking. Therefore it is important to understand how and where immune responses 
develop. 
1.3.2.1. Localisation of immune responses 
 Once mature, T and B cells continuously traffic between the blood and the secondary 
lymphoid organs, a process called homing (von Andrian et al., 2003; Cyster, 2003a). 
Secondary lymphoid organs (SLOs) are responsible for collecting antigens and facilitate their 
exposure to recirculating lymphocytes (Cyster, 2005). In addition, lymphoid organs provide a 
suitable environment for maintenance and development of B and T cells (Cyster, 2005). 
Secondary lymphoid tissues comprise the lymph nodes; which are clustered at sites such as 
the groin, axillae, neck and small intestine; the spleen, which collects blood-borne antigens, 
the mucosal lymphoid tissues of the gut (Peyer’s patches), the nasal and respiratory tract, the 
urogenital tract and other mucosa. Lymph nodes are interconnected by lymphatic vessels, 
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which drain extracellular fluid (lymph) from tissues through the lymph nodes and back into 
the blood (Melody, 2001). This allows them to screen for antigens.  All SLOs have a specific 
structure adapted to T and B cell activation (Itano et al., 2003). The best example is the lymph 
nodes.   
 Within SLOs, B cells are concentrated in regions called follicles where they screen 
follicular DCs (Willard-Mack, 2006). Stimulation of B cells results in the formation of a 
germinal centre that will be referred as secondary follicles. Once differentiated into plasma 
cells, they migrate to the medullary cord where they will secrete antibodies released in the 
lymph (Shapiro-Shelef et al., 2005).  
 T cells are located in the paracortical area where they survey DCs. T cell stimulation 
does not lead to germinal centre formation but causes enlargement of the paracortex. This 
compartmentation is possible only because of the combinatorial action of chemokines, 
integrins and selectins which guide the B and T cells to their respective zone (Cyster, 2003b; 
von Andrian et al., 2003). Although chemokines are essential for T and B cells repositioning 
in the lymphoid tissues, it has been debated that this process was not caused by chemokines 
gradients as initially determined. In fact, T and B cell migration is governed by the” type” of 
High Endothelial Venules (HEV) (Miyasaka et al., 2004). HEV are specialised for continuous 
capture and migration of recirculating lymphocytes (Miyasaka et al., 2004). They display 
different recognition signals that allow selective entry of the cells in their homing 
compartment (Wei et al., 2003).  Homing of B cells to the follicle is guided by interaction of 
CXCR5 that is expressed on mature B cells, with CXCL13 expressed in the surroundings 
follicular stromal cells (Ansel et al., 2000; Cyster et al., 2005). T cells and DCs migration to 
the paracortex depends on CCR7 and its ligands CXCL19 and CXCL21 (Forster et al., 1999; 
Gunn et al., 1999). Both chemokines are made by paracortical stromal cells but also by HEV 
and DCs (Cyster, 1999). These characteristics of B and T cell homing differs in the spleen 
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lacking the HEV. Instead, B and T cells enter the spleen by terminal arterioles opening into 
the marginal sinuses or the red pulp (van Ewijk et al., 1985). 
 In the periphery, the endothelium characteristics vary according their location in the 
different levels of the vascular tree and between different organs (Aird et al., 2005). Thus, 
post-capillary venules of other tissues are for example specialised sites for recruitment of 
leukocytes following inflammation/infection insult. Other endothelium display differences in 
their expression profile of recruitment molecules but also phenotypic distinction such as 
fenestration in the islets (Henderson et al., 1985). 
1.3.2.2. The life of a T cell 
 T cells continuously traffic in the circulation through the secondary lymphoid organs 
to screen for antigens. In inflamed tissues, DCs take up antigens and bring them to the SLOs 
where they stimulate antigen-specific T cells (Jensen, 2007). Upon stimulation, naive T cells 
proliferate into effector T cells equipped to migrate to the site of inflammation/infection (Boes 
et al., 2004).  
 Most lymphocytes fail to recognise their antigen and spend 12 to 18 hours for T cells 
and 24 hours for B cells, in the SLOs. After that, they recirculate in the blood either via the 
lymph or directly into the circulation (Cyster, 2003b).  Lymphocytes spend only 30 minutes in 
the blood and then home back to (likely another) SLOs (Delves et al., 2000). This cycle is 
repeated over and over again for several months (Cyster, 2005). Sequestration of T cells in the 
SLOs is crucial for the appropriate screening of antigens presented by DCs and is possible 
because of specific retention signals. Recent work has shown that CCR7 is not only required 
for T cell entry into SLOs but also for their retention and motility within the T cell zone 
(Pham et al., 2008; Okada et al., 2007). However, the CCR7 signal needs to be overcomed to 
allow T cell egress from the lymphoid organs. This process is controlled by sphingosine-1-
phosphate (S1P) (Mandala et al., 2002). 
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 Sphingosine-1-Phosphate (S1P) and T cell egress  
 S1P is a sphingolipid derived from the phosphorylation of sphingosine in a reaction 
catalysed by two isoforms of the sphingosine kinase, SPHK1 and SPHK2 (Figure 1-5a) 
(Spiegel, Milstien, 2003).  SPHK1 is located in the plasma membrane, whereas SPHK2 is in 
the mitochondria, endoplasmic reticulum and nucleus (Spiegel, Milstien, 2011). 
 As a bioactive compound S1P has a short half-life of 15 minutes (Venkataraman et al., 
2008) as it becomes rapidly dephosphorylated back to sphingosine and this makes it available 
for ceramide and sphingolipid synthesis. Alternatively, it is irreversibly cleaved by S1P lyase 
into its tran-2-hexadecenal and ethanolamine phosphate metabolites (Bandhuvula et al., 2007) 
(Figure 1-5b). 
 The involvement of S1P in T cell egress from the lymph node was first revealed with 
the discovery of FTY720 as an immunosuppressive agent (Fujita et al., 1996). FTY720 
immunosuppresses through sequestration of T cells in SLOs (Mandala et al., 2002). The fact 
that FTY720 shares structural analogy with S1P lead to its discovery as an agonist of four of 
the five S1P receptors, S1PR1, S1PR3, S1PR4 and S1PR5 (Brinkmann et al., 2002). It was 
demonstrated that high levels of S1P cause T cell sequestration in the lymph nodes in the 
same way as FTY720 (Mandala et al., 2002). This is consistent with the existence of a S1P 
gradient guiding T cells out of the SLOs, where S1P is low, to the circulation where S1P 
concentrations are high (Figure 1-5c). Measurement of S1P concentrations in the plasma is 
difficult because of its binding to albumin and high-density-lipoprotein (HDL) (Murata et al., 
2000). However, it has been generally accepted that S1P concentration in the plasma is in the 
micromolar range (Pappu et al., 2007).  
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Figure 1-5: S1P and T cell migration 
(a) S1P synthesis is catalysed by SPHK1 and SPHK2 (Spiegel et al., 2011, copyright number: 
2814670919041) and (b) S1P synthesis. SPHK1 located at the plasma membrane and SPHK2 
at the endoplasmic reticulum (ER), mitochondria and nucleus, phosphorylate sphingosine. 
S1P produced in the ER can be degraded by the S1P lyase or dephosphorylated by the S1P 
phosphatase. At the membrane, S1P is exported through a transporter under the right cytokine 
stimuli. It then binds to high density lipoprotein (HDL) or albumin in the circulation and 
activates S1PR signalling. (c) In SLOs, S1P promotes the egress of T cell (green) to the 
lymph or blood where S1P is more abundant. S1P is produced by radiation-resistant cells such 
as endothelial cells (green squares) and red blood cells (RBC). After egress, T cells internalise 
the S1PR1 (S1P1) in response to high S1P levels (Schwab et al., 2007, copyright number: 
2814670695281). 
 
 
 
 
 
Sphingosine-1-phosphate lyase
a) b)
c) SLOs
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In the lymph, S1P was measured in the nanomolar range as well as in the interstitial fluid of 
SLOs (Pappu et al., 2007; Schwab et al., 2005). S1P is produced by radiation-resistant cells 
(Pappu et al., 2007) such as endothelial cells and red blood cells (Schwab et al., 2005, 
Schwab et al., 2007), which is consistent with the direction of the gradient.   
 Subsequent studies in S1PR1-/- mice models have shown that the egress of T cells is 
dependent on S1PR1 (Matloubian et al., 2004). Thus, lymphocytes lacking or with low level 
of S1PR1 cannot exit the lymph nodes. Then it was shown that naive T cell express high level 
S1PR1 when located in the lymph nodes which allow their recirculation. If the naive T cell 
meets with its antigen, activation results in decrease of S1PR1 expression. This allows the T 
cell to be sequestrated in the lymph node in order to proliferate. Once the effector T cells are 
generated they up-regulate S1PR1 permitting the egress from lymph nodes to migrate to the 
site of inflammation/infection. Once in the circulation S1PR1 expression is down-regulated. 
The expression of S1PR1 enables T cells to sense the S1P gradient that drives T cells out of 
the lymph nodes while allowing the over-riding of the CCR7 mediated retention signals 
(Pham et al., 2008). 
 S1P was for a long time considered as a promoter of T cell migration out of SLOs. 
However, recent evidence show that S1PR1 stimulation inhibit migration of lymphocytes 
from non-lymphoid peripheral tissues to afferent lymphatic vessels (Ledgerwood et al., 2008), 
and this is clearly an area that requires further investigation. 
 
 The multistep adhesion cascade 
 Effector and memory T cells are mobilised into the blood during an inflammatory 
response. Tissues are separated from the blood by the vascular endothelium constituted of 
endothelial cells (EC) that line all blood vessels. EC are tightly held together by junctions. 
They secrete an extracellular matrix called the basement membrane, which offer barriers and 
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anchors to EC (Nourshargh et al., 2005). EC located in post-capillary venules display a wide 
range of adhesion molecules and chemokines allowing efficient recruitment of leukocytes to 
sites of inflammation/infection (Aird et al., 2005). This process highly depends on the 
activation of EC by cytokines such as TNF-α, IFN-γ and IL-1β, usually secreted following 
inflammation (Springer, 1995). The adhesion cascade to EC can be separated into eight steps 
(Figure 1-6):  
1- Margination 
2- Capture/ Rolling  
3- Activation by chemokines  
4- Integrin activation/ Arrest  
5- Lipid induced activation 
6- Migration over the endothelium 
7- Trans-endothelial migration 
8- Sub-endothelial migration 
 Initial capture to the endothelium is only possible because of a phenomenon called 
margination (Schmid-Schönbein et al., 1980). This process represents the exit of free flowing 
leukocytes from the blood to tissues. The mechanism of margination involves the interaction 
of red blood cells with leukocytes flowing in the same vessel. Because the flow of 
erythrocytes is fast and localised down the centre of the vessels, it causes displacement of 
leukocytes towards the vessels wall (Goldsmith, Spain, 1984; Schmid-Schönbein et al., 1980; 
Abbit, Nash, 2003). At this point, selectins or rolling receptors capture the lymphocytes 
allowing their rolling on the endothelium until encounter with the right inflammation signals 
that will firm their adhesion (Springer, 1995; Middleton et al., 2002). There are three types of 
selectins which all have an N-terminal domain homologous to Ca2+ lectins: P-selectin, L-
selectin and E-selectin. L-selectin is selectively expressed on almost all types of leukocytes 
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but on a subset of memory T cells (Springer, 1994; vonAndrian et al., 1993). P-selectin was 
first discovered on platelets but has now been found on EC as well as E-selectin in inflamed 
conditions (Springer, 1994). It is now recognised that mainly P-selectin mediate T cell 
capture/rolling (Luscinskas et al., 1995). E-selectin is crucial for adhesion of memory T cells 
(Picker et al., 1991; Shimizu et al., 1991). However, inhibition of P- and E-selectin on T cells 
induces a partial decrease of rolling (Luscinskas et al., 1995). This has been explained by the 
evidence showing the capacity of α4β1 (VLA-4-Very Late Antigen-4) integrins to support 
lymphocyte rolling on vascular cell adhesion protein-1 (VCAM-1) (Alon et al., 1995; Berlin 
et al., 1995; Johnston et al., 1996; Luscinskas et al., 1995). 
 After capture/rolling, T cells receive an activating signals through chemokines. 
Chemokines are small chemoattractant cytokines (8-16 kDa) subdivided into 4 families 
depending on the position of two highly conserved cysteines in the amino acid sequence: 
CXC, CX3C, CC or C. Inflamed EC up-regulate the expression of chemokines allowing 
downstream activation of integrins. Cinamon et al. determined the importance of CXCR4 
binding to its ligand, CXCL12 (SDF-1) for lymphocyte migration (Cinamon et al., 2001a; 
Cinamon et al., 2001b). In inflamed conditions, IFN-γ production is likely to occur at the site 
of inflammation.  
 IFN-γ induces surface expression of the chemokines CXCL9 (Mig), CXCL10 (IP-10) 
and CXCL11 (I-TAC) on the endothelium (Mazanet et al., 2000; Piali et al., 1998). These 
chemokines specifically bind to CXCR3, a G-protein-coupled receptor (GPCR) chemokine 
receptor highly expressed on effector and memory T cells (McGettrick et al., 2009; Piali et 
al., 1998). Inhibition of CXCR3 signalling reduces T cell adhesion on IFN-γ/TNF-α 
stimulated EC indicating its importance in firm adhesion of T cell (Piali et al., 1998; 
Curbishley et al., 2005). However, this is only possible if there is a local production of IFN-γ.  
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 Chemokines binding to their receptor induces integrins activation by triggering a 
complex intracellular signalling cascade within milliseconds (Ley et al., 2007). This process 
is identified as “inside-out signalling” that increases the affinity of integrins, by extension of 
the tail and their valency on the T cell surface resulting in binding to their ligands on the 
endothelium (Ley et al., 2007; Hogg et al., 2011). For T cell migration, this is mainly 
mediated by CXCR3 signalling that activates LFA-1 (αLβ2-Lymphocyte function-associated 
antigen-1) binding to ICAM-1 and VLA-4 (α4β1) binding to VCAM on EC as inhibition of 
these suppress T cell adhesion in vivo and in vitro (Johnston et al., 1996; Johnston et al., 
2000; Alon et al., 1995).  
  For a long time, chemokine signals and re-organisation of the actin cytoskeleton 
during spreading of the EC were believed to be sufficient to support T cell transmigration. 
However, recent evidence demonstrates the importance of prostaglandin D2 (PGD2) in this 
process (Ahmed et al., 2011). In this study, antagonism of the PGD2 receptor (DP-2, CRTH2) 
on memory T cells resulted in the blockade of transmigration, but not adhesion. PGD2, a 
member of the eicosanoid family and is highly produced by mast cells. During allergy and 
asthma it is released in excessive quantities causing vasodilatation, flushing, hypotension and 
syncopal episodes (Roberts, Sweetman, 1985). A similar process involving PGD2 was found 
for neutrophil transmigration via action on the DP-1 receptor (Tull et al., 2009). Whilst the 
mechanism underlying PGD2 action is not fully characterised, it may involve an action on 
CCR7 for migration across lymphatic EC (Ahmed et al., 2011). 
 After attachment, T cells migrate on the surface (Middleton et al., 2002). This 
mechanism involves polarisation of T cells. Actin polymerisation at the front results in 
creation of a leading edge and the formation of a uropod at the back through actin-myosin 
based contraction (Soriano et al., 2011). This causes detachment at the back and attachment at 
the front (Kinashi, 2005).  
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 Until recently, it was believed that T cells could transmigrate through endothelium 
only by using a paracellular route, located at intercellular junctions. However, it is now clear 
that T cells can also directly cross the endothelium using a transcellular route, both ways 
involving different mechanism and molecules. The paracellular path involves molecules such 
as CD31, CD99, PECAM1, ICAM-2, LFA-1, JAM-A, B, C and VE-cadherin that accumulate 
at the extravasation site (Ley et al., 2007; Muller, 2003). The intracellular route works 
through ligation of ICAM-1 resulting in its internalisation into actin- and caveolae-rich 
regions. These link together and form an intracellular channel referred as vesiculo-vacuolar 
organelles, permitting the migration of the lymphocytes (Ley et al., 2007; Millan et al., 2006). 
 
 
Figure 1-6: Schematic representation of the adhesion cascade leading to insulitis in T1D 
Insulin circulates through endothelial cells from the beta-cells into the blood circulation. 
Endothelial cells are also important for the transfer of nutrients and oxygen to beta-cells. 
However, auto-reactive T cells, activated in the pancreatic lymph nodes, are recruited by 
chemotaxis to the islets and can cross the endothelial cells after rolling, by interacting with 
adhesion markers such as ICAM, VCAM and E-selectin. Autoreactive T cells then migrate 
into the islets to recognise auto-antigens and cause the auto-immune destruction of beta-cells.  
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1.3.3. Vascular function in T1D 
 In T1D, islet specific T cells are activated in the draining pancreatic lymph nodes 
following presentation of auto-antigens (Hoglund et al., 1999). They then traffic to the islets 
via the islet microcirculation. The islet microcirculation is characterised by a dense network 
of capillaries lined by a distinctive fenestrated endothelium (Vajkoczy et al., 1995; Olsson et 
al., 2006). High vascularisation of the islets is crucial for nutrient, oxygen and insulin transfer 
between beta-cells and the circulation. This is allowed by the unique structure of the islet. 
Each beta-cell is located no more than one cell away from a capillary and the endothelial 
fenestration allows small molecules to quickly diffuse through the small pores in the 
endothelium (Henderson, Moss, 1985). However, islet endothelial cells also represent the 
portal of entry of auto-reactive T cells in T1D (Figure 1-6). Islet endothelial cells express 
common endothelial markers such as von Willebrand factor, CD31, ICAM-1, VCAM-1 and 
E-Selectin (Lozanoska-Ochser et al., 2008).  
 Studies in diabetic mice models and pancreatic biopsies of human islet from T1D 
patients show that islet endothelial cells in T1D adopt an inflammatory phenotype. Indeed, the 
expression of ICAM-1, VCAM-1 and E-selectin, is increased on islet endothelium from 
mouse model of T1D and in patient (Hanninen et al., 1992; Hanninen et al., 1993; Rasmussen 
et al., 2002; Xie et al., 2008). These molecules facilitate the adhesion and transmigration of 
auto-reactive T cells from the blood to the inflamed pancreas via interaction with their 
corresponding ligands on the T cell surface. These ligands, such as LFA-1 (αLβ2) and VLA-4 
(α4β1), are also increased on activated T cells and monocytes in T1D (Xie et al., 2008; 
Shimizu et al., 1991). The expression of adhesion molecules on both endothelial cells and 
lymphocytes is modulated by cytokines (Ding et al., 2000). Islet endothelial cells also express 
high levels of MHC class I and II, which are up-regulated during inflammation characterising 
T1D (Itoh et al., 1993; Somoza et al., 1994). Co-stimulatory molecules such as CD86 and 
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ICOS-L are also expressed on islet endothelial cells (Lozanoska-Ochser et al., 2008). The 
presence of presenting and co-stimulatory molecules confirms the involvement of islet EC in 
the progression of insulitis. Indeed, due to the inflammatory milieu, islets EC presentation of 
auto-antigens such as GAD65 activates and facilitates the migration of GAD65 specific auto-
reactive T cells into the islets (Greening et al., 2003; Marelli-Berg et al., 1999). Blocking of 
PSGL-1 in mice attenuates incidence of T1D (Huang et al., 2005). T cell transmigration 
through the islet EC is increased by activation of integrins either by TCR-mediated change of 
LFA-1 (αLβ2) avidity or by chemokine signalling emphasis (Katagiri et al., 2003). A number 
of chemokines are associated with the development of T1D. Interestingly, CXCL10 
circulating levels are higher in newly diagnosed patients (Shimada et al., 2001). As mentioned 
earlier, CXCL10 is crucial for T cell migration and binds to CXCR3 highly expressed on 
effector and memory T cells. It has been found to be produced by beta-cells at high levels, 
resulting in excessive recruitment of T cells to the islets (Frigerio et al., 2002, Rhode et al., 
2005). CXCL10 blockade prevents diabetes in mice by blocking T cell infiltration in the 
pancreas (Frigerio et al., 2002; Cristen et al., 2003). The CCL21-CCR7 interaction is also 
involved in the emigration of auto-reactive T cells in the islets (Savinov, Burn, 2010). CCL21 
is also expressed in the islet region, especially in the inflamed pancreatic lymphatics (Qu et 
al., 2005). CCL21 is essential to facilitate the recruitment of auto-reactive T cells in the 
pancreatic lymph nodes where they meet with their auto-antigen (Savinov et al., 2003).  
 These examples whilst reflecting the complexity behind the control of autoreactive T 
cell migration, also reveals potential target to stop its progression. However, the implications 
of such a variety of mechanisms imply that targeting single pathways may not be efficient for 
therapy. In addition, it is now recognised that development of T1D is influenced not only by 
genetic factors that predispose to immune defects but also the environment (Fourlanos et al., 
2008; Wilkin, 2001) (Chapter 1-section 2). The line of research in this PhD originated from a 
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basic hypothesis built on a recent understanding of environmental contributions to the 
development of T1D. 
2. T1D, obesity and insulin resistance 
 
 Genes associated with risk in humans include HLA complex especially HLA-DR and 
HLA-DQ, CTLA-4, PTPN22 and IL-2RA (Concannon et al., 2005; Nejentsev et al., 2007; 
Concannon et al., 2009). As mentioned before (Chapter 1-section 1.2), the prevalence of 
diabetes has been rising for the last decade. This rapidity suggests a role for the environment. 
This is supported by evidence that T1D subject’s frequency with high risk HLA-DR 
genotypes has decreased over the last decades (Hermann et al., 2003a and b). 
Possible environmental triggers include viral infection, vaccination, toxins, increasing obesity 
and insulin resistance (IR) (Knip et al., 2005; Pang, Narendran, 2008).  
 IR is a condition in which the bioactivity of insulin is decreased. This results in 
increased requirement of insulin to maintain normal blood glucose levels. IR is generally 
caused by weight gain and physical inactivity. It can be measured by different methods. 
Measurement of fasting insulin is the most convenient way but not the most accurate. The 
Homeostasis Model Assessment (HOMA) is another simple way to measure IR. This model 
will mathematically estimate insulin sensitivity (HOMA %S) and level of beta-cell function 
(HOMA %B) by direct measurement of fasting plasma glucose and fasting plasma insulin 
(Matthews et al., 1985). The most accurate way of measuring IR in patients with T1D, is the 
euglycaemic hyperinsulinaemic clamp; however, this test is more complicated (DeFronzo et 
al., 1979, Pang, Narendran, 2008). A constant dose of insulin (40mU/min/m2) is continuously 
administrated to the subject. Glucose is also administrated, and the clamp test consists in 
measuring how much glucose is required to maintain the plasma blood glucose levels 
constant, this reflecting the whole body glucose disposal rate (GDR) capacity. A low GDR is 
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associated with insulin resistance. The GDR can also be estimated in subjects with T1D 
(eGDR), using HbA1c, blood pressure (HTN) and Waist/Hip ratio (WHR). With this method 
the estimated GDR can be calculated by the following equation: 24.31-12.22WHR-3.29HTN-
0.57HbA1c. This score correlates well with clamp-derived values in adult T1D subjects 
(Williams et al., 2000). The estimated GDR appears to be the easiest way to predict IR in 
T1D and has now been used in a number of studies (Orchard et al., 2003). 
 Interestingly, about 26% of patients with T1D are insulin resistant (McGill et al., 
2008). Recently, three surveys on pre-T1D patients in Australia (Fourlanos et al., 2004), 
United States (Xu P et al., 2007) and Europe (Bingley PJ et al., 2008) suggest that IR is 
associated with the accelerated development of T1D. Obesity is a common cause of IR and its 
incidence has been dramatically increased in the last 10 years (James et al., 2004). Previous 
reports have shown that people who develop T1D are heavier in early childhood than healthy 
controls (Baum et al., 1975; Johansson et al., 1994; Hypponen et al., 1999; Bruining et al., 
2000). In addition, fatter children develop T1D at a younger age in some studies (Kibirige et 
al., 2003). Therefore, obesity, IR and T1D may be related, and this may provide an 
explanation for the rise in T1D. However, how does IR influence the rate of development of 
T1D? 
 IR may lead to beta-cell stress, and this may invite autoimmunity, resulting in early 
development of T1D (Dahlquist, 2006). Other suggestions involve direct influence of IR on 
islet autoimmunity. Direct beta-cell apoptosis can be induced by glucotoxocity and 
lipotoxicity both of which are associated with IR. This also increases antigen presentation by 
beta-cell, causing acceleration of auto-immunity (Bjork et al., 1992; Trudeau et al., 2000).  
Other mechanisms involve an effect of the adipose tissue that has been shown to regulate T 
cell immunity. Indeed, fat accumulation associated with IR, induces a shift in the balance of 
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adipose tissue resident T cells (Nishimura et al., 2009; Winer et al., 2009, Feuerer et al., 
2009).  
 I am interested in the effect of adipose tissue derived cytokines (adipokines) on 
immunity, and whether this may mediate the association between IR and T1D, and the 
accelerated incidence of T1D that has been described in epidemiological studies.  
3. Adipokines 
3.1. Leptin 
3.1.1. Pleiotropic properties of leptin 
 Leptin is a 16kDa peptidic hormone, a product of the ob gene located on chromosome 
7, secreted mainly by white adipocytes in proportion to the body fat mass (Zhang et al., 1994; 
Geffroy et al., 1995). Leptin is composed of four α-helix and two β-sheets similarly to the 
structure of the IL-6 family of cytokines (Zhang et al., 1997). The leptin receptor, a product of 
the db gene, is a member of the class I cytokines receptors family including gp-130 and IL-6 
receptor (Tartaglia et al., 1995). By alternative splicing, at least 5 different transcripts, named 
ObR-a to ObR-e, are produced from the db gene in mice. In humans, only the ObR-a, b, e and 
another poorly characterised variant, not present in mice, are so far characterised (Figure 1-
7a). The different isoforms have in common the extracellular part, the transmembrane 
domain, apart from ObR-e which is soluble, but have a variable intracellular domain. All 
isoforms but ObR-e contain the JAK (Janus-family tyrosine kinase) binding Box 1 motif. 
However, only ObR-b displays the four tyrosine residues (Tyr974, Tyr985, Tyr1077 and 
Tyr1138) required for efficient signalling. Once phosphorylated, the tyrosines represent 
docking sites for signalling proteins containing SH2 domains, involved in the JAK/Stat 
signalling pathway (Chen et al., 1996; Lee et al., 1996; Cioffi et al., 1996). Although, 
JAK/Stat signalling is recognised as the main pathway activated by leptin, the MAPK 
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(Mitogen-activated protein kinase) cascade is also involved in the leptin signalling (Figure 1-
7b). Studies have shown that despite lack of the four tyrosines, OBR-a is able to transmits 
signals, although substantially weaker than OBR-b. 
 
Figure 1-7: Leptin receptors and their signalling pathways in mice and humans 
(a) Leptin receptor isoforms in mice and humans showing the conserved cysteines and motifs 
in the extracellular region (blue) and Box 1 present on all isoforms but the soluble form and 
the two sets of tyrosine in the intracellular region that are specific to lLEPR (ObR-b) 
(Friedman et al., 1998; copyright license number: 2817160481320). (b) lLEPR (ObR-b) 
signalling involves the JAK/STAT pathway but can also trigger the MAPK cascade (LaCava 
et al., 2004; copyright license number: 2817160655753). 
 
 However, the pathway activated by OBR-a is controversial. Studies have reported 
activation of both MAPK and JAK/Stat pathways (Bjorbaek et al., 1997; Yamashita et al., 
1998). ObR-a has been involved in regulation of leptin transport into the brain (Hileman et 
al., 2002). Finally, ObR-e is a soluble form of the leptin receptor. It circulates in the blood 
where it binds to leptin and consequently prevents its degradation and clearance (Huang et al., 
2000). 
a)
b)
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 Leptin regulates body weight through the control of appetite and metabolism 
(Friedmanet al., 1998). The metabolic effects of leptin are mediated through its interaction 
with lLEPR in the hypothalamus region, which is involved in the regulation of the appetite 
(Mercer et al., 1996). Leptin deficient mice (ob/ob) or leptin receptor deficient mice (db/db) 
have a severe obesity phenotype characterised by an increase in food intake and decrease in 
energy expenditure. Leptin administration to these mice restores the obesity phenotype 
(Pelleymounter et al., 1995). Leptin receptors expression has also been detected in peripheral 
tissues such as adrenal gland (Tena-Sempere et al., 2000), placenta (Senaris et al., 1997), 
stomach (Mixet al., 2000), ovary (Karlsson et al., 1997), muscles, heart, kidneys, adipocytes 
(Kielar et al., 1998), liver, pancreatic beta-cells and immune cells (Friedman et al., 1998; 
Zhang et al., 2005). As a result, leptin has the potential to influence reproduction (Chehab et 
al., 1996), insulin secretion (Friedman et al., 1998), haematopoiesis (Benett et al., 1996), 
angiogenesis (Park et al., 2001), metabolism of bones (Ducy et al., 2000), lipids and glucose 
(Friedman et al., 1998), and both the innate and adaptive immune response (Lord et al., 1998, 
Sanchez-Margalet et al., 2003, Matarese et al., 2004). 
3.1.2. Leptin in immunity 
3.1.2.1. Leptin modulates innate and adaptive immunity 
 Although a major role of leptin is to regulate body weight, leptin is now recognised to 
have important effects on both innate and adaptive immune responses (Figure 1-8). A number 
of studies have observed immune abnormalities in ob/ob and db/db mice (Boillot et al., 1986; 
Palmer et al., 2006; Papathanassoglou et al., 2006). Firstly, thymic reduction and 
consequently decrease in T cells number and their precursors is observed in ob/ob or db/db 
mice (Howard et al., 1999). In these animals, T cells responses are not efficiently stimulated 
because of the concomitant decrease in APCs functions. In humans, leptin deficiency is also 
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associated with obesity and lymphopenia (Farooqi et al., 2002). The studies in leptin 
deficiency models indicate the important role of leptin as a pro-inflammatory cytokine.  
Leptin was reported to dose-dependently enhance the proliferation of peripheral blood 
mononuclear cells (PBMC) and highly purified CD4+ T cells, both co-stimulated with an 
allogenic stimulator (Lord et al., 1998). Leptin does not enhance the proliferation of db/db 
mice allogenic splenocytes even at high concentration (100nM), showing that the leptin effect 
is specific to leptin receptor signalling on CD4+ T cells. This article also showed that the T 
cell production of IL-2 and IFN-γ is leptin dose-dependent. Other studies have shown a 
similar effect of leptin from 0nM to 100nM specifically on CD4+ and CD8+ T cells stimulated 
with phytohaemagglutanin (PHA) or concanavalin A (Martin-Romero et al., 2000). In 
addition to its action on proliferation, leptin seems to skew T cell responses to T helper (Th1) 
by inhibiting differentiation to T helper 2 (Th2) (La Cava et al., 2004). Another important 
effect is the ability of leptin to inhibit T cell apoptosis by down-regulation of the Fas and Bcl-
2 pathways. This has also been observed on B cells in addition to an increased production of 
IgG2a and TNF-α, IL-6 and IL-10 (Papathanassoglou et al., 2006; Agrawal et al., 2011; Lam 
et al., 2010). 
 On the other hand, other reports have noticed that leptin can suppress peripheral 
lymphocyte function when administrated by intracerebroventricular injection. It appears that 
in contrast to its direct activating effect, leptin is able to suppress lymphocytes function 
indirectly through the activation of the sympathetic nervous system (Okamoto et al., 2000).  
This new paradoxical suppressing effect of leptin has been attributed to an interesting 
heterogeneity of cellular behaviour between naive and memory T cells which were 
differentially affected by leptin (Lord et al., 2002). It appears that leptin inhibits the anti-CD3-
driven proliferation of memory T cells, whereas the naive CD3+ T cells proliferation was 
enhanced in co-stimulation conditions.  
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Figure 1-8: Leptin and immunity 
Leptin can influence both innate and adaptive immunity. In innate immunity, leptin modulates 
neutrophil activation as well as monocytes and macrophages capacity to produce cytokines. 
Leptin can also increase APCs phenotype and function, in addition to cytotoxicity of NK 
cells. In the adaptive immunity, leptin has direct effects on thymic homeostasis and T cell 
proliferation. Leptin can skew immune responses towards a Th1 phenotype and inhibit Th2 
responses as well as Treg proliferation and their immune-regulation capacities. Leptin can 
also stimulate B cell proliferation and reduce apoptosis of T and B cells. In conclusion, leptin 
has several pro-inflammatory actions on the immune system (Adapted from LaCava et al., 
2004). 
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However, in these conditions there is still an important production of pro-inflammatory 
cytokines. These findings show further complexity in the action of leptin on the immune 
system. 
 A few years later, the same group reported that leptin can also act as a negative signal 
for the proliferation of human FoxP3+CD4+CD25+ Treg in vitro (DeRosa et al., 2007). In this 
study, the authors also reported that Treg produce leptin. Anti-leptin antibody blockade 
restores Treg proliferation during CD3/CD28 bead stimulation in vitro. This effect is also 
noticed in vivo when Treg from normal mice are transferred into leptin-deficient mice 
resulting in Treg proliferation and expansion. Treg from db/db mice show higher proliferation 
in vitro than Treg from normal mice, suggesting that the effect of leptin is specific to leptin 
receptor signalling. Interestingly, Treg from NOD mice deficient for the leptin receptor, 
proliferate more than Treg from the normal NOD mice in response to antigen-specific 
stimulation with GAD65. In these conditions, T effectors cells proliferation is reduced. These 
findings are consistent with the potential involvement of leptin in autoimmunity in T1D 
because Treg are an important regulator of autoimmunity.  
 Leptin also modulate innate immunity. LEPR is highly expressed on neutrophils, 
resulting in down-regulation of apoptosis, increased activation and chemotaxis (Bruno et al., 
2005; Cadelfie-Chezet et al., 2003). Leptin promotes the activation of phagocytosis by 
monocytes/macrophages, their proliferation, the secretion of pro-inflammatory cytokines 
(TNF-α, IL-1, IL-6) and nitric oxide without preliminary co-stimulation with PHA (Zarkesh-
Esfahani et al., 2001; Santos-Alvarez et al., 1999). MHC molecules expression is up-
regulated on APCs as well as co-stimulatory and adhesion molecule (Mattioli et al., 2005). 
On natural killer (NK) cells, leptin induces an increase in perforin production (Zhao et al., 
2003). 
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3.1.2.2. Leptin and migration of immune cells 
 There are a number of studies of leptin action on inflammatory cell migration. Leptin 
stimulates chemotaxis of neutrophils, monocytes, macrophages and DCs (Cadelfie-Chezet et 
al., 2003; Gruen et al., 2007; Mattiolo et al., 2005). In monocytes and macrophages, leptin 
acts as a chemoattractant by increasing calcium influx as well as the activation of the Janus 
kinase (JAK) and the phosphatidylinositol 3-kinase (PI3K) signalling pathways (Gruen et al., 
2007). However, the mechanism underlying leptin effects are varied. In DCs, studies reported 
that leptin intensifies DCs migration by both favouring cytoskeleton dynamics and up-
regulating CCR7 surface expression (Mattiolo et al., 2005). 
3.1.3. Leptin in T1D 
3.1.3.1. Circulating levels 
 Data regarding plasma leptin levels in T1D are conflicting (Table 1-1). Most reports 
including patients with long-duration of T1D have shown higher circulating leptin 
concentration compared to healthy controls (HC) (Kiess et al., 1998; Luna et al., 1999; 
Hanaki et al., 1999; Fluck et al., 1999; Kirel et al., 2000; McCormick et al., 2001; Soliman et 
al., 2002; Bideci et al., 2002; Sandoval et al., 2003; Lo et al., 2004; Gilliam et al., 2006). 
Generally, insulin therapy induces an increase in circulating leptin levels in T1D, suggesting 
that leptin secretion is controlled by insulin (Bideci et al., 2002; Soliman et al., 2002; Kiess et 
al., 1998). However, some reports have shown no effects of insulin (Luna et al., 1999; Kirel 
et al., 2000; McCormick et al., 2001). Adding more controversy, some studies have shown no 
differences or even lower leptin levels between T1D and HC before or after insulin therapy. 
These studies seem to mainly involve newly diagnosed or pre-diabetes patients (Lo et al., 
2004; Hanaki et al., 1999; Gilliam et al., 2006). From these studies, we can conclude that 
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leptin levels are lower or similar to HC in pre and newly T1D. After insulin treatment, leptin 
levels rise which explain the high levels observed in long-duration of diabetes patients.  
 Measuring circulating levels is complex. First, leptin levels follow a diurnal cycle and 
change with food intake. Leptin in circulation can also be bound to its soluble receptor 
isoform (Tu et al., 2008). The proportion of leptin-bound is not defined and causes variations 
in leptin measurement. Another factor influencing leptin levels is puberty. Indeed, studies 
have shown elevation of circulating leptin levels from pre-puberty to puberty to adulthood in 
healthy or diabetic or obese patients (Verrotti et al., 1998; Ahmed et al., 2001). For this 
reasons measurement and interpretation of leptin levels in patients versus controls should be 
done cautiously, and these differences may explain discrepancies between reports in this area. 
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Study 
n 
HC 
n T1D 
Mean age 
T1D 
(years) 
Mean BMI 
T1D 
(kg/m2) 
Mean 
HbA1c 
(%) 
T1D 
duration 
(months) 
Mean leptin 
T1D (ng/ml) 
Mean 
leptin HC 
(ng/ml) 
Effect of  
insulin 
therapy on 
leptin levels 
in T1D 
Bideci et 
al.,2002 
12 16 13±2.6 21.2±2.7 10.2±1.9 80±31 19.1±7.6 6.1±2.9 increased 
Sandoval et 
al., 2003 
15 16 28±3 27±2 8.4±0.7 NA 13.8±3 5.4±1 NA 
Luna et al., 
1999 
66 43 10±0.6 17.5±0.4 10.5±0.3 
4.8 
years±0.8 8.6±1.0 
4.1±0.4 no effect 
Kirel et al., 
2000 
35 35 12.7±3.4 18.1±2.5 11.9±3,5 35±45 0.83±0.3 1.5±0.94 no effect 
Soliman et 
al., 2002 
10 45 7.9±1.5 17.2±1.7 8.1±1.8 
Newly vs 
3.5years 
±2.5 
Newly: 
1.1±0.8 
T1D 
long:2.1±1.4
* 
1.3±1.5 increased 
Kiess et al., 
1998 
710 
13 
newly 
134 
T1D 
long 
9.8±3.7 15.2±3 10±1.9 NA 
Newly: 
1.28±1.6 
T1D long: 
5.18±5.48* 
2.2 increased 
McCormick 
et al., 2001 
NA 17 8.6±4.9 15.5±1.8 10.9±1.6 Newly 
Newly: 
4.3±1.1Insul
in treated: 
5.1±3.3ns 
NA No effect 
Lo et al., 
2004 
33 58 10.98±4.61 19.11±2.73 8.70±1.59 Newly 5.19±3.37ns 5.03±3.36 NA 
Hanaki et 
al., 1999 
19 19 9.8±1 16.8±0.5 11.6±0.6 Newly 3.3±0.2* 6.2±0.9 
increased 
time 
dependently 
Fluck et al., 
1999 
NA 28 8.75±4.05 15.79±2.47 11.3±1.9 Newly 1.37±0.56 NA 
increased 
time 
dependently 
Gilliam et 
al., 2006 
33 26 26.4 24.9 NA 
Pre-
diabetes 6.5 
5 NA 
Table 1-1: Circulating leptin in T1D 
Some studies report lower or unchanged circulating leptin levels in T1D subjects (bold green), 
especially in newly diagnosed before insulin therapy. Other reports show higher leptin levels 
(bold red) either in long duration T1D or after initiating insulin treatment.   
 
3.1.3.2. Influence in T1D  
 Because of its pro-inflammatory action and its association with IR; leptin may a role 
in islet autoimmunity in T1D. In support, leptin accelerates T1D in NOD mouse (Matarese et 
al., 2002). In this study, a leptin surge was observed at a pre-clinical stage before 
hyperglycaemia but after the beginning of T cell infiltration. Leptin administration at 1μg/kg 
every 36h for two weeks, favoured early inflammatory infiltration and accelerated diabetes in 
the female NOD mice. The infiltrating T cells were skewed to a Th1 phenotype due to an 
increase in IFN-γ production mediated by leptin. In this context, Th1 cytokines favour 
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initiation and progression of autoimmune responses by influencing antigen processing, 
presentation and co-stimulation on APCs (Rabinovitch et al., 2003). The leptin effect may 
then possibly result in either an increase in auto-reactive T cells priming or the reduction of T 
cell apoptosis.  
 Although definitive studies are needed in T1D, there is a potential for leptin to play a 
role in the development of T1D. 
3.2. Adiponectin 
3.2.1. Adiponectin and its receptors 
 Adiponectin (AQ) was first identified in mouse adipocytes as adipocyte complement 
related protein of 30 kDa (Acrp30) (Scherer et al., 1995) and then AdipoQ (Hu et al., 1996). 
It was then identified in humans by large-scale random sequencing of human adipose tissue 
cDNA (Maeda et al., 1996) and in plasma as gelatine binding protein (GBP28) (Nakano et al., 
1996). Adiponectin is a 28kDa protein secreted by the adipose tissue and encoded by the 
AdipoQ gene located on chromosome 3q21 (Kissebah et al., 2000). Adiponectin shares 
structural homologies with the family of the complement C1q (Wong et al., 2004). Its 
structure includes a carboxy terminal globular head and a collagenous tail. By non-covalent 
links the collagenous tails associate to form dimers and trimers referred as low molecular 
weight adiponectin (LMW). Further disulfide bridges and post-transcriptional modifications 
result in formation of the medium and high molecular weight (MMW and HMW) species 
present in the circulation along with the LMW form (Figure 1-9) (Waki et al., 2003; Tsao et 
al., 2003; Richards et al., 2006). Adiponectin has also been detected in the blood as a globular 
form resulting from cleavage of the collagenous tail by leukocyte elastase (Waki et al., 2005). 
 Two seven transmembrane G-coupled receptors (GPCR) have been identified to 
specifically bind adiponectin, adiponectin receptor 1 and 2 (AR1 and AR2) (Yamauchi et al., 
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2003). Both receptors are ubiquitously expressed and differ by their specificity to the different 
species of adiponectin. AR1 binds preferentially to globular adiponectin while AR2 engage 
the full-length proteins preferentially (Yamauchi et al., 2003). Both AR1 and AR2 are GPCR 
integrated in the membrane. However, their N-terminal is intracellular and their C-terminal is 
extracellular which is the opposite of most GPCR topology (Figure 1-9) (Yamauchi et al., 
2003).  
 Sequence alignment reveals that 69 amino acids in the N-terminal of AR1 and 79 
amino acids for AR2 are specific for each receptor. Adiponectin binding to both receptors 
stimulates the activation of AMP-activated protein kinase (AMPK), peroxisome-proliferator 
activated-receptor-α (PPAR-α), p38 mitogen-activated protein kinase, nuclear factor κB (NF- 
κB) and ERK-1/2 (Figure 1-9) (Yamauchi et al., 2003, Tang et al., 2007). Recent studies 
have identified APPL1 as an intermediate in the coupling of AR1 and AR2 with their 
signalling pathways (Cheng et al., 2007; Mao et al., 2006). Both AR1 and AR2 have been 
mainly detected in the adipose tissue and skeletal muscle as well as beta-cells, osteoblasts-like 
cells and interestingly in PBMC (Pang, Narendran, 2008). In this population, AR1 and AR2 
are mainly expressed on monocytes then NK cells and B cells. Little expression is detected on 
T cells, which express it at high levels intracellularly (Wilk et al., 2011). T-cadherin has also 
been identified as an adiponectin receptor and is able to activate the AMPK pathway (Hug et 
al., 2004). It has been recently been shown to mediate the cardioprotective effect of 
adiponectin in mice (Denzel et al., 2010). 
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Figure 1-9: Adiponectin signalling pathways 
LMW, MMW and HMW preferentially bind to AR2 but can also bind AR1. These receptors 
can also bind globular adiponectin. AR1/2 are GPCR exposing C-terminal at the cell surface 
and N-terminal intracellularly. APPL1 is an intermediate for the recruitment of AMPK, 
PPAR-α or p38 MAPK. The activation of these signalling cascades upon adiponectin binding 
causes regulation of gene expression that mediates the metabolic and immune control by 
adiponectin. In addition, T-cadherin is now recognised as another receptor for the HMW of 
adiponectin and may be involved in mediating its cardiovascular protection role (Adapted 
from Kadowaki et al., 2008). 
 
3.2.2. Adiponectin role in metabolism 
 Studies in adiponectin knock-out mouse model revealed a crucial role of adiponectin 
as an insulin sensitizer (Maeda et al., 2002; Kubota et al., 2002). These mice developed 
insulin resistance in response to a high fat diet. Replenishment of adiponectin in these mice 
ameliorates insulin resistance (Yamauchi et al., 2001).  
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 Adiponectin ameliorates insulin sensitivity by stimulating the uptake of glucose and 
fat oxidation and down-regulating gluconeogenesis and tissue triglyceride contents 
(Kadowaki et al., 2005). The different forms of adiponectin appear to preferentially induce 
AMPK, PPAR-α or P38 MAPK pathways depending on the tissue location. For example, 
globular adiponectin and full-length adiponectin induce AMPK activation in skeletal muscle, 
but only the full length adiponectin activates AMPK in the liver (Yamauchi et al., 2002). 
Knocking out these receptors individually has also provided some interesting data. Studies in 
the murine AR1 knock-out model show that AR1 is responsible for the metabolic effects of 
adiponectin as these mice are obese with impaired glucose tolerance. Conversely, AR2 knock-
out is protective as these mice are resistant to high fat diet-induced obesity (Bjursell et al., 
2007). 
 In humans, adiponectin circulating levels vary between 3 to 30µg/ml, classing it as the 
most abundant adipokine in the circulation (Arita et al., 1999). In contrast with leptin, 
adiponectin is reduced in conditions such as obesity and consequently insulin resistance and 
T2D, as well as coronary heart disease, stroke, non-alcoholic fatty liver disease and several 
types of cancers (Zhu et al., 2008). It is also recognised that mutations in the AdipoQ gene are 
associated with T2D (Menzaghi et al., 2007, Li et al., 2009).  
 
3.2.3. Anti-inflammatory properties of adiponectin 
 Adiponectin has been widely reported as an anti-inflammatory cytokine (Figure 1-10). 
It was first evidenced by observation of high levels of the pro-inflammatory cytokines TNF-α 
and IL-6 in the adipose tissue of adiponectin knock-out mice (Maeda et al., 2002; Uji et al., 
2009). Adiponectin anti-inflammatory action has mainly been reported on innate immunity 
(Figure 1-10). Co-culture of adiponectin with macrophages stimulated with 
lipopolysaccharide (LPS) alters the production of toll-like receptor (TLR)-mediated pro-
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inflammatory cytokines such as IFN-γ, IL-6 and IL-8 and their phagocytosis capabilities 
(Yokota et al., 2000, Wolf et al., 2004). This effect can be mediated by inhibition of the 
action of NF-κB (Yamaguchi et al., 2005).  
 Adiponectin can also induce production of anti-inflammatory cytokines such as IL-10 
and IL-1RA, by monocytes, macrophages and DCs (Wolf et al., 2004; Kumada et al., 2004; 
Wulster-Radcliffe et al., 2004). It has also been reported to alter presentation and co-
stimulation by macrophages (Wolf et al., 2004) and foam cell formation. Recent evidence in 
mice demonstrates a novel effect of adiponectin on DCs function. Indeed, this study shows for 
the first time that adiponectin reduces differentiation of DCs into efficient APCs as it down-
regulates the expression of CD86 as well as up-regulation of PDL-1 (Program death ligand) 
(Tsang et al., 2010). However, these experiments were conducted in media containing bovine 
serum that is likely to contain high levels of adiponectin. These DCs were efficient at 
inducing proliferation of Treg. These observations have been confirmed in humans in our 
group and using serum-free media. Indeed, monocytes derived DCs express lower levels of 
CD86 which alter their capacity to prime antigen-specific T cells responses (Pang et al., 
submitted).  
 It is becoming clear that adiponectin has an anti-inflammatory action on T cells by 
modulating APCs, in consistence with the low expression of adiponectin receptors on T cells 
and very high on APCs. However, direct effects of adiponectin on T cells have also been 
reported (Wilk et al., 2011). In this study, the authors show that adiponectin receptor 
expression is up-regulated upon antigen stimulation, resulting in modulation of cytokines 
profile and induction of apoptosis of antigen-specific T cells. However, these experiments 
were realised in presence of bovine serum which already contains high levels of biologically 
active adiponectin. No direct effect has been reported on B cells. The only effect observed for 
this lineage, is the inhibition of B cell lymphoid progenitor differentiation (Yokota et al., 
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2003). Adiponectin also inhibits neutrophil and NK cell cytotoxic capacities by inhibition of 
superoxide and perforin production respectively (Magalang et al., 2006; Kim et al., 2006). 
 However, controversial data showing pro-inflammatory effects of adiponectin have 
also been reported. It seems that adiponectin can also induce pro-inflammatory cytokine 
production such as IL-6, TNF-α and IL-8, by human monocytes and macrophages as well as 
complement activation and NF-κB stimulation (Tsatsanis et al., 2005; Peake, Shen, 2010; 
Haugen et al., 2007).  
 It has been suggested that the different forms of adiponectin could have different 
functional effects. For example, low and high molecular weight adiponectin induce apoptosis 
of monocytes and activation of macrophages suppression capacities in addition to IL-10 
production, but the high molecular weight form also induce IL-6 secretion by monocytes 
(Neumeier et al., 2006). The exact profile of each form of adiponectin is poorly understood 
and remains to be determined.  
 These effects could also depend on the experimental settings. For example, difference 
in duration of LPS stimulation could influence the responses of monocytes and macrophages 
(Saijo et al., 2005; Tsatsanis et al., 2005). Post-transcriptional modifications observed in 
mammals might also play an important role in adiponectin-mediated action (Richards et al., 
2006), as these are absent from the non-mammalian sources of adiponectin. Finally, it could 
be attributed to LPS contamination, which is observed in all commercially available sources 
of adiponectin (Turner et al., 2009). 
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Figure 1-10: Adiponectin and immunity 
Several studies have reported the anti-inflammatory action of adiponectin on both innate and 
adaptive immunity. Adiponectin reduces antigen-specific T cells responses as well as 
cytokines production and increases rate of T cell apoptosis. Adiponectin can also decrease NK 
cell cytotoxicity but no effect has been reported on mature B cells. Adiponectin interferes 
with APCs differentiation by modulating MHC, co-stimulatory and adhesion molecules 
expression as well as reducing phagocytosis and production of pro-inflammatory cytokines. It 
can also reduce neutrophil function. On the other hand, pro-inflammatory properties have also 
been reported for macrophages and monocytes which display higher capacity to produce pro-
inflammatory cytokines in presence of adiponectin. In addition, adiponectin is able to activate 
the complement and NF-κB pathway. These differences have been attributed to the use of the 
different form of adiponectin but this issue still need to be addressed.  
 
 
3.2.4. Adiponectin modulates immune cells migration 
 Adiponectin concentrations correlate with flow mediated vasodilatation in healthy 
young men (Torigoe et al., 2007) and low adiponectin levels associate with vascular diseases 
such as CVD and atherosclerosis in humans (Zhu et al., 2008). Animal models deficient in 
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adiponectin are more susceptible to vascular disorders (Matsuda et al., 2002). For example, 
knock-out of adiponectin in the apolipoprotein E (ApoE)-/- mice model of atherosclerosis 
accelerates the formation of vascular plaque and its over-expression resulted in a marked 
reduction in atherosclerotic lesions (Okamoto et al.,  2002). 
 Further evidence in the adiponectin knock-out mouse model show that adiponectin 
attenuates rolling, adhesion and migration of leukocytes through endothelium (Cao et al., 
2009, Ouedraogo et al., 2007). In this model, leukocyte rolling and adhesion were increased 
by 2 and 5 fold respectively. This comes with an increase of VCAM-1 and E-selectin on 
endothelial cells and a decrease of nitric oxide (NO) production. When adiponectin was 
administrated to the knock-out mice, these changes were restored.  The mechanism 
underlying the attenuation of transmigration by adiponectin is not fully understood. NO 
production in endothelial cells helps prevent “over-transmigration” by inducing 
vasorelaxation and intensifying the blood flow (Huang et al., 2003).  Some evidence in 
animal models show that adiponectin stimulates the production of NO in vascular endothelial 
cells as well as the phosphorylation of the endothelial NO synthase (eNOS) and this was 
blocked by inhibition of AMPK (Chen et al., 2003; Motoshima et al., 2004).   
 In vitro assay treatment of human aortic EC with adiponectin for 18h along with TNF-
α, reduces adhesion of THP-1 monocytic cells by inhibition of VCAM-1, E-selectin and 
ICAM-1 (Ouchi et al., 2000). In addition, over-expression of AR1 in human EC ameliorates 
adiponectin-mediated suppression of ICAM-1 and NF-κB expression and activation (Zhang et 
al., 2009). In this system this is also mediated by stimulation of NO production (Deng et al., 
2010). 
Other mechanisms involve capture of chemokines by adiponectin. Its complex 
multimeric nature allows binding of the globular heads to chemokines such as SDF-1, MIP-
1α, RANTES, and MCP-1 (Masaie et al., 2007). This affects chemokine signalling and at the 
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same time allows adiponectin to be transported to inflamed tissues where it can regulate EC 
physiology and potentially leukocyte migration. 
3.2.5. Adiponectin in T1D 
 In contrast to the low levels observed in diseases such as obesity and T2D, elevated 
adiponectin concentrations have been reported in chronic inflammatory and autoimmune 
diseases such as T1D, systemic lupus erythematosus, rheumatoid arthritis and osteoarthritis 
(Frystyk et al., 2005; Rovin et al., 2005; Senolt et al., 2006; Filkova et al., 2009). Here, 
adiponectin seem to have contrasting effects. For example, studies have shown a detrimental 
role for adiponectin as it activates pro-inflammatory processes in joints leading to degradation 
of the matrix (Ehling et al., 2006). In contrast, adiponectin has been involved in maintenance 
of cartilage homeostasis in osteoarthritis and anti-inflammatory properties on synovial 
fibroblast from rheumatoid arthritis patients (Chen et al., 2006; Lee et al., 2008).  
 Adiponectin is also higher in adults with T1D (Frystyk et al., 2005; Imagawa et al., 
2002; Perseghin et al., 2003, Zhi et al., 2011). In addition, high levels of adiponectin were 
associated with higher all-cause and cardiovascular mortality (Forsblom et al., 2011). Several 
questions arise from these observations as adiponectin is considered as a protective agent 
against cardiovascular diseases. There are a number of potential explanations. First, the 
recruited patients are old and therefore at risk of large vessels disease. The higher adiponectin 
may therefore be a compensatory mechanism to protect from this complication (Sattar, 2011). 
They are also likely to have completely lost endogenous insulin secretion. This is responsible 
for the higher adiponectin levels observed (Cook, Semple, 2010).  
 Interestingly, circulating adiponectin is decreased in the months before onset of T1D 
but levels appear to be restored to baseline after onset (Truyen et al., 2007). Lower 
adiponectin levels before the onset of T1D could therefore contribute to the development of 
chronic inflammation.  
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4. Hypothesis  and aims 
 
 We hypothesise that differences in the leptin and/or adiponectin axis predispose to the 
activation and/or recruitment of autoreactive T cells to the inflamed pancreatic islets in T1D. 
 
 Our overarching aim is to understand how adipokines modulate autoimmunity in T1D. 
The specific aims of this thesis are: 
1. To characterise the expression and function of leptin and its receptors on PBMC. 
2. To examine the effect of T1D on leptin and its receptors.  
3. To examine the effect of leptin and adiponectin on T cell migration. 
  
 Understanding the mechanism leading to the activation and the infiltration of 
inflammatory cells into the islets is important because it may help develop strategies to 
protect insulin-producing beta-cells from the destructive autoimmune process. The potential 
involvement of leptin and adiponectin is important because therapies such as exercise and 
other drugs may be used to modulate their circulating levels or receptor expression, and 
therefore modulate the recruitment of autoreactive immune cells into the islets.      
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1. Material 
1.1. List of main reagents 
Reagent Supplier 
Catalogue 
number 
Working 
concentration/dilution 
Use/Application 
RNA easy kit Qiagen 74104 NA RNA extraction 
Random primers Promega C1181 NA Reverse transcription 
Superscript II reverse 
transcriptase 
Invitrogen 180-01-002 10U Reverse transcription 
RNase out Invitrogen 10777-019 10U Reverse transcription 
Superscript buffer Invitrogen 18064-14 1X Reverse transcription 
dNTPs Promega U120-3A 10mM 
Reverse transcription, 
conventional PCR 
BioTaq polymerase Bioline 21040 1U Conventional PCR 
MgCl2 Promega 21040 4mM Conventional PCR 
Agarose Bioline BIO-41025 5% Conventional PCR 
Loading buffer Bioline BIO-37045 1X Conventional PCR 
Ethidium bromide Fluka 46067 1X Conventional PCR 
Taqman Master Mix 
Applied 
biosystems 
P02016 1X qPCR 
Lympholyte-H VH Bio CL5010 1X PBMC isolation 
Histopaque 1119 Sigma-Aldrich 11191 1X PBMC isolation 
Histopaque 1077 Sigma-Aldrich 10771 1X PBMC isolation 
PBS Sigma-Aldrich P4417 1X 
Washes, cell sorting, FACS 
staining 
BSA Sigma-Aldrich A7030 5% Cell Sorting Buffer 
EDTA Sigma-Aldrich 93302 200mM Cell Sorting Buffer 
RPMI 1640 
Gibco 
Invitrogen 
21875 1X PBMC culture 
CellGroSCGM CellGenix 10802 1X Cell culture  
CellGroDC CellGenix 20801 1X DCs Differentiation 
M199 
Gibco 
Invitrogen 
31150 1X 
HUVEC culture high serum, 
PBL assays 
Endothelial basal Promocell C-22110 1X HUVEC culture low serum 
Optimem 
Gibco 
Invitrogen 
51985 1X Transfection 
FCS 
Gibco 
Invitrogen 
16000 10-20% PBMC, HUVEC culture 
Penicillin/ Streptomycin 
Gibco 
Invitrogen 
10378016 1:500 Cell Culture 
Gentamycin Sigma-Aldrich G1272 35µg/ml HUVEC culture 
Amphotericin B Sigma-Aldrich A2942 2.5µg/ml HUVEC culture high serum 
Epithelial growth factor (EGF) Sigma-Aldrich SRP3027 10ng/ml HUVEC culture high serum 
Hydrocortisone Sigma-Aldrich H6909 1µg/ml HUVEC culture high serum 
Trypsin 
Gibco 
Invitrogen 
25200056 2.5mg/ml HUVEC culture 
PHA Sigma L1668 2 to 10µg/ml T cell activation 
CD3/CD28 Beads Invitrogen 111.31D 1bead to 8 T cells T cell activation 
PMA Sigma-Aldrich P1585 50ng/ml 
Intracellular Cytokines 
measurements 
Ionomycin Sigma-Aldrich I0634 1µM 
Intracellular Cytokines 
measurements 
Tetanus Toxoid Protein Calbiochem 582231 5µg/ml T cell activation 
Proinsulin B-C peptide Mimotopes NA 10µg/ml T cell activation 
Tetanus Toxoid Peptide Mimotopes NA 10ng/ml Transmigration 
Recombinant Human leptin R/Dsystems 398-LP 0 to 100nM Western Blot, functional assays 
IL-4 Peprotech 200-04 1µg/ml DCs Differentiation 
GM-CSF Peprotech 300-03 1µg/ml DCs Differentiation 
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Reagent Supplier 
Catalogue 
number 
Working 
concentration/dilution 
Use/Application 
LPS Sigma-Aldrich L2654 10µg/ml DCs maturation 
CFSE Invitrogen V12883 1.25nM T cell proliferation 
Recombinant Human Leptin 
R/Fc Chimera 
R/Dsystems 389-LR/CF 50µg/ml Anti-human LEPR blocking 
Propidium Iodide (PI) Sigma-Aldrich P4170 1ng/ml FACS dead cells staining 
FcR Blocker Miltenyi Biotec 120-000-442 1:20 
Fc receptor blocking for FACS 
specific staining 
Permeabilisation buffers eBioscience 00-5523 1X Intracellular staining 
Dextran-FITC Sigma-Aldrich FD-4 0.1mg/ml DCs uptake 
W146 
Cayman 
chemicals 
10009109 1µM Transmigration 
S1P 
Cayman 
chemicals 
62570 0-100µM Transmigration 
CXCL10 Peprotech 300-12 20ng/ml Chemotaxis 
SDF-1α Peprotech 300-28A 250ng/ml Chemotaxis 
Prostaglandin D2 (PGD2) 
Cayman 
chemicals 
12010 1nM Chemotaxis 
IFN-γ Peprotech 300-02 10ng/ml HUVEC activation 
TNF-α R/Dsystems 210-TA-010 100U/ml HUVEC activation 
Adiponectin NovoNordisk NA 0 to 15µg/ml PBL Transmigration 
Nucleofector kit T cells Lonza VPA-1001 NA T Cell transfection 
Lipofectamine RNAi max Invitrogen 13778 3µl in 1ml PBL and HUVEC transfection 
Brefeldin A Sigma-Aldrich B5936 10µg/ml Secretion blockade 
AMPK compound C Merck 171261 1µg/ml Transmigration 
Accutase Sigma-Aldrich A6964 1X Phenotyping transmigrated PBL 
B cell depletion kit StemCell 19054 NA Transmigration 
CD4 enrichment kit StemCell 19052 NA T cell proliferation 
CD19 microbeads Miltenyi Biotec 130-050-301 NA Transmigration 
CD56 microbeads Miltenyi Biotec 130-050-401 NA Transmigration 
CD3 microbeads Miltenyi Biotec 130-050-101 NA Transmigration 
CD25 microbeads Miltenyi Biotec 130-092-983 NA Treg depletion 
CD14 beads Miltenyi Biotec 130-050-201 NA DCs experiments 
LS column Miltenyi Biotec 130-042-401 NA Cell sorting 
Zymosan Sigma-Aldrich Z4250 1mg Mice Peritonitis  
Collagenase Sigma-Aldrich C5894 1X HUVEC isolation 
Gelatin Sigma-Aldrich G1393 2% HUVEC culture 
Table 2-1: List of reagents 
 
1.2. Antibodies 
 The conjugated antibodies used to detect human markers in flow cytometry are listed 
in Table 2-2. Details of the unconjugated primary anti-human antibodies and their conjugated 
secondary are presented in Table 2-3. Conjugated antibodies against mouse markers are 
shown in Table 2-4. 
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2. Methods 
2.1. Measurement of gene expression 
2.1.1. PBMC isolation 
 Venous blood was collected from healthy volunteers, T1D and T2D subjects following 
consent. In some cases, anonymised buffy coats were obtained from the Birmingham blood 
centre. Full ethics approval is in place for this work. PBMC were isolated by density-gradient 
sedimentation over Ficoll-Hypaque by centrifugation at 800g for 25 minutes using 
Lympholyte-H (VH Bio). After centrifugation, PBMC were harvested from the Ficoll-Plasma 
interface and washed twice in fresh RPMI 1640 (Gibco) by centrifugation at 700g for 12 
minutes. At the last wash, cells were resuspended in 10ml of RPMI and counted manually 
using a haemocytometer. Preparations contained both lymphocytes and monocytes 
populations as determined by flow cytometry based on their forward/side scatter profile.  
2.1.2. RNA extraction 
 Total mRNA was extracted using the RNAeasy Minikit (Qiagen) according to the 
manufacturer’s protocol. Briefly, PBMC were first lysed then added to a column, after three 
washes, mRNA was eluted from the column with water. RNA concentration was measured 
using Nanodrop spectrofluorimeter (LabTech) and RNA was stored at -80°C. 
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Table 2-2: Anti-human antibodies used in flow cytometry 
 
Antibody Supplier 
Catalogue 
number 
Clone 
Optimised 
volume for 
100ul 
Use to identified 
Human antibodies 
CD3-APC (allophycocyanin) eBioscience 17-0038-71 UCHT1 5 T cells 
CD3-PerCpCy5.5 (Peridinin 
Chlorophyll Protein 
Complex-Cyanine 5.5) 
eBioscience 45-0037-42 OKT3 5 T cells 
CD4-FITC(Fluorescein 
isothiocyanate) 
eBioscience 11-0048-42 OKT4 5 CD4+ T cells 
CD4-PE (Phycoerythrin) BD Pharmingen 555347 RPA-T4 2 CD4+ T cells 
CD4-PerCP BD Pharmingen 345770 SK3 2 CD4+ T cells 
CD4-TR (Texas Red) eBioscience 93-0048 OKT4 7 CD4+ T cells 
CD4-APC BD Pharmingen 555349 RPA-T4 5 CD4+ T cells 
CD8-PE eBioscience 12-0086-73 OKT8 5 CD8+ T cells 
CD8-PB (Pacific Blue) eBioscience 48-0086 OKT8 5 CD8+ T cells 
CD45RO-APC BD Pharmingen 340438 UCHL1 4 Memory T cells 
CD25-PE Miltenyi Biotec 130-091-024 4E3 7 Treg 
CD25-APC Miltenyi Biotec 130-092-858 4E3 7 Treg 
FoxP3-APC Miltenyi Biotec 17-4776-42 PCH101 7 Treg 
CD19-PECy7 eBioscience 25-0199 HIB19 7 B cells 
CD19-PE BD Pharmingen 12-0199 HIB19 7 B cells 
IgD-PerCpCy5.5 BD Pharmingen 561315 IA6-2 6 B cells subsets 
IgM-FITC Invitrogen MGM01 NA 6 B cells subsets 
CD38-PE BD Pharmingen 555460 HIT2 6 B cells subsets 
CD27-APC BD Pharmingen 337160 L128 7 B cells subsets 
CD56-PE eBioscience 12-0569-42 MEM188 5 NK cells 
CD56-APC eBioscience 17-0567 CMSSB 5 NK cells 
CD14-PE eBioscience 12-0149-73 61D3 5 Monocytes 
CD14-APC eBioscience 17-0149-42 61D3 5 Monocytes 
CD11c-PE BD Pharmingen 12-0116-101 3.9 5 Monocytes, DCs 
HLA-DR-FITC BD Pharmingen 555811 L243 5 Monocytes, DCs 
CD80-FITC BD Pharmingen 557226 L307.4 5 DCs 
CD1a-PE eBioscience 12-0019 HI149 6 DCs 
CD83-APC BD Pharmingen 334098 HB15E 5 DCs 
CD86-FITC BD Pharmingen 555657 2331 5 DCs 
DC-SIGN- PerCPCy5 BD Pharmingen 334098 DCN46 5 DCs 
DP-2 R&D Systems FAB3338F 301108 10 PGD2 receptor 
CD49d/CD29-PE 
(α4β1/VLA-4) 
R&D Systems FAB17781P P5D2 3 Integrin 
CD18/CD11a-FITC 
(αLβ2/LFA-1) 
R&D Systems FAB1730F 212701 3 Integrin 
CXCR3-PE US Biological C8349-02 2Ar1 6 Chemokine receptor 
ICAM-APC BD Pharmingen 559771 HA58 3 Adhesion molecule 
IFN-γ-PE BD Pharmingen 340452 25723.11 0.5 Cytokines 
IL-10-APC BD Pharmingen 554707 JES3-19F1 6 Cytokines 
IL-21-APC BD Pharmingen 560463 3A3 N2.1 3 Cytokines 
IL-2-PE BD Pharmingen 341116 5344.111 0.5 Cytokines 
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Antibody Supplier 
Catalogue 
number/Clone 
Working 
Concentration 
Unconjugated primary antibodies 
Mouse Anti-LEPR R/D Systems MAB867/52263 10µg/ml 
Mouse IgG2b Isotype control eBioscience 14-4737-85 10µg/ml 
Mouse Monoclonal Anti- Leptin Sigma L-3160/LEP-13 10µg/ml 
Rabbit anti-AR1 Phoenix Peptides G-001-44 5µg/ml 
Rabbit anti-AR2 Phoenix Peptides G-001-23 5µg/ml 
Rabbit anti-S1PR1 Cayman biochemicals 10005228 5µg/ml 
Rabbit anti-S1PR4 Cayman biochemicals 13489 5µg/ml 
Mouse anti-E-selectin Sigma-Aldrich S-9555/1.2B6 1/100 
Rabbit anti-VCAM Abcam Ab58838-100 1/100 
Conjugated secondary antibodies 
Donkey anti-mouse AlexaFluor 488 Invitrogen A-21202 1/400 
Goat anti-rabbit AlexaFluor 488 Invitrogen A-11008 1/250 
Isotypes 
IgG1-APC Ebioscience 17-4714 0.5-7µl 
IgG1-FITC Ebioscience 11-4614-80 0.5-7µl 
IgG1-PE BD Pharmingen 534680 0.5-7µl 
IgG1-PB Biolegend 400131 0.5-7µl 
IgG1-PerCpCy5.5 Biolegend 400531 0.5-7µl 
Table 2-3: Unconjugated primary, conjugated secondary antibodies and isotype controls 
used in flow cytometry 
 
Antibody Supplier 
Catalogue 
number 
Clone 
Optimised volume 
for 100ul 
Use to identified 
Mouse antibodies 
CD3-FITC eBioscience 11-0031 145-2C11 1:50 T cells 
CD3-PECy7 eBioscience 25-0031 145-2C11 1:50 T cells 
CD4-PB eBioscience 48-041 GK1.5 1:100 CD4+ T cells 
CD8-TR Invitrogen MCD0817 5H10 1:200 CD8+ T cells 
CD11c-PECy7 eBioscience 25-0114 N418 1:50 DCs 
CD19-APC eBioscience 1D3 17-1093 1:50 B cells 
CD44-FITC eBioscience IM7 11-0441 1:500 
Naive/ effector/ 
memory T cells 
CD45-PerCpCy5.5 eBioscience 30-F11 45-0451 1:200 Leukocytes 
CD62L-PE eBioscience MEL-14 12-0621 1:500 
Naive/ effector/ 
memory T cells 
B220-APC Cy7 eBioscience RA3-6B2 51-0452 1:100 B cells 
gp38-PE eBioscience 8.1.1 12-5381 1:200 Macrophages 
F4/80-APC AbD Serotec CI:A3-1 MCA497APCT 1:20 Macrophages 
Table 2-4: Anti-mouse antibodies used in flow cytometry 
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2.1.3. Reverse transcription 
 To convert RNA to cDNA, random primers (Promega) were annealed to 1µg of 
mRNA for five minutes at 70°C, after which the following mastermix was added to give a 
final volume of 30µl: 10U Superscript II Reverse Transcriptase (RT), 10U RNAout RNase 
inhibitor, 1X Superscript Buffer  (all from Invitrogen) and 10mM dNTPs (Promega). The 
reaction was run at 37°C for one hour, followed by five minutes at 95°C. Reactions run 
without RT were used as negative controls. 
2.1.4. Conventional PCR 
 cDNA (2µl) was amplified using Taq DNA polymerase (1U)(Promega), 
MgCl2(4mM), dNTPs (2mM), the appropriate primers at 100μM (Table 2-5) and water to 
complete to  20μl. The reaction was began at 95°C for 5 minutes, then a denaturation step (1) 
at 94°C for 1 minute, followed by primer annealing (2) during one minute, at the appropriate 
temperature depending on the pairs used (62 to 70°C) and a elongation step (3) at 72°C for 
one minute. Step 1, 2 and 3 were repeated for 35 cycles and followed by two minutes at 72°C 
and 4°C at the end of the reaction. The PCR products were then ran on a 5% agarose 
electrophoresis gel containing ethidium bromide. 
 
Target Forward  (5'-3') Reverse (5'-3') 
Predicted 
product size 
(bp) 
For conventional PCR 
Leptin CAGCGGTTGCAAGGCCCAAGAAGCCC GAGGAGACTGACTGCGTGTG 300 
lLEPR GAAGATGTTCCGAACCCCAAGAATTG CTAGAGAAGCACTTGGTGACTGAAC 427 
sLEPR GGGAAGTTGGGCACATTGGGTTCA CCATTGAGAAGTACCAGTTCAGTCTTTACC 329 
AR1 TGCCCTCCTTTCGGGCTTGC GCCTTGACAAAGCCCTCAGCGATAG 526 
AR2 GGAGCCATTCTCTGCCTTTC ACCAGATGTCACATTTGCCA 467 
For real-time PCR 
sLEPR 
Forward :CACACCAAAGAATGAAAAAGC 
Reverse:AGAATGTCCGTTCTCTTCTGA 
Probe: CCCCAAGAATTGTTCCTGGGCA 140 
Table 2-5: Probes and primers used for conventional and real-time PCR 
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2.1.5. Real-Time PCR 
 Quantitative PCR (qPCR) was performed in duplicate and triplicate on a real-time 
PCR machine (Stratagene) or ABI 7500 (Applied Biosystems). Each reaction was composed 
of the adequate quantities of both reverse and forward primers, Taqman probes, Taqman 
Universal Mastermix (Applied Biosystems), endogenous controls: hypoxanthine 
phosphoribosyltransferase 1(HPRT1) or 18S, cDNA and nuclease free water at a total volume 
of 25µl. For leptin and its long form receptor (lLEPR), Taqman gene expression assay kit 
(Hs00174492_m1 for lLEPR and Hs00174877-m1 for leptin) designed by the manufacturer 
(ABI) were used, and for the short leptin receptor isoform (sLEPR), custom primers and 
probe were designed (Eurogentec) (Table 2-5). For both receptors, primers and probes were 
picked to target the intracellular region on the receptors enabling to differentiate the different 
isoforms. Relative quantification of leptin and sLEPR and lLEPR gene expression, 
normalised to HPRT1 ran in duplex and was calculated by the ΔΔCt method, after validating 
their relative efficiencies on a standard curve. Samples were considered valid when ΔCt SD > 
0.3 (see Chapter 3). Expressions of AR1 (Hs00360422_m1), AR2 (Hs00226105_M1), 
ICAM-1 (Hs0016932_m1), VCAM-1 (Hs00365486_m1), E-selectin (Hs00174057_m1), 
CXCL9 (Hs00171065_m1), CXCL10 (Hs00171042_m1), CXCL11 (Hs00171138_m1), 
SPHK1 (Hs01116530_g1), SPHK2 (Hs00219999_m1), SIPR1 (Hs00173499_m1), S1PR4 
(Hs02330084_s1) were realised in singleplex reactions on the ABI 7500. Relative expression 
was calculated by the ΔΔCt normalised to 18S. All the probes used were labelled with a FAM 
(tetrachlorofluorescin) marker except for the endogenous controls that were labelled with a 
VIC marker. Relative expression units (REU) were calculated using the following equation: 
REU= 2 ΔCt. 
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2.2. Measurement of protein expression 
2.2.1. Flow cytometry 
 About 106 PBMC were centrifuged at 700g for 7 minutes in polyprene tubes (BD 
Bioscience), resuspended by gentle agitation and pre-incubated 2 minutes with 3 µl of FcR 
Blocker (Miltenyi Biotec). For immunophenotyping, PBMC were stained for 20 minutes at 
4°C with antibodies for PBMC markers (Ebioscience, BD Pharmingen, and Miltenyi Biotec) 
used at the manufacturer’s recommended concentration (Table 2-2).  
Where directly conjugated antibodies were not available, the following primary and 
secondary antibody combinations were used to analyse expression of LEPR, leptin, AR1/2, 
S1P1/4, E-selectin and VCAM-1 as follows (Table 2-3). PBMC were stained with the 
relevant unconjugated monoclonal antibodies during 20 minutes at 4°C. Subsequently 
samples were labelled with the relevant secondary antibodies conjugated to Alexa 488 (same 
channel as FITC on the flow cytometer) for 20 minutes at 4°C. Isotype controls and secondary 
only conditions were used as negative controls.  
 For intracellular staining, the Ebioscience permeabilisation/fixation kit was used 
following the manufacturer’s protocol. Briefly, PBMC were first permeabilised and fixed in 
1:4 ratio of permeabilisation/fixation solution 1 and 2 during 30 minutes at 4°C. The cells 
were then washed in the permeabilisation buffer at 700g for 10 minutes. 10 µl of FcR Blocker 
were then added to the cells suspension and PBMC were stained with the relevant antibodies 
for 30 minutes at 4°C.  
 Samples were assayed using a FACSCalibur (BD Pharmingen) with Cell quest 
software or a Cyan (Dako) with Summix software and then analysed using FlowJo software. 
Viable cells were routinely gated using Propidium Iodide (2µ/tube) (PI) and using side-
forward scattering. Between 10000 and 50000 events per sample were recorded and plotted as 
frequency of positive cells or mean fluorescence intensity (MFI). 
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2.2.2. Western Blot 
 PBMC cell lysates were obtained in a lysis buffer containing 1% Triton X, 50mM Tris 
HCl pH8.0, 150mM NaCl and protease inhibitor cocktail (Sigma).  Total cellular proteins 
were analysed using 12% SDS-PAGE under reducing conditions as previously reported. After 
electrophoresis, proteins were transferred onto a nitrocellulose filter membrane (Amersham) 
using the I-Blot semi-dry transfer system (Invitrogen). Membranes were blocked with 8% 
non-fat milk in PBS 0.5% Tween for one hour at room temperature and then incubated 
overnight at 4°C with the primary antibody at 1/500 to 1/1000 dilutions. Membranes were 
subsequently washed 3 times in PBS 0.5 % Tween, incubated one hour at room temperature 
with a secondary goat anti-mouse or goat anti-rabbit IgG antibody conjugated to horseradish 
peroxidise (Dako) and washed again 3 times in PBS 0.5 % Tween. Peroxidase 
chemifluorescent activity was detected with the ECL Plus system (Amersham). To confirm 
the specificity of the bands detected, samples stained with secondary antibody alone or 
recombinant proteins to block the antibodies during 12 hours before probing were performed 
(Burnette, 1981). 
2.3. ELISA assay 
 Serum leptin levels were measured in healthy, T1D and T2D subjects using leptin 
Quantikine ELISA kit (R/D Systems) following the manufacturer’s protocol. Serum samples 
were diluted 1:20 in buffer and plates were read using the Victor Multilabel 1420 counter 
machine (Wallac-PerkinElmer). The leptin concentrations in the serum were determined using 
the calibration curve determined using recombinant leptin and were expressed as ng/ml. 
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2.4. Cell sorting 
2.4.1. Positive selection of PBMC subsets 
 Sub-populations of the following mononuclear leukocytes were obtained by magnetic 
cell sorting out of pre-isolated PBMC from whole blood following the manufacturer protocol: 
monocytes (CD14), CD3+T cells, B lymphocytes (CD19), and NK lymphocytes (CD56). 
Briefly, whole PBMC were pelleted at 700g for 10 minutes, labelled with the appropriate anti-
CD microbeads and incubated 15 minutes at 4°C. Cells were then washed in PBS 0.5% BSA 
2mM EDTA (MACS buffer) and loaded on the prepared LS column (magnetic column) 
(Miltenyi Biotec) placed in the magnetic field. Unlabelled cells that pass through the column 
were collected and column was washed three times with 3ml of MACS buffer. The column 
was then removed from the magnetic field and magnetically labelled cells were flushed out 
the column by adding 5ml of buffer and flush out a second time with 2ml of buffer. Samples 
were then counted and labelled with the appropriate anti CDs. Purity and yield was checked 
by flow cytometry. Purity between 80%-98% was obtained for each sorting and was 
considered satisfactory. 
2.4.2. Negative selection of PBMC subsets 
 In some conditions, it is essential to use negatively selected or “untouched” PBMC as 
for instance anti-CD3 microbeads activates T cells and B cells seem to be sensitive to CD19 
microbeads.  
 CD4+ CD25- T cells and CD19+ B cells were sorted by depletion using the EasySep 
enrichment kits according to the manufacturer’s instructions (Stemcell). Briefly, the antibody 
cocktail was added at 50 µl for 5.107 cells in a 15ml falcon tube for 10 minutes at room 
temperature. The dextran-coupled beads were added at 75µl per 5.107 cells for 5 minutes at 
room temperature. Total volume was adjusted to 9ml with MACS buffer and the tube was 
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places in the magnet for 5 minutes. Purified cells were then poured into a new tube and these 
last two steps were repeated twice to increase purity. CD4+ CD25-T cells were then isolated 
by CD25+ depletion using anti-CD25 microbeads. Cell sorting purity was assessed by flow 
cytometry. Purity between higher than 96% was obtained for each sorting and was considered 
satisfactory. 
2.5. DCs Phenotyping and function 
2.5.1. Monocyte-derived DCs generation 
 Monocytes were isolated by magnetic cell sorting in sterile conditions (described 
section 2.4.1) and resuspended in serum or serum-free media (CellGroDC supplemented with 
PS and Glutamine). CD14+ monocytes (5.105) were suspended in 500μl of media in 24-wells 
plate. IL-4 and recombinant human granulocyte macrophage colony stimulating factor (GM-
CSF) were added to the wells at a final concentration of 1000U/ml each. For some conditions, 
leptin was added to the DCs at 10nM. Cultures were incubated at 37°C for a total period of 
5/6 days and were re-fed at day 2 with either media with serum or CellGroDC containing IL-4 
and GM-CSF at 1000U/ml.  
 Isolated monocytes as well as DCs at day 5/6 were labelled with antibodies against 
CD14, CD1a, CD80, CD83, CD86, DC-SIGN and HLA-DR and analysed by flow cytometry. 
Immature DCs (imDCs) were defined as cells with the following expression profile: CD14-, 
DC-SIGN+++, CD1a+++, HLA-DR++, CD86+, CD80+ and CD83+. 
2.5.2. imDC dextran-FITC uptake 
 imDCs were generated as previously described. 250000-500000 imDCs were 
transferred into cold (4°C) or 37°C tubes, washed in cold or warm PBS and finally 
resuspended in 1ml of cold or warm PBS. Dextran-FITC (Sigma) was added at 0.1mg/ml 
during 10 minutes at 4°C or 37°C. Cells were then washed two times at 700g during 10 
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minutes at 4°C in cold PBS. Finally, cells were transferred to polyprene tubes and analysed by 
flow cytometry. Dextran-FITC uptake was calculated by subtracting the mean fluorescence 
intensity (MFI) at 4°C to the MFI at 37°C. 
2.6. T cell responses measurement 
2.6.1. CFSE labelling 
 Whole PBMC or CD4+CD25- sorted T cells were labelled with CFSE in order to 
follow their proliferation in response to the different stimuli, such as PHA 
(phytohemagglutinin), CD3/CD28 beads, anti-CD3 and Tetanus Toxoid protein. Cells were 
washed twice in PBS to remove all traces of foetal calf serum (FCS), counted and 
resuspended at 2.107 cells/ml in PBS. CFSE was added to the cells at a ratio of 1:1 at a 
concentration of 2.5µM, vortex and incubated for 10 minutes under agitation at room 
temperature. After 10 minutes, an equal volume of FCS was added to the solution to quench 
the labelling reaction and incubated 1 minute. Cells were then washed twice in RPMI 1640 
and resuspended to the desired concentration in the appropriate media. 
2.6.2. Cell stimulation 
 PBMC or CD4+CD25- T cells and monocytes were cultured in serum (RPMI 1640 
supplemented with Penicillin/Streptomycin (PS) and 10% FCS and serum-free conditions 
(CellGroSCGM supplemented with PS).  
 To assess T cell responses, T cell proliferation was followed on whole PBMC or fresh 
sorted CD4+CD25- T cells using either monocytes or imDCs as APCs or CD3/CD28 beads as 
stimulator. 
 For basic PBMC or CD4+CD25- T cells with monocytes stimulation, 2.105CFSE-
labelled PBMC or CD4+CD25- T cells were suspended in 100μl of culture media in a 96-wells 
plate. Cells were stimulated for either 3 days in the presence of 3-5µg/ml PHA, CD3/CD28 
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beads (8:1 ratio) or 0.5µg/ml anti-CD3 antibody OKT3 (gift from Prof David Samson, 
University of Birmingham) made up in 50µl. 2.104 monocytes were added to CD4+CD25- T 
cells to provide co-stimulation. 
 For stimulation of CD4+CD25- T cells with imDCs. In order to provide an allogenic 
stimulation, after sorting CD4+CD25- T cells were transferred in a flask in serum media, 
incubated for 5/6 days during the DCs generation. At day 5/6, CFSE labelling was performed 
on the CD4+CD25- T cells, before co-culture with the imDCs. T cells were plated at a 
concentration of 2.105cells per 100µl in a 96-round bottom well plate either in serum or 
serum-free condition with 2.104 imDCs and 0.5µg/ml of anti-CD3 during 3-4 days. 
For antigen-specific response measurement, 5µg/ml of Tetanus Toxoid protein from 
Clostridium tetani (Calbiochem) was added to the assays and incubated for 7 days. 
Proliferation was analysed by flow cytometry by measurement of CFSE dilution.  
2.6.3. Intracellular cytokine staining 
 CD4+CD25- T cells stimulated with CD3/CD28 Dynabeads for 5 days were re-
stimulated with 50ng/ml of PMA and 1μM of ionomycin for 6 hours. Protein trafficking and 
secretion was then stopped by addition of 10μg/ml of Brefeldin A for 4-5 hours. Cells were 
then transferred to a FACS tube and fixed 10 minutes at room temperature in 3% PFA in PBS. 
Cells were then centrifuged 5 minutes at 700g, permeabilised with 50μl of 0.1% Saponin and 
centrifuged 5 minutes at 700g. Goat serum was added to block unspecific staining prior to 
antibodies labelling. Cells were washed two times and analysed by flow cytometry. 
2.7. Adhesion and migration assays 
2.7.1. Human Umbilical Vascular Endothelial Cells (HUVECs) culture 
 Human umbilical cords were obtained from the Women’s Hospital, Birmingham. Full 
ethics approval is in place for this work and written consent was obtained before sample was 
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taken. Endothelial cells were isolated using collagenase digestion as previously described 
(Cooke et al., 1993). Briefly, cords sections of about 3-4 inches, without clamp or needle 
damages were sprayed with ethanol 70%. The vein was cannulated and washed twice with 
PBS, incubated with collagenase (1X) and incubated at 37°C for 15 minutes. Cords were then 
massaged for one minute and flushed with PBS into a new tube. Cells were centrifuged at 
400g for five minutes and resuspended in 5 ml of complete M199 medium (Gentamycine 
sulphate, 35μg/ml; human epidermal growth factor, 10ng/ml; hydrocortisone, 1μg/ml; 
penicillin-streptomycin, 1/500; amphotericin, 2.5µg/ml; gentamycin, 35µg/ml and 20% heat 
inactivated FCS). HUVECs were cultured in 4ml of M199 complete media in 25cm2 flasks 
pre-coated with 2% gelatine. 
 Confluent HUVECs were washed with a 0.02% EDTA solution and trypsinised. One 
flask of HUVECs was resuspended in 8ml of low serum endothelial media and seeded in 8 
wells of a 12-wells plate. 24 hours later, medium was replaced with low serum endothelial 
medium containing 10ng/ml IFN-γ and 100U/ml TNF-α for 24 hours.  
For the flow conditions, HUVEC were seeded in Ibidi slides (Ibidi). After 24 hours, classic 
media was replaced by low serum medium containing 10ng/ml IFN-γ and 100U/ml TNF-α for 
24 hours.  
 HUVEC were treated with either 10nM of leptin or 0.0001 to 10μg/ml of adiponectin 
for 24 hours prior to migration along with the TNF-α/IFN-γ treatment. Due to the AMPK 
inhibitor Compound C (AMPKi) toxicity overnight, TNF-α/IFN-γ treated HUVEC were 
incubated 30 minutes with 1μg/ml of AMPK inhibitor. The compound was then washed and 
adiponectin was added for one hour and finally washed prior to transmigration assay. 
 HUVEC were also purchased from Provitro, passaged three times in low serum 
endothelial media (Promocell) and frozen in low serum CryoSFM freezing media 
(Promocell). Four days before the transmigration experiment, HUVEC were defrosted and 
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cultured into 25cm2 flasks. After 2 days, cells were transferred into 12 well plates and used in 
transmigration assay. 
2.7.2. PBL Migration assay through HUVECs endothelium 
2.7.2.1. Static assays 
 PBMC were isolated from blood by histopaque gradient. Lymphocytes were prepared 
by panning PBMC onto culture plastic during 30 minutes at 37°C to remove the monocytes 
(Rainger et al., 2001). Peripheral Blood Lymphocytes (PBL) were then counted, resuspended 
in M199 2% BSA at 1million cells/ml. Prior to transmigration, 1.106 PBL were treated with 
adiponectin at 0.0001 to 15μg/ml at room temperature under agitation and washed after one 
hour. 
 For the AMPKi experiments, 1.106 cells were incubated 30 minutes at room 
temperature under agitation with AMPKi compound C at 10μg/ml. Cells were then washed 
and incubated one hour with adiponectin as described above. 
 To obtain the following PBL subsets listed in Table 2-6, we used negative or positive 
selection as described in section 2.4: 
 
 Before addition of lymphocytes, HUVEC were washed twice with M199 0.15% BSA 
to remove the excess cytokines. 1x106of PBL or different fractions listed above, were added 
to the HUVEC for 6 minutes at 37°C. 
 
 Non-adherent cells were removed by gentle wash with M199 0.15% BSA. Each well 
was then video recorded using a phase-contrast videomicrosope. To measure the percentage 
of migration, five fields were briefly and randomly recorded. Velocity of cells underneath the 
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endothelium was recorded during 5 minutes on a single field. Videomicroscopy was realised 
in a Perspex box allowing maintenance of temperature at 37°C (Figure 2-1a).  
Table 2-6: List of PBL subsets and treatments used in adhesion and migration assays 
 
2.7.2.2. Flow assays 
 The Ibibi slide was connected to a Harvard withdrawal syringe pump, which delivered 
flow at a rate equivalent to a wall shear stress of 0.1 Pa. At the other end, the channel was 
connected to an electronic switching valve (Lee Products, Gerards Cross, UK), which selected 
flow from two reservoirs containing PBL in PBS 0.02%BSA (PBSA) or cell-free PBSA 
(Figure 2-1a, c). PBL were perfused for 4 minutes over the HUVEC followed by cell-free 
wash buffer during approximately 2 minutes. Video recordings were made of a series of 
microscope fields along the centreline of the flow channel after the 2 min of washout. 
Fraction Definition Mode of selection 
Concentration , 
ratio 
Treatments 
T cells CD3+ T cells 
Positive selection of 
CD3+ B cells 
1x106 Adiponectin- 1h 
Bs-ve PBL B cell negative PBL 
Positive selection of 
CD19+ B cells 
1x106 
Adiponectin- 1h 
S1P-30min 
Bs reconstitution 
B cell negative PBL + 
B cells added back 
Negative selection of 
B cells added back 
10:1 (Bs-vePBL: 
B cells added 
back) 
Adiponectin on B 
cells added back-1h 
Pre-treatment of Bs-
ve PBL with W146 
(10µM) for 30min 
 
NKs NK cells 
Positive selection of 
CD56+ NK cells 
1x106 Adiponectin- 1h 
Bs + NKs 
NK cells + B cells 
added back 
Bs:Negative selection 
of B cells added 
back;  NKs: Positive 
selection of CD56+ 
NK cells 
10:1 (NKs: B 
cells added back) 
Adiponectin on B 
cells added back-1h 
NKs + Ts NK cells + T cells  
Ts: Positive selection 
of B cells and NK 
cells; NKs: Positive 
selection of CD56+ 
NK cells 
10:1 (Ts: NK 
cells added back) 
Adiponectin on NK 
cells added back-1h 
Sup Bs PBL 
Supernatant B cells on 
Bs-ve PBL 
Negative selection of 
B cells  
1x106 
Adiponectin on B 
cells, centrifugation 
and supernatant 
added on Bs-ve 
PBL for 30 min 
BrefA Bs PBL 
B cell negative PBL + 
B cells treated with 
Brefeldin A added back 
Negative selection of 
B cells added back 
10:1 (Bs-ve PBL: 
B cells added 
back) 
Brefeldin A-4h and 
adiponectin in the 
last hour 
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Figure 2-1: Illustrations of the static and flow systems 
(a) Photographic representation of the system used to record PBL adhesion and migration. A: 
Perspex box, B: Phase contrast microscope, C: Heating block, D: Harvard withdrawal syringe 
pump, E: Video camera, F: computer. (b) In both static and flow assays, phase bright PBL 
(white circles) are firmly adhered on the top of the endothelium and phase dark PBL (black 
spread cells) have transmigrated across the endothelium. (c) Schematic representation of the 
flow system. (d) Example of a field recorded with a phase bright PBL circled in green and a 
phase dark PBL circled in red. 
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2.7.2.3. Analysis of the video recordings 
 The recordings were analysed with Image-Pro 6.2 software (Media Cybernetics). In 
both static and flow conditions, phase bright lymphocytes on the HUVEC surface were 
classified as adherent (typically with distorted shape and actually migrating slowly on the 
surface). Phase dark lymphocytes were identified as transmigrated cells (spread and migrating 
below the surface of the HUVEC) (Figure 2-1b, d). Both populations were counted and 
averaged for the 5 fields and the percentage of transmigrated lymphocytes was calculated. 
The number of total adherent cells was calculated in cells per mm2 using the calibrated 
microscope field dimensions and multiplied by the known surface area of the HUVEC to 
calculate the total number of adherent cells. Total adhesion normally ranged between 350 to 
680 cells/mm2 on stimulated endothelium. Under flow conditions, some phase bright adherent 
lymphocytes were classified as rolling-adherent (spherical cells moving over the surface much 
slower than free flowing cells). 
2.7.3. Phenotyping of migrating lymphocytes 
 After acquisition, HUVEC monolayers were gently washed with EDTA 0.02% until 
adherent lymphocytes were removed (top fraction) in both static and flow assays. HUVEC 
were treated with accutase for 30s at 37°C and the reaction was blocked by adding M199 10% 
FCS. Both top and migrated lymphocytes fraction were harvested and labelled for flow 
cytometry. 
2.7.4. Adiponectin receptors, SPHKs knock-down 
2.7.4.1. On HUVEC 
 HUVEC were plated in a 12 well plate (87500 cells per well) for 24 hours or until 
about 80% confluence. The relevant siRNA (Table 2-7) were added at a final concentration of 
50nM to 83.75µl or 82.5µl if duplex of Optimem media, 1.5µl of RNAi Lipofectamine was 
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mixed with 13.5µl of Optimem and these were incubated 10 minutes at room temperature. 
15µl of Lipofectamine mix was added to each siRNA singleplex or duplex, gently mixed and 
incubated for a further 10 minutes. HUVEC were washed twice with PBS and 400µl of 
Optimem was added to the Lipofectamine siRNA duplexes. After gentle agitation, the mix 
was added on the HUVEC and incubated at 37°C for four hours. The mix was then replaced 
with the classic low serum media without antibiotics. After 48 hours, HUVEC were 
stimulated with TNF-α/IFN-γ for an additional 24 hours before measuring PBL adhesion and 
migration as described previously. For the SPHKs knock-down experiments, siRNA 
concentrations were increased to 100nM and transfection was realised twice, once as before, 
then left for 24 hours and once prior to cytokines stimulation. Scramble siRNAs (Thermo 
Scientific) pool and untransfected cells were used as negative controls. 
 
 ON-TARGETplus SMART pool (Thermo Scientific) 
Target siRNA1 siRNA2 siRNA3 siRNA4 
AR1 GACAAGAGCAGGCGUGUUC GGCUAAAGGACAACGACUA CCUUUAUGCUGCUCGAAUU GAGAAGGGCAAACGGGUAA 
AR2 GGAGUGAGGUACAAGACGA GAGAAGAACUUGAACGUUU CAGACUUGCUCUUCGGUCA GAAGGUCGGUGGCGAGUGA 
SPHK1 GGAAAGGUGUGUUUGCAGU GAAAUCUCCUUCACGCUGA GAUGGGGAAUUGAUGGUUA CGACGAGGACUUUGUGCUA 
SPHK2 CCACUGCCCUCACCUGUCU GCUCCUCCAUGGCGAGUUU GAGACGGGCUGCUCCAUGA CAAGGCAGCUCUACACUCA 
Table 2-7: Sequences of siRNA pool used for HUVEC and lymphocytes 
 
2.7.4.2. On lymphocytes 
 Transfection of PBL with the relevant siRNA (Table 2-7) was performed using the 
Amaxa technology following the manufacturer’s instructions (Lonza). Briefly, 1x106 PBL in 
100µl of Nucleofactor buffer was supplemented with 100nM of the relevant siRNA, scramble 
control or siRNA-FTIC (ThermoScientific). The mix was transferred to an electroporation 
cuvette and programme U-014 was applied on the Amaxa machine. At the end of the 
program, 500µl of RPMI 10% FCS without antibiotics was added to the cuvette and the mix 
was transferred to 1.4ml of RPMI 10% FCS into a 6 well plate. PBL were also transfected 
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using a lipid-mediated delivery. The relevant siRNA (Table 2-7) were added at a final 
concentration of 100nM to 9.5µl or 9µl if duplex of Optimem media, 2µl of RNAi 
Lipofectamine was mixed with 8µl of Optimem and these were incubated 10 minutes at room 
temperature. 10µl of Lipofectamine mix was added to each siRNA singleplex or duplex, 
gently mixed and incubated for a further 10 minutes. After gentle agitation, the mix was 
added on the PBL, 80µl of RPMI 10%FCS without antibiotics was added and the cells were 
transferred into a 96 well plate.   
For both mode of transfection, PBL were incubated for 48 hours before staining for the 
relevant targets and analysis by flow cytometry. 
2.8. Identification of Agent X 
2.8.1. Purification of supernatants 
 B cells (2x105-5x105) were incubated in presence or absence of adiponectin at 
15µg/ml. Adiponectin (15µg/ml) was added in M199 and used as a negative control. The 
peptides from the three samples were purified using C18 solid phase extraction column from 
Supelco (DSC-18). The column was conditioned by adding 1ml of 0.1% trifluoroacetic acid 
(TFA) in acetonitrile (ACN), which like all additions was allowed to drip through the under 
column under gravity. The column was then equilibrated with 0.1% TFA/water and the 
sample, adjusted to 0.1% TFA, was added to the column.  The column was washed with 1ml 
of 0.1% TFA/water and the peptides eluted using 0.1% TFA/acetonitrile (1ml) which was 
dried under vacuum and the samples resuspended 20 l in 0.1% formic acid in 2% 
acetonitrile.  
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2.8.2. Mass spectrometry 
2.8.2.1. Principle 
 The samples were analysed using the (Liquid chromatography) LC-MS/MS (Tandem 
Mass spectrometry) system described in Figure 2-2. The sample was sprayed in the mass 
spectrometer after the peptides were resolved using a C18 reverse phase nano-bore column 
using High pressure Liquid Chromatography (HPLC). Briefly, in this approach the samples 
are loaded onto the column in a low concentration of solvent allowing virtually all the 
peptides to bind, and the peptides are then eluted using a gradient of increasing solvent such 
that the more hydrophobic the peptide is the longer it is retained on the column. 
 
Figure 2-2: Schematic representation of the mass spectrometry system used for the 
identification of Agent X. 
 
 
 The HPLC eluate is linked directly to an electro spray ionization (ESI) based mass 
spectrometer which generates gas phase ions in the electrospray source by creating a very fine 
aerosol (a Taylor cone) as the eluate exits the end of the nano-bore HPLC system, that 
facilitates evaporation of the eluate liquid.  This is aided by heating the source (180oC). By 
applying a strong electric field (1-2 Kv) to eluate the peptides becoming ionized and are 
drawn into the mass spectrometer by an electrostatic attraction where they are transferred into 
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the actual ion-trap using quadrupoles to direct their movement. The ion-trap allows separation 
of the ions according to their mass to charge ratio (m/z). The ion trap works by trapping ions 
between five electrodes by applying an electromagnetic field in three dimensions and an 
initial MS analysis determines the charge to mass ratio (m/z) of the ions in the sample.  The 
ion-trap is then programmed to isolate the most abundant ion species and fragment it by 
increasing vibrational energy and intruding a small amount of nitrogen such that the ions 
collide with the inert gas and the break or fragment (collision induced dissociation or CID), 
typically at the peptide bond.  The m/z values of the fragments are then determined which is 
termed MS/MS.  Some newer mass spectrometers can also fragment ions using a different 
approach, termed electrotransfer dissociation (ETD), which is complementary to CID.  LC-
MS/MS displays high resolution and sensitivity and allows fragmentation of the selected 
parent ions giving products ions, essential to determine the sequence of the parent ion and 
identify the peptide in a protein database.  
2.8.2.2. Experimental design 
 10l of the purified samples was subjected to an LC-MS/MS analysis using a gradient 
of 2-36% ACN in 0.1% formic acid over 30 min at 350nL/min using a Dionex Ultimate 3000 
HPLC system. The HPLC column was an Acclaim PepMap100 (75M I.D. x 25cm C18 3uM 
particle size) connected to a Bruker ETD Amazon ion trap mass spectrometer with an online 
nanospray source fitted with a metal needle with a 10M tip. 1,600 volts was applied to the 
end plate and the drying gas set to 6.5 litres/min at 180oC.  An MS survey scan from 350 to 
1600 m/z was performed and the five most intense ions in each survey scan were selected for 
CID (collision induced dissociation) fragmentation. After ions were fragmented twice they 
were placed on an exclusion list for 0.5 min. The raw data was processed using the Bruker 
DatAnalysis peak detection program to select peaks which were then searched using the 
Mascot search engine (version  2.1) using the SwissProt protein database. The minimum mass 
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accuracy for both the MS and MS/MS scans were set to 0.5Da and no protease selection was 
used.  The peptides were filtered using a minimum Mascot score of 30.  The data output was 
analysed via the Bruker ProteinScape software package. 
2.9. In vivo experiments 
2.9.1. Mice 
 C57BL/6 and BALB/c mice were housed in the animal facilities at the University of 
Birmingham. BALB/c B cells knock-out (Jh-/-) were generated and kindly donated by Lucy 
Walker. All experiments were performed in accordance with United Kingdom Home Office 
regulations. Mice were used between 6 and 8 weeks of age and were sex and age matched 
unless otherwise indicated.  
2.9.2. Peritoneal inflammation 
 Peritonitis was induced by the intraperitoneal injection (IP) of 1mg type A zymosan as 
previously described (Rajakariar et al., 2008). Peritoneal cavity washout cells were collected 
with PBS at 48h post injection. Erythrocytes in the peritoneal exudates were lysed and cells 
were enumerated with a Counter Coulter before FACS staining (antibodies Table 2-3). Tubes 
containing the cells from the peritoneal exudates were fully acquired on the FACS to 
accurately count the cells. Gates were set up on all cells in the peritoneum and the number of 
T cells was determined based on CD3 expression. Blood was drawn by cardiac puncture 
under the armpit and processed like the peritoneal exudates.  
 
Agent X was administrated to the B cell KO mice as following: 
Day 1: Intravenous tail injection of Agent X or scramble (100µg) 
Day1 + 4 hours: Intraperitoneal injection of Zymosan (1mg) or PBS + Agent Xor scramble 
(100µg) 
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Day 1 + 24 hours: Intravenous Tail injection of Agent X or scramble (100µg) 
Day 1 + 48h: Cardiac puncture + peritoneal lavage  
 
3. Statistics 
 
 Data are expressed as mean ± standard deviation (SD) or standard error of the mean 
(SEM). Data have been analysed using Prism software, using one or two-way ANOVA 
followed by Dunnett’s or Bonferroni’s multiple comparisons post-test; and t-test for normal 
Gaussian distributions. If the data did not pass the Kolmogorov-Smirnov normality test, data 
were analysed using Mann-Whitney t-test. P-value less than 0.05 were considered significant. 
 
Chapter 3-         Leptin and leptin receptor expression on PBMC in health and type 1 diabetes 
72 
 
 
 
 
 
 
 
 
 
 
 
3. CHAPTER 3- ANALYSIS OF LEPTIN AND 
LEPTIN RECEPTOR EXPRESSION IN 
HEALTH AND DIABETES 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3-         Leptin and leptin receptor expression on PBMC in health and type 1 diabetes 
73 
 
1. Introduction 
 
 Leptin acts through ObR-a and ObR-b receptors in mice, and through the short and 
long isoforms of the receptor (sLEPR and lLEPR respectively) in humans. A number of 
studies have now reported sLEPR and lLEPR expression by PBMC. Some studies have 
analysed expression of both receptors on whole human PBMC using semi-quantitative PCR 
(Tsiotra et al., 2000). LEPR expression had also been reported on CD4+ and CD8+ T 
lymphocytes (Martin Romero et al., 2000; Lord et al., 1998 and 2002) as well as monocytes 
(Zarkesh-Esfahani et al., 2001) and DCs  (Mattioli et al., 2005) using flow cytometry and 
semi-quantitative PCR. LEPR expression has also been widely reported on mouse 
lymphocytes, DCs, NK cells and Treg using semi-quantitative PCR, western blotting, flow 
cytometry and confocal microscopy (Zhao et al., 2003; Siegmund et al., 2004; 
Papathanassoglou et al., 2006; De Rosa et al., 2007). Similarly, leptin expression has been 
reported in mouse effector CD4+CD25- T cells, Treg and monocytes using confocal 
microscopy and immunoblotting (De Rosa et al., 2007; Sanna et al., 2003; Matarese et al., 
2005). These observations suggest the existence of a local autocrine loop for the pro-
inflammatory action of leptin.   
 Interestingly, leptin-deficient mice are protected from nephrotoxic nephritis, a form of 
autoimmune kidney disease (Tarzi et al., 2004) and encephalomyelitis (EAE). A surge in 
leptin levels is observed in mice before development of EAE (Sanna et al., 2003). Leptin 
administration to these mice worsens disease by increasing the secretion of pro-inflammatory 
cytokines (Matarese et al., 2001a and b) and leptin neutralization results in protection from 
disease (Matarese et al., 2001b). In humans, subjects with multiple sclerosis have elevated 
plasma leptin (Matarese et al., 2005). This increase correlates with increased circulating pro-
inflammatory cytokines as well as reduced Treg number. 
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 With regard to T1D, a study of leptin administration to NOD mice has demonstrated 
significant acceleration of disease, associated with about three times more histological lesions 
than the PBS control (Matarese et al., 2002). Furthermore, females NODs (which are more 
disease prone than male) had higher circulating leptin levels. These data suggest a pro-
inflammatory effect of leptin in islet immunity. 
To our knowledge, no study has investigated a role of leptin and its receptors in T1D. In this 
chapter, we aimed to characterise the expression of leptin and both of its receptors on human 
PBMC in health and T1D. 
2. Results 
2.1. Leptin receptors are expressed by PBMC. 
2.1.1. Gene expression of sLEPR and lLEPR on PBMC. 
 We first aimed to confirm the expression of both leptin receptors isoforms at mRNA 
level using conventional PCR (35 cycles of amplification). We used intron-spanning primers 
and we showed amplification products at the expected size for sLEPR (329pb) and lLEPR 
(427pb) on whole PBMC from healthy controls (HC) and T1D subjects (Figure 3-1). mRNA 
from pancreas and pre-adipocytes were used as positive controls. The reverse transcriptase 
(RT) negative (-ve) and water controls were negative for each condition, thus revealing that 
the amplification was specific to mRNA and not to genomic DNA (gDNA) contamination. 
Expression of lLEPR was found on CD3+ T cells and also on monocyte-derived immature and 
mature DCs (Figure 3-1a, b). 
 The expression of lLEPR, sLEPR and leptin was quantified by real-time PCR. First, 
the technique for relative quantification in duplex was validated using the ΔΔCt method 
(Livak, Schmittgen, 2001). Standard curves were measured by dilution series of the target 
gene against the endogenous control, HPRT1. In singleplex reaction, the Ct of the dilutions 
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for lLEPR, leptin and sLEPR were parallel to HPRT1 with an R2 close to 1 indicating the 
goodness of the curve fitting (Figure 3-2a, c, e). The efficiency of the reaction is also shown 
by plotting the ΔCt (Ct target gene- Ct endogenous control). In this case, the slope gradient 
being ≤0.1 shows the reliability of HPRT1 used as an endogenous control with the three 
targets genes lLEPR, sLEPR and leptin (Figure 3-2b, d, f). Quantitative measurement of both 
receptors and leptin by real-time PCR showed their expression on whole PBMC from HC and 
T1D subjects (Chapter 3-section 2.5). 
 
 
Figure 3-1: LEPRs are expressed on PBMC 
(a) sLEPR and (b) lLEPRexpression can be detected in total PBMC mRNA from HC and 
T1D (patients a and b) by RT-PCR. RT-ve and water controls demonstrate absence of gDNA 
contamination in the samples. Pancreas and pre-adipocytes mRNA were used as positive 
controls. The predicted amplicon size for sLEPR was 329bp and for lLEPR was 427bp. Data 
are representative of two independent experiments. 
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Figure 3-2: Validation of quantitative real-time PCR in duplex 
(a, b) Ct and ΔCt were determined for lLEPR, (c, d) sLEPR and (e, f) leptin after serial 
dilutions of pre-adipocytes mRNA converted into cDNA. Linear regressions are shown for 
each condition and the R2 and the slope (red), determined by the equation y=ax+b, were used 
to measure the amplification efficiency of the target genes in duplexes. 
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2.1.2. Distribution of LEPR on PBMC and subpopulations at a protein level 
 Then we aimed to quantify LEPR expression on PBMC at a protein level by flow 
cytometry. Anti-LEPR antibody and its secondary antibody concentrations were first 
optimised and the optimal concentrations were determined to be 10μg/ml for the anti-LEPR 
antibody and 5μg/ml for the secondary antibody. LEPR appears to be expressed on whole 
PBMC, but also on lymphocytes and monocytes subpopulations (Figure 3-3). The labelling 
specificity of anti-LEPR was validated by the absence of staining with the IgG1 isotype 
control and by specific blocking with a recombinant LEPR protein. PBMC were co-stained 
with anti-LEPR and phenotypic markers to assess its expression on each CD4+, CD8+, CD14+, 
CD19+ and CD56+ cell subtypes (Figure 3-3 b, c, d, e, f). The specificity of labelling was 
shown on each subpopulation with the isotype and the blocking controls. LEPR expression 
was determined on viable cells recognised by propidium iodide (PI) and forward/side scatter 
gating (Figure 3-3a). 
 We observed an average LEPR frequency of 6.1±4.3 % for CD3+ T cells. Within this 
population, CD4+ and CD8+ T cells have 19.7±24.1% and 13.1±12.4% of LEPR positive cells 
respectively. The proportion of LEPR on CD19+ cells and CD14+ monocytes is 41.8±21.8% 
and 82.9±12.7% respectively. Only 7.8±5.7% of CD56+ NK cells expressed the surface 
receptor (Figure 3-4c). Treg were identified on basis of CD4+CD25+FoxP3+ expression 
(Figure 3-4a). FoxP3 expression was detected only on the CD4+CD25+ population as shown 
by the red histogram and about 20.5±11.8% of Treg expresses LEPR. LEPR expression has 
also been detected on monocyte-derived DCs (27±5.1%) (Figure 3-4b, c). All together, we 
observed that monocytes are the main cells expressing LEPR, followed by DCs, B cells and 
Treg.T lymphocytes also express the receptor but at a lesser extent. A similar profile was 
observed when considering mean fluorescence intensities on each subset (Figure 3-4d). 
Chapter 3-         Leptin and leptin receptor expression on PBMC in health and type 1 diabetes 
78 
 
 
 
Figure 3-3: Distribution of LEPR expression on PBMC subpopulations 
(a) Cells were co-labelled with the different cell markers and anti-LEPR antibody and 
analysed by flow cytometry. The upper row shows gating on viable cells based on PI and 
forward/side scatter. Monocytes and lymphocytes populations can be distinguished on the 
forward/side scatterplots. The other dot plots show gating on PBMC subpopulations (b) CD3+ 
T lymphocytes, (c) CD3+CD4+ T lymphocytes, (d) CD3+CD8+T lymphocytes, (e) CD14+ 
monocytes, (f) CD19+B lymphocytes and (g) CD56+ NK cells where LEPR expression was 
measured as shown on histograms (red). Isotype control (solid grey) and blocking (blue) of 
the LEPR staining show the specificity of the LEPR labelling for each subset of PBMC. Data 
are representative of at least three independent experiments. 
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Figure 3-4: Distribution of LEPR expression on PBMC subpopulations 
(a) Treg were identified based on their CD4+ CD25+ and FoxP3+ expression. (b) Monocytes-
derived DCs were generated and LEPR expression was measured by flow cytometry. (c) The 
percentage of LEPR + (FL1+) cells and (d) the MFI were determined on PI, FSC-H/SSC-H 
and subsets gated cells. Data are represented as mean±SEM and were analysed using one-way 
ANOVA and Bonferroni’s multiple comparisons post-test. Pool of at least three experiments. 
*p≤0.05; **p≤0.01; ***p≤0.001. 
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2.1.3. LEPR expression on T lymphocytes upon activation 
 We went on to determine the effect of T cell activation on the expression of LEPR, 
using PHA as a T cell stimulator. LEPR expression was found to be slightly but not 
significantly increased after PHA stimulation for five days on all T lymphocytes, and both 
CD4+ and CD8+ T lymphocytes populations (Figure 3-5). The degree of T cells activation 
was confirmed with the increase in size and granularity observed on the forward/side scatter 
dot plots and the increase of CD25 expression, commonly up-regulated upon T cell 
stimulation (Figure 3-5a). It appears that the LEPR up-regulation following stimulation with 
PHA is higher for CD4+ T cells than for CD8+ T lymphocytes. 
2.2. Expression of leptin by PBMC 
 DeRosa et al. have previously reported leptin expression by Treg using confocal 
microscopy and western blot experiments. Our aim here was to examine the expression of 
leptin in PBMC. 
2.2.1. At an RNA level 
 We first analysed leptin expression by PBMC using conventional PCR. This method 
allowed detection of amplicons for leptin at the expected size of 180pb in both pre-adipocytes 
(positive control) and PBMC (Figure 3-6a). The absence of a band in the RT-ve and water 
negative controls shows the specificity of the reaction.  
2.2.2. At a protein level 
 We went on to attempt detection of leptin at a protein level, using immunoblotting and 
flow cytometry. Immunoblotting of PBMC lysate revealed a light band at 16kDa, consistent 
with the predicted molecular weight of leptin and the recombinant leptin size (Figure 3-6b). 
However, leptin could not be detected in serum samples. Our data suggests that leptin is 
produced in low quantity by PBMC. We then proceeded to examine expression by flow 
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cytometry. PBMC were fixed and permeabilised with the buffers used for FoxP3 staining. 
The anti-leptin antibody was used at 10μg/ml and detected with the donkey anti-mouse 
Alexa488 secondary antibody at 5μg/ml. Intracellular leptin was detected in whole PBMC 
(Figure 3-6c). The labelling specificity was confirmed by the absence of staining with the 
isotype control. These results indicate that PBMC are able to produce leptin themselves. 
 
 
Figure 3-5: T cell activation up-regulates LEPR 
PBMC were treated with 5µg/ml of PHA for 5 days. (a) Up-regulation of CD25 expression,as 
well as the increase in forward/side scatter on CD3 gated T cells demonstrates they have been 
stimulated. LEPR expression was measured on unstimulated and stimulated CD3 T cells and 
the CD4 and CD8 subsets and quantified as (b) a percentage of cells expressing the receptor 
and (c) with MFI. Data are shown as mean±SEM and were analysed using one-way ANOVA 
and Bonferroni’s multiple comparisons post-test. Pool of at least three experiments. No 
significant differences were found. 
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Figure 3-6: PBMC express leptin 
(a) Leptin expression can be detected in total PBMC mRNA from healthy subjects by RT-
PCR. RT-ve and water controls show no evidence of gDNA contamination in the samples. 
Pre-adipocytes mRNA was used as positive controls. The predicted amplicon size for leptin 
was 180bp. (b) Leptin was detected in PBMC lysate by western blot and (c) on 
fixed/permeabilised PBMC by flow cytometry. Data are representative of two experiments. 
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2.3. Effect of T1D on leptin and leptin receptors expression on PBMC 
 Leptin is known to modulate the function of leukocytes in both innate and adaptive 
systems in addition to its other pleiotropic effects. For these reasons, we aimed to identify any 
potential difference of LEPR and leptin levels in T1D compared to healthy controls (HC). 
2.3.1. LEPR expression on PBMC, lymphocytes and monocytes from T1D, HC and T2D 
subjects at a protein level. 
 We recruited 49 Caucasian male diabetic subjects (T1D and T2D) from the Diabetes 
Clinics of the Birmingham University Hospital as well as 19 Caucasian male subjects 
matched for age with T1D patients. Clinical parameters of HC, T1D and T2D subjects are 
described in Table 3-1. We found no significant differences for age, body mass index (BMI), 
and waist/hip ratio (WHR) between HC and T1D subjects. However, these parameters were 
significantly higher for T2D subjects compared to HC and T1D.  
 Peripheral blood was collected from each subjects, serum was isolated and frozen at -
80°C. The day after collection, PBMC were isolated, labelled and analysed by flow 
cytometry. LEPR expression was estimated by MFI on PI and forward/side scatter gated cell 
population. MFI was calculated on LEPR positive population with limits determined on the 
isotype control. 
 This T1D study revealed that T1D subjects exhibit significantly higher expression of 
LEPR on whole PBMC, lymphocytes and monocytes compared to HC and T2D subjects 
(Figure 3-7, 8). However, there were no significant correlations between LEPR expression 
and age, BMI, HbA1c and eGDR levels in T1D. 
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 HC T1D T2D 
n 19 24 21 
Age (years) 29.17 ± 6.40 34.84 ± 10.17 54.80 ± 11.45* 
BMI (Kg/m2) 25.39 ± 2.45 24.43 ± 3.43 35.33 ± 7.31* 
WHR 0.89 ± 0.06 0.90 ± 0.09 1 ± 0.08* 
Duration of diabetes 
(years) 
NA 13.44 ± 9.76 9.65 ± 6.81 
HbA1c (%) NA 9.08 ± 1.52 8.85 ± 1.93 
Insulin dose (total 
daily/Kg) 
NA 0.86 ± 0.26 NA 
eGDR (mg/Kg/min) NA 6.60 ± 6.78 NA 
Systolic BP (mmHg) NA 137.13 ± 18.83 140.96 ± 14.81 
Diastolic BP (mmHg) NA 84.25 ± 9.71 85.12 ± 8.99 
Total Cholesterol (mmol) NA 4.38 ± 0.56 4.09 ± 0.94 
Triglycerides (mmol) NA 1.58 ± 1.04 2.34 ± 1.41 
 
Table 3-1: Clinical parameters of study patients 
Data are represented as Mean ± SD and analysed using t-test. No significant differences for 
age, BMI and WHR were found between HC and T1D subjects. Age, BMI and WHR were 
significantly higher for T2D subjects than HC and T1D (*). No significant differences were 
found for duration of diabetes, glycated haemoglobin (HbA1c), systolic and diastolic blood 
pressure (BP), cholesterol and triglycerides between T1D and T2D. 
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Figure 3-7: LEPR expression on PBMC from HC (blue), T1D (red) and T2D (orange) 
subjects by flow cytometry 
(a) LEPR expression is higher in T1D subjects in whole PBMC, (b) lymphocytes and (c) 
monocytes subpopulations compared to HC and T2D subjects. Data are shown as Mean 
Fluorescence Intensity (MFI) ± SEM and analysed using non-parametric Mann-Whitney t-test 
as some data test failed the Kolmogorov normality tests (meaning it does not follow Gaussian 
distribution). *p≤0.05, **p≤0.01. 
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Figure 3-8: Representative histograms and dot plots of LEPR expression in HC and T1D 
(a) PBMC, (b) lymphocytes and (c) monocytes were gated as previously described. Gates 
were set on the isotype control (solid grey) and LEPR expression was determined by 
calculation of the MFI on the LEPR positive population. Gates show the percentage of LEPR 
positive cells, which is also higher in T1D on PBMC, lymphocytes and monocytes. 
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2.3.2. sLEPR and lLEPR gene expression on PBMC from T1D, HC and T2D subjects 
 We then analysed the expression of both lLEPR and sLEPR in HC, T1D and T2D 
using q-PCR.We confirmed that PBMC from T1D display higher relative gene expression of 
LEPR compared to HC and T2D subjects. Using sequence specific primers for the long and 
short isoforms of LEPR, we showed that the difference in LEPR expression was due to a 
significantly higher expression of the long but not the short isoform of LEPR (Figure 3-9a, 
b). We characterised that lLEPR tend to be predominant on PBMC from T1D subjects. 
However, this is different in HC and T2D subjects, as sLEPR isoforms is predominant in 
these patients (Figure 3-9c, d, e). Moreover, we revealed a positive correlation between 
LEPR expression at a protein level with lLEPR at mRNA level, but not for sLEPR, using 
linear regression analysis (Figure 3-10). 
2.3.3. Circulating leptin levels in health and diabetes 
Finally, we assessed concentrations of leptin in serum using immunoblotting. Leptin 
could not be detected using this method even in undiluted serum samples (Figure 3-11a). 
Only unspecific bands at 30 and 60kDa were observed in the serum lanes. The presence of a 
band at 16kDa in the recombinant leptin lane (lane 2) and its blocking (lane 1) demonstrate 
that the appropriate controls have worked.  
 Because immunoblotting was not sufficiently sensitive to detect leptin in serum, we 
assessed circulating leptin concentrations by ELISA. This assay revealed no significant 
difference in leptin in T1D compared to HC subjects (Figure 3-11b). However, significant 
higher circulating level of leptin was noticed in T2D subjects. In all subjects, leptin 
significantly and positively correlated with BMI and insulin dosage in T1D (Figure 3-12).  
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Figure 3-9: sLEPR and lLEPR expression on PBMC 
(a) Expression of the lLEPR and (b) sLEPR was quantified and compared in (c) HC, (d) T1D 
and (e) T2D subjects. Relative LEPR expression was quantified by real-time quantitative PCR 
using HPRT1 as endogenous control. Data were analysed using Mann-Whitney t-test. ** 
p≤0.01. 
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Figure 3-10: Correlation between LEPR expression at a protein level and mRNA level 
Correlations between mRNA level of (a) lLEPR and (b) sLEPR with protein expression of 
LEPR were determined using linear regression analysis, showing correlation for the lLEPR 
only. 
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Figure 3-11: Circulating leptin levels in health and disease 
Circulating leptin in HC, T1D and T2D subjects’ were measured by (a) Western Blot and (b) 
ELISA. Data were analysed using Mann-Whitney t-test. ***p≤0.001. 
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Figure 3-12: Correlations between circulating leptin and BMI or insulin dose 
(a) Correlation between leptin levels and BMI was determined by linear regression analysis in 
all subjects from the HC, T1D and T2D groups (b). Correlation between leptin levels and 
insulin dose was determined by linear regression analysis in the T1D group. 
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3. Discussion 
 
 We demonstrate that LEPR is highly expressed on monocytes, B cells and Treg and to 
a lower extent on T cells. We show for the first time that subjects with T1D express higher 
levels of LEPR on whole PBMC, monocytes and lymphocytes. The functional role of this 
remains unclear and will be examined in the next chapter. 
 
 Characterisation of leptin and LEPR on PBMC in health 
 LEPR expression on whole PBMC was confirmed by both conventional PCR and flow 
cytometry in healthy controls. PCR allowed us to measure expression of both the short and 
long form leptin receptors isoforms using intron-spanning primers designed in the 
intracellular region of LEPR. The epitope recognised by the anti-LEPR antibody is located on 
the extracellular N-terminal region, and the difference between the two isoforms is located in 
the C-terminal intracellular region. Thus, the antibody does not allow us to distinguish 
between sLEPR and lLEPR by flow cytometry (Bennett et al., 1996). Conventional PCR 
allowed us to confirm the expression of sLEPR and lLEPR on whole PBMC, T cells and 
monocyte-derived DCs. The expression was not due to gDNA contamination as we used 
intro-spanning primers and the controls without reverse-transcriptase are clear. Flow 
cytometry analysis allowed us to characterise the expression of LEPR on PBMC sub-
populations. Previous studies identified LEPR on whole PBMC, monocytes, DCs, 
macrophages, NK cells and CD4+ or CD8+ T cells (Martin Romero et al., 2000; Lord et al., 
1998 and 2002; Zarkesh-Esfahani et al., 2001; Mattioli et al., 2005). However, the expression 
of LEPR on these cells was not quantified and compared, and most studies have looked in 
mice (Zhao et al., 2003; Siegmund et al., 2004; Papathanassoglou et al., 2006; De Rosa et al., 
2007). In agreement with the literature, we found LEPR on these subsets using a monoclonal 
antibody optimised for flow cytometry. LEPR is highly expressed on CD14+ monocytes, and 
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slightly less on CD19+ B cells and monocytes-derived DCs followed by expression on Treg. 
LEPR expression was found on CD4+ and CD8+ T cells at a lower extent. We found no 
expression of LEPR on NK cells in contradiction with other studies in mice and humans 
(Zhao et al., 2003).  
 Quantification of LEPR on each subset was measured as the frequency of cells 
expressing the receptors as well as surface expression by MFI. Both ways show the same 
profile of expression. Additionally, specificity of LEPR labelling was confirmed using an 
isotype control and by blocking the antibody with recombinant LEPR prior staining. This 
confirms the reliability of our technique to quantify LEPR expression by flow cytometry 
unlike in other studies that have not used isotype or blockade (Papathanassoglou et al., 2006; 
De Rosa et al., 2007; Martin Romero et al., 2000; Mattioli et al., 2005; Zarkesh-Esfahani et 
al., 2001).  
 We show that LEPR expression is increased on stimulated CD4+ and CD8+ T cells 
with regard to frequency of LEPR positive cells, and also surface expression characterised by 
MFI. This was also reported by others with mice and human lymphocytes (Papathanassoglou 
et al., 2006; Sanchez-Margalet et al., 2002). In these studies, LEPR expression is also 
increased on CD4+ and CD8+ T cells after anti-CD3 or PHA stimulation as well as on mouse 
B cells and macrophages. These data suggests that LEPR is a marker of cell activation and is 
in agreement that T cells are sensitive to leptin only in stimulation conditions (Lord et al., 
1998). 
 Interestingly, DeRosa et al. revealed that CD4+ T lymphocytes and Treg produce leptin. 
In this study, the authors detected leptin at a protein level by immunoblotting and confocal 
microscopy (De Rosa et al., 2007), however, no other studies have confirmed this to date. We 
therefore aimed to quantify leptin expression in PBMC at both RNA and protein level. We 
confirmed low leptin expression in PBMC by conventional as well as immunoblotting and 
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flow cytometry. However, problems of non-specific intracellular binding can occur, 
particularly when using a polyclonal antibody in flow cytometry and western blotting. Thus, 
the specificity of the labelling would optimally require to be confirmed by blocking the leptin 
antibody with recombinant leptin beforehand. Although flow cytometry and classic western 
blotting are commonly used to identify and quantify protein expression, in this case these are 
not optimal to prove production of leptin by PBMC. Leptin production by PBMC should be 
determined using immunoprecipitation followed by mass spectrometry analysis. This method 
would confirm leptin presence in PBMC in a qualitative manner. 
 
 Effect of T1D on leptin and LEPR expression 
 A number of studies have shown that leptin deficiency is associated with protection 
against inflammatory and autoimmune disease. Leptin-deficient mice do not develop 
nephrotoxic nephritis and experimental arthritis as well as atherosclerosis and similarly in 
mice lacking LEPR (Tarzi et al., 2004; Busso et al., 2002; Taleb et al., 2007), T cell-mediated 
hepatitis (Faggioni et al., 2000), chronic intestinal inflammation (Mykoniatis et al., 2003) and 
EAE (Sanna et al., 2003; Matarese et al., 2001). Similarly, leptin neutralisation in mice 
protects from development of EAE (DeRosa et al., 2006). However, leptin deficiency is 
associated with reduction in thymus size and frequency of immune cells causing defects in T 
cell mediated immunity (Chandra et al., 1980; Fernandes et al., 1978). Therefore, absence of 
leptin predisposes to infections and this was not investigated in these studies.    
 Because leptin has been shown to accelerate the progression of T1D in the NOD 
mouse model and other autoimmune disease models, we believe that leptin has a potential 
involvement in the development of T1D in humans (Matarese et al., 2002). We thus aimed to 
identify any difference in circulating leptin levels and LEPR expression on PBMC in T1D. 
Contrary to what we expected and to the current literature, T1D is not associated with high 
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circulating leptin serum levels. All our patients with T1D were matched with our healthy 
controls for ethnicity, gender, BMI, age and WHR in contrast to the studies that observed a 
difference. Within the T1D group, all patients were matched for ethnicity, gender, BMI, age, 
WHR, HbA1c, duration of diabetes, insulin treatment, lipid profile and prevalence of vascular 
complications. This indicates the reliability of the differences found between the groups, in 
opposition to previous studies lacking this level of control (Kiess et al., 1998; Lunaet al., 
1999; Hanaki et al., 1999; Fluck et al., 1999; Kirel et al., 2000; McCormick et al., 2001; 
Soliman et al., 2002; Bideci et al., 2002; Sandoval et al., 2003; Lo et al., 2004; Gilliam et al., 
2006). In addition, studies have shown that leptin levels vary according to a diurnal cycle 
(Sandoval et al., 2003). This means that studies investigating circulating concentrations of 
leptin should be consistent for the time of sampling. This has not been mentioned in the 
studies considered. In our study, blood sampling was always consistently drawn in the 
afternoon and serum was isolated straight away and stored at -80°C for all patients and HC. 
 We believe that in matched subjects, leptin levels are unchanged in T1D compared to 
HC. Nevertheless, much of the destructive autoimmune process occurs before the onset of 
clinical diabetes. Leptin levels may possibly be high before the onset of T1D. Supporting this 
hypothesis, a surge in serum leptin occurs at preclinical stage, before the onset of 
hyperglycaemia in the NOD mouse model (Matarese et al., 2002) as well as before 
development of EAE (Sanna et al., 2003). To our knowledge, no studies in humans have 
investigated leptin levels in pre-T1D. Leptin levels have only been measured in long lasting 
T1D as well as some newly diagnosed patients. However, the data are highly contradictory 
and it is therefore difficult to draw a conclusion. Most of the studies show higher levels in 
long duration of disease in correlation with insulin dosage. Even though, we found unchanged 
leptin levels in our matched cohort, we agree that leptin levels positively correlate with 
insulinisation. Studies in pre-T1D have shown that insulin resistance is a risk factor for 
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developing T1D (Fourlanos et al., 2004). If leptin levels are shown to be higher in pre-T1D, 
association between IR and development of T1D could well be contributed to by leptin. 
Additionally, study in pre-T1D would show leptin levels independently of insulinisation, as 
these patients are generally not on insulin.  
 We also show that circulating leptin concentrations in T2D are higher compared with 
HC and T1D. Leptin levels positively correlated with BMI and WHR in all groups. The BMI 
of our group of patients with T2D being significantly higher than HC and T1D, this explains 
the rise in leptin levels in this group. This is in agreement with the current literature showing 
higher leptin levels in obese T1D and also T2D (Verroti et al., 1998). 
 In T1D, we found that LEPR is highly expressed on circulating immune cells 
compared to HC and T2D. On the other hand, in T2D, LEPR expression is not higher 
showing that the rise observed in T1D is specific to the disease and not to high blood level of 
glucose. Alternatively, reduced expression of LEPR on PBMC from T2D compared to T1D 
could be due to the high leptin circulating levels. Indeed, leptin has been shown to 
downregulate the expression of the lLEPR on hepatocytes (Liu et al., 2005), neuroblastoma 
cells (Hikita et al., 2000) and in the brain (Mitchell et al., 2009) but there are no evidence on 
PBMC. 
 We found no significant correlations between LEPR on PBMC, monocytes and 
lymphocytes and all the parameters measured in the study except for a negative association 
between LEPR and BMI. This is in agreement with previous findings showing a significantly 
lower expression of both sLEPR and lLEPR in overweight versus lean subjects (Tsiotra et al., 
2000). This observation could explain why expression of LEPR in T2D is lower than in the 
T1D group. Indeed, T2D might be associated with higher LEPR expression but because these 
patients tend to have high BMI, this compensates the receptor levels on PBMC. Therefore, it 
would be worth examining the expression of LEPR in leaner patients with T2D. 
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Additionally, we observed a significant correlation between the levels of LEPR on PBMC at a 
protein level and lLEPR gene expression. Interestingly, this correlation was not found for the 
short isoform. This implies that only the functional long form of the receptor is modulated in 
T1D and therefore suggests a potential functional significance as lLEPR only seems to induce 
signalling cascades mediating leptin actions (Chen et al., 1996; Lee et al., 1996; Cioffi et al., 
1996).   
 We did not find any correlation between expression of LEPR on PBMC and subsets 
and index of insulin resistance in our T1D cohort, which would support our general working 
hypothesis. Several explanations could account for this observation. 
 First, insulin resistance was measured by eGDR calculation in our cohort of T1D. Although 
this method has been validated for adult patients with T1D (Williams et al., 2000), the most 
common and accurate technique is the euglycaemic hyperinsulinaemic clamp because it 
measures direct response of insulin to glucose in vivo. Supporting this, we found that the 
levels of LEPR on PBMC in T2D are not different from HC. Indeed, T2D is a condition 
strongly associated with insulin resistance. Measurement of insulin resistance was not 
accomplished in these patients and the eGDR method is not validated in this disease. On the 
other hand, the difference could only be specific to the autoimmune context of T1D. Indeed, 
independently of insulin resistance, leptin has widely been reported as a modulator of immune 
function. This is again supported by the level of LEPR in T2D that has no association with 
autoimmunity. Furthermore, surveys have reported a negative correlation between insulin 
resistance and LEPR expression in adipose tissue (Huan et al., 2003). Similarly, over-
expression of LEPR in the hypothalamus improves peripheral insulin sensitivity in skeletal 
muscle (German et al., 2009). Finally, high levels of LEPR could also be due to insulin 
treatment. For instance, insulin has been reported to induce up-regulation of LEPR in 
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neuroblastoma cells (Hikita et al., 2000). However, we found no correlation between insulin 
dosage and LEPR levels in our cohort of patients. 
 We believe that high expression of LEPR on PBMC potentially makes them more 
responsive to the pro-inflammatory effects of leptin. This is supported by a study revealing 
that autoimmunity in the NOD mouse model is the consequence of T conventional hyper-
responsivity rather than a Treg dysfunction (D’Alise et al., 2008). We believe that this hyper-
responsiveness could be partly attributed to the high leptin receptor expression and the 
subsequent leptin effect. Because T cells are hyper-responsive and Treg proliferation is 
limited, Treg themselves are not sufficient to efficiently regulate T cell responses. This 
potential mechanism, even if consistent with our findings in addition to previous studies, 
requires to be investigated in a T1D context. 
 Although our data in T1D is novel, studies have shown modulation of LEPR 
expression in other diseases. LEPR expression is decreased on PBMC from chronically-
infected hepatitis B (HBV) and hepatitis C (HCV) patients, whilst leptin levels are decreased 
(Stefanou et al., 2006). These data suggests that lower circulating leptin and LEPR expression 
contribute to the virus-mediated down-regulation of immune responses. Indeed, less receptor 
on PBMC reduces the ability of leptin to stimulate immune responses against the pathogen 
(Stefanou et al., 2006). These studies show for the first time how crucial LEPR modulation of 
immune cells and how it correlates with the pro- or anti-inflammatory context. In addition, 
Frisullo et al. found higher expression of LEPR on PBMC from patients with relapsing 
multiple sclerosis (Frisullo et al., 2007). The levels of LEPR on PBMC were restored in 
remitting patients. In addition, leptin levels were unchanged in relapsing patients compared to 
HC. This suggests that even though leptin concentrations are unchanged, PBMC are more 
sensitive to its action as they express more of the receptor (Frisullo et al., 2004). These data 
and our study, in contrast with the infection model, suggests that higher levels of LEPR are 
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associated with up-regulation of pro-inflammatory immune responses and indicate that 
therapy targeting LEPR rather than leptin itself may be more appropriate for treatment of 
autoimmune diseases. 
 
 Conclusions 
 Taken together these data demonstrate for the first time a difference in LEPR 
expression in T1D. LEPR is globally augmented at both protein and RNA level on PBMC, 
lymphocytes and monocytes from patients with T1D compared to matched controls and to 
patients with T2D. We propose the high expression on LEPR on immune cells contributes to 
the inflammation that characterises T1D.  
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1. Introduction 
 
 In this chapter, we aimed to demonstrate functional relevance for the higher 
expression of LEPR detected on PBMC from patients with T1D.  
 T cell proliferation and pro-inflammatory cytokine production have been reported to 
increase in the presence of leptin (Martin- Romero et al., 2000; Lord et al., 1998; Zarkesh-
Esfahani et al., 2001). However, these studies have used techniques such as thymidine 
incorporation or up-regulation of CD25 to quantify T cell proliferation. We wished to validate 
these results using alternative measures of proliferation.  
 Carboxyfluorescein (CFSE) is a highly permeable dye that labels intracellular 
molecules. CFSE allows measurement of T cell proliferation as it progressively halves 
between daughter cells following each division (Lyons et al., 2000), a dilution that can be 
measured by flow cytometry. To our knowledge, no studies have looked at antigen-specific 
responses in presence of leptin. Furthermore, some of the published experiments were 
conducted in media containing bovine serum that contains leptin, which cross-reacts with 
human leptin receptors. We therefore aimed to validate these observations in serum-free 
conditions. 
 We also wished to examine the effect of leptin on antigen presenting cells (APCs) 
such as dendritic cells (DCs). Studies in humans have shown that leptin promotes production 
of pro-inflammatory cytokines by DCs with a concomitant decrease of IL-10 secretion and 
increases their survival and migratory capacities (Mattioli et al., 2005 and 2008). These DCs 
polarise T cells towards a Th1 phenotype and are very efficient at activating CD8+ cytotoxic T 
cells (Mattioli et al., 2008). Additionally, DCs from ObR deficient mice expressed lower co-
stimulatory molecules and had decreased capacity to stimulate allogenic T cells (Lam et al., 
2006). 
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 Ultimately, we developed interest for lymphocyte migration and how adipokines 
might influence their recruitment to the endothelium. Leptin has previously been linked to the 
promotion of leukocyte migration (Cadelfie-Chezet et al., 2003; Gruen et al., 2007; Mattioli 
et al., 2005). Indeed, leptin has been identified as a chemoattractant for THP-1 monocytes and 
DCs using Boyden chamber assays (Gruen et al., 2007; Mattioli et al., 2008). However, more 
detailed information of the functions of leptin in regulating leukocyte recruitment is lacking 
and there is no data on the regulation of lymphocyte trafficking. Thus for leptin, the data are 
limited to experiments using cell lines in assays lacking realistic barriers for trafficking (i.e. 
endothelial cells). 
 Here, we aimed to measure the effect of leptin on the migration of peripheral blood 
lymphocytes (PBL) across endothelial cells. We chose human umbilical vein endothelial cells 
(HUVEC) as a model of endothelium. HUVEC have been widely used to study leukocyte 
recruitment in both static and flow conditions (Luscinskas et al., 1989; Furie et al., 1991; 
Luscinskas et al., 1995; Bahra et al., 1998; Luu et al., 2003; Butler et al., 2005; Sheikh et al., 
2005). HUVEC express classic endothelial markers such as CD31, von Willebrand factor 
(vWF), ICAM-1, VCAM-1 and E-selectin. In this system, we cultured HUVEC on clear 
plastic and stimulated them with TNF-α and IFN-γ for 24 hours prior to measurement of 
recruitment as described in Material and Methods (Chapter 2, section 4.7.2). In these 
conditions, TNF-α/IFN-γ stimulation allows up-regulation of E- and P-selectin, ICAM-1 and 
VCAM-1 (Bevilacqua et al., 1989; Bahra et al., 1998; Lidington et al., 1999). HUVEC 
stimulation also induces surface presentation of chemokines such as CXCL9, 10 and 11 
important for lymphocyte recruitment as well as IL-8, CXCL1, CXCL5, CCL2 and PAF 
important to support monocyte and neutrophil recruitment (Huber et al., 1991; Kuijpers et al., 
1992; Beck et al., 1999; Ding et al., 2000; Piali et al., 1998). The model is essentially that 
already reported by McGettrick et al. in which the stimulation of the interferon inducible 
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CXC chemokines (CXCL9-11) is essential for efficient lymphocyte recruitment (McGettrick 
et al., 2009).  
 PBL were added to stimulated HUVEC for 6 minutes and recruitment measured using 
phase contrast video-microscopy in both static and flow conditions. This technique has been 
widely used to measure recruitment of T cells, neutrophils and monocytes. It allows 
identification of phase bright firmly adhered PBL recruited on the endothelium and phase 
dark PBL located underneath the endothelium and which have therefore achieved trans-
endothelial migration (transmigration). The effect of leptin was measured by treatment of 
HUVEC with this agent over the 24 hours of TNF-α and IFN-γ stimulation, or by pre-
treatment of PBL for one hour prior to addition to the HUVEC. This allowed the direct effects 
on HUVEC or PBL to be distinguished. 
 In this chapter, we intended to analyse the effect of leptin on T cell proliferation using 
the CFSE dilution technique with mitogenic and antigen-specific stimulators. We then sought 
to measure production of pro and anti-inflammatory cytokines by T cells and aimed to analyse 
the effect of leptin on monocyte-derived imDCs phenotype and function. Finally, we 
investigated the effect of leptin on lymphocyte recruitment to the endothelium. 
2. Results 
2.1. Leptin has no effect on T cell proliferation 
 T cell proliferation assays were conducted in serum-free media, and cell proliferation 
measured by flow cytometry. Live cells were gated by PI exclusion labelled cells and CFSE 
dilution quantified by gating on CD3+ or CD4+CD25- T cells (Figure 4-1). Using these 
conditions, the addition of leptin in physiological and supra-physiological doses did not 
influence mitogenic (PHA), CD3/CD28, anti-CD3, or antigen (Tetanus Toxoid protein- TT 
protein) induced proliferation of PBMC from healthy subjects (Figure 4-2, Figure 4-3, 
Figure 4-4 and Figure 4-5 respectively). 
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 Previous studies have measured the effect of leptin on purified CD4+ T cell 
proliferation. We therefore sorted healthy controls’ CD4+CD25- T cells and monocytes for co-
stimulation, using anti-CD3 or Tetanus toxoid protein as stimulators. T cell and T 
cells+monocytes, or T cells+anti-CD3 or Tetanus toxoid protein were used as unstimulated 
controls. Once again, the addition of recombinant leptin did not influence T cell proliferation 
(Figure 4-6 and Figure 4-7). 
 In conclusion, the current literature showing that T cell proliferation is increased in the 
presence of leptin cannot be reproduced in our hands using serum-free media. 
 
 
Figure 4-1: Gating strategy for measuring T cell proliferation using flow cytometry 
(a) CFSE labelled PBMC were isolated from the peripheral blood and cultured for 5 days and 
(b) stimulated with PHA (3µg/ml). Live cells were gated on PI staining and lymphocytes on 
forward/side scatter. Stimulation induces a dramatic increase in granularity and size. 
Unstimulated cells did not proliferate as indicated by the absence of CFSE dilution. PHA 
stimulation resulted in a dilution of CFSE. Data are representative of at least three 
independent experiments. 
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Figure 4-2: Leptin has no effect on PHA-induced T cell proliferation 
(a) PBMC were isolated from the peripheral blood, labelled with CFSE and stimulated with 
3µg/ml PHA in absence or presence of leptin at 1 and 10nM for three days. PHA induced T 
cell proliferation was measured by CFSE dilution. (b) T cell proliferation was significantly 
induced by PHA but no significant differences were found with leptin at 1 or 10nM. Data are 
mean±SEM and were analysed using one-way ANOVA and Bonferroni’s multiple 
comparisons post-test. Pool of at least three experiments. ***p≤0.001. 
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Figure 4-3: Leptin has no effect on CD3/CD28 beads-induced T cell proliferation 
(a) PBMC were isolated from the peripheral blood, labelled with CFSE and stimulated with 
CD3/CD28beads (8:1, cells to bead) in absence or presence of leptin at 10 and 100nM for 
three days. CD3/CD28 beads induced T cell proliferation was measured by CFSE. (b) T cell 
proliferation was significantly induced by CD3/CD28 beads, but this was not affected by the 
addition of leptin. Data are mean±SEM and were analysed using one-way ANOVA and 
Bonferroni’s multiple comparisons post-test. Pool of at least three experiments. ***p≤0.001. 
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Figure 4-4: Leptin has no effect on Anti-CD3-induced T cell proliferation 
(a) PBMC were isolated from the peripheral blood, labelled with CFSE and stimulated with 
0.5µg/ml of anti-CD3 in absence or presence of leptin at 0.1 to 100nM for three days.Anti-
CD3 induced T cell proliferation was measured by CFSE dilution. (b) T cell proliferation was 
significantly induced by anti-CD3 but no significant differences were found with leptin. Data 
are mean±SEM and were analysed using one-way ANOVA and Bonferroni’s multiple 
comparisons post-test. Pool of at least three experiments. ***p≤0.001. 
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Figure 4-5: Leptin has no effect on Tetanus Toxoid protein-induced T cell proliferation 
(a) PBMC were isolated from the peripheral blood, labelled with CFSE and stimulated with 
5µg/ml TT protein in absence or presence of leptin at 1 or 10nM for seven days.Antigen 
specific TT protein induced T cell proliferation was measured CFSE dilution. (b) T cell 
proliferation was slightly induced by TT protein but no significant differences were found 
with or without leptin. Data are mean±SEM and were analysed using one-way ANOVA and 
Bonferroni’s multiple comparisons post-test. Pool of at least three experiments. 
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Figure 4-6: Leptin has no effect on anti-CD3 and monocytes-induced T cell proliferation 
(a) Monocytes and CD4+ CD25- T cells were isolated from PBMC. T cells were labelled with 
CFSE and stimulated with anti-CD3 (0.5µg/ml) and monocytes at 1 to 10 ratio, in absence or 
presence of leptin at 1 to 100nM for three days.T cell proliferation was measured CFSE 
dilution. (b) T cell proliferation was significantly induced in presence of both monocytes and 
anti-CD3 but no significant differences were found with leptin. Data are mean±SEM and were 
analysed using one-way ANOVA and Bonferroni’s multiple comparisons post-test. Pool of at 
least three experiments.*p≤0.05. 
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Figure 4-7: Leptin has no effect on TT protein and monocytes-induced T cell 
proliferation 
(a) Monocytes and CD4+ CD25- T cells were isolated from PBMC. T cells were labelled with 
CFSE and stimulated with TT protein (3µg/ml) and monocytes at 1 to 10 ratio, in absence or 
presence of leptin at 1 to 100nM for three days.T cell proliferation was measured by CFSE 
dilution. (b) T cell proliferation was significantly induced in presence of both monocytes and 
TT protein but no significant differences were found with leptin. Data are mean±SEM and 
were analysed using one-way ANOVA and Bonferroni’s multiple comparisons post-test. Pool 
of at least three experiments. *p≤0.05. 
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2.2. Leptin has no effect on T cell cytokines production 
 Pro-inflammatory cytokines, such as IFN-γ, IL-2, IL-21, IL17 and TNF-α, are 
involved in the pathogenesis of T1D. Given the well-characterized pro-inflammatory effect of 
leptin in immunity, we wished to characterise the effect of leptin on cytokine production by T 
cell.   
 CD4+CD25- T cells were stimulated with CD3/CD28 Dynabeads in serum-free media 
for five days in presence of leptin at 0; 0.1; 1; 10 and 100nM. At day 5, cells were re-
stimulated with PMA and protein secretion was stopped with Brefeldin A. Then, cells were 
fixed and stained for intracellular cytokines.  
The addition of physiological or supra-physiological amounts of leptin did not influence the 
production of either pro- or anti-inflammatory cytokines such as IFN-γ, IL-17, IL-2, IL-21 
and IL-10 (Figure 4-8, 9 and 10) 
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Figure 4-8: Leptin has no significant effect on IFN-γ and IL-17 production 
(a) CD4+CD25- T cells were stimulated with CD3/CD28 beads (8:1) for 6 days. Cells were re-
stimulated with PMA/Ionomycin over night before blockade of protein secretion with 
Brefeldin A. Leptin was added in the cultures at 0, 0.1, 1, 10 and 100nM. IFN-γ and IL-17 
production was measured by intracellular staining. Pool of two experiments realised in 
duplicate for (b) IFN-γ and (c) IL-17. Some conditions have fewer values because of cell 
death and lack of staining. Data were analysed using one-way ANOVA and Dunnett’s 
multiple comparisons post-test. No significant differences were found. 
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Figure 4-9: Leptin has no significant effect on IL-2 and IL-21 production 
(a) CD4+CD25- T cells were stimulated with CD3/CD28 beads (8:1) for 6 days. Cells were re-
stimulated with PMA/Ionomycin over night before blockade of protein secretion with 
Brefeldin A. Leptin was added in the cultures at 0, 0.1, 1, 10 and 100nM. IL-2 and IL-21 
production was measured by intracellular staining. Pool of two experiments realised in 
duplicate for (b) IL-2 and (c) IL-21. Some conditions have fewer values because of cell death 
and lack of staining. Data were analysed using one-way ANOVA and Dunnett’s multiple 
comparisons post-test. No significant differences were found. 
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Figure 4-10: Leptin has no significant effect on IL-10 production 
(a) CD4+CD25- T cells were stimulated with CD3/CD28 beads (8:1) for 6 days. Cells were re-
stimulated with PMA/Ionomycin over night before blockade of protein secretion with 
Brefeldin A. Leptin was added in the cultures at 0, 0.1, 1, 10 and 100nM. IL-10 production 
was measured by intracellular staining. (b) Pool of two experiments realised in duplicate for 
IL-10. Some conditions have fewer values because of cell death and lack of staining. Data 
were analysed using one-way ANOVA and Dunnett’s multiple comparisons post-test. No 
significant differences were found. 
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2.3. Leptin has no reproducible effect on co-stimulatory molecule expression by DCs 
 Here, we wished to examine the effect of leptin on the process of DCs differentiation. 
DCs are routinely differentiated from monocytes from the peripheral blood in presence of IL-
4 and GM-CSF in medium containing 10% bovine serum. Because bovine serum contains 
leptin with the potential to cross react with the human leptin receptor, we needed to develop a 
serum-free system in which DCs would be efficiently differentiated. CellGroDC serum-free 
media (CellGenix) has been previously shown to be the optimal medium for the generation of 
DC (Napoletano et al., 2007).  
 Using CellGroDC serum-free media, we were able to differentiate cells with 
phenotypic characteristics of DCs (Figure 4-11). In brief, magnetic sorted monocytes 
showing classic phenotypic markers (CD14+++, CD11c++, HLA-DR++, CD86+, CD1a-, CD80-, 
CD83-and DC-SIGN-, Figure 4-11a) were differentiated into immature DCs (imDCs) in 
serum-free conditions. After 5 days, the cells showed a decreased expression of CD14 and an 
increase in the classical DCs markers (DC-SIGN+++, CD1a+++, HLA-DR++, CD86+, CD80+ 
and CD83+, Figure 4-11b). This phenotype was similar to the one of DCs generated in serum 
containing medium (Figure 4-11c). The only difference regularly found between serum and 
serum-free generated DCs, was a lower frequency of CD1a+ DCs in serum-free conditions. 
Finally, these DCs were used to stimulate CD4+CD25- T cells using anti-CD3 stimulator and 
no differences were found in their capacity to co-stimulate T cells (Figure 4-11d). 
 We then sought to investigate the effect on leptin on imDCs phenotype and function. 
In this assay, leptin was added at a concentration of 10nM during monocytes to DCs 
differentiation. ImDCs were harvested after 5 days and classic DCs markers were analysed by 
flow cytometry. Live cells were identified by gating out PI positive cells and on the 
forward/side scatter profile (Figure 4-12a). Normally, in serum conditions, all DCs express 
CD1a. Because, not all our cells express CD1a in serum-free conditions, we gated on CD1a+ 
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cells to ensure we looked at fully differentiated DCs and analysed all markers expression on 
this subset. Under these conditions, we found that presence of leptin during differentiation 
induced a near significant increase in the frequency of CD86 positives imDCs (Figure 4-12-a 
histograms and b). A trend was also observed for CD86 surface expression in presence of 
leptin (Figure 4-12c). 
 We then aimed to test the capacity of the DCs generated in presence of leptin, to 
stimulate T cells. ImDCs were then co-cultured with CD4+CD25-CFSE+ labelled T cells in 
serum-free media and stimulated with anti-CD3 antibody for three days. T cells co-activated 
with DCs differentiated in presence of leptin exhibited significantly higher proliferation 
compared to T cells stimulated by DCs generated without leptin (Figure 4-13).  
We also looked at the expression of other DCs markers such as CD80, DC-SIGN and HLA-
DR in presence or absence of leptin at 10nM (Figure 4-14a, b). Leptin did not affect the 
expression of these markers on DCs suggesting that the effect is specific to CD86 (Figure 4-
14c). 
 We then proceeded to repeat these experiments with a new batch of leptin from the 
same source. Despite a number of experiments, the results could not be reproduced (Figure 4-
15). 
 
 
Chapter 4-                                                  An examination of the effects of leptin on immunity 
117 
 
 
Figure 4-11: Phenotype of DCs generated in serum-free media 
(a) Cell surface marker expression was examined on monocytes and (b) imDCs generated in 
serum-free or (c) 10% of bovine serum conditions using flow cytometry. Other than a 
decrease in CD1a, there were no differences observed in the phenotype of serum and serum-
free generated imDCs. (d) DCs were generated in 10% serum or serum-free media and co-
cultured with CFSE labelled CD4+CD25- T cells. Proliferation was analysed by CFSE dilution 
quantification. Data are representative of three independent experiments. 
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Figure 4-12: Leptin induces a near significant increase of CD86 expression on DCs 
(a) Cell surface marker expression was examined on imDCs generated in serum-free with or 
without leptin using flow cytometry. DCs were gated on their forward/side scatter profile and 
live cells selected with PI negative staining. CD86 expression was measured on CD1a+ DCs. 
(b) Frequency of CD86 is not significantly increased on CD1a+ DCs in the presence of leptin 
at 10nM and similarly when considering (c) CD86 surface expression (MFI). Pool of at least 
four experiments Data are mean±SEM and were analysed using t-test.  
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Figure 4-13: DCs generated in presence of leptin have higher T cell stimulatory capacity 
(a) ImDCs generated in serum-free medium with or without leptin were co-cultured with 
CSFE labelled CD4+CD25- T cells. Anti-CD3 was used to stimulate T cells and T cell 
proliferation was measured by CFSE dilution. (b) T cells were gated on their forward/side 
scatter profile and live cells were selected with PI negative staining. DCs treated with leptin 
have significantly higher capacity to stimulate T cells in presence of anti-CD3. Pool of at least 
three experiments carried out in triplicates. Data were analysed using t-test. **p≤0.01, 
***p≤0.001. 
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Figure 4-14: Leptin does not affect other imDCs markers 
(a) Cell surface marker expression was examined on imDCs generated in serum-free with or 
without leptin using flow cytometry. DCs were gated on their forward/side scatter profile and 
live cells were selected with PI negative staining. CD1a+ DCs were gated and CD80 (a), DC-
SIGN and HLA-DR (b) expression were measured. (b) Leptin did not induce any difference in 
the frequency of CD1a+CD80+, DC-SIGN+ or HLA-DR+ DCs. Pool of at least three 
experiments (except HLA-DR, N=1). Data were analysed using one-way ANOVA and 
Bonferroni’s multiple comparisons post-test. 
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Figure 4-15: Leptin effect on CD86 expression is batch-dependent 
(a) Cell surface marker expression was examined using flow cytometry on imDCs generated 
in serum-free media in the presence of a new batch of leptin. DCs were gated on their 
forward/side scatter profile and live cells were selected with PI negative staining. CD1a+ DCs 
were gated and CD86 expression was measured. (b) This batch of leptin did not induce a 
difference in the frequency of CD1a+CD86+ DCs. Pool of at least three independent 
experiments. Data were analysed using t-test. 
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2.4. Leptin has no effect on antigen uptake by APCs 
 We then sought to further investigate the effect of leptin on the function of DCs by 
measuring their capacity to take up antigen. Magnetic sorted monocytes were differentiated 
into imDCs in serum-free in presence of leptin. Dextran-FITC was added at 0.1mg/ml to DCs 
for 7 minutes at either 4°C or 37°C. These differences allowed us to quantify by flow 
cytometry, the amount of Dextran-FITC that is internalised (37°C) and which is bound to the 
cell surface (4°C). Dextran-FITC uptake is then quantified by subtracting the MFI or 
percentage of Dextran-FITC positive cells at 4°C to 37°C.  
Under these conditions, DCs efficiently internalised Dextran-FITC at 37°C but not at 4°C 
(Figure 4-16a). The gate to measure Dextran-FITC uptake was set up on the control DCs 
without the antigen. Dextran-FITC uptake is unchanged in DCs differentiated in the presence 
of leptin (Figure 4-16b). The cell surface binding of Dextran-FITC measured at 4°C on DCs 
was also confirmed to be similar in the presence of leptin.  
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Figure 4-16: Leptin has no effect on antigen uptake by DCs 
(a) DCs were differentiated in presence of 10nM leptin. Dextran-FITC was added for 7 
minutes at 37°C and at 4°C, washed two times using PBS at 4°C and uptake was analysed by 
flow cytometry. Dot plots representative of Dextran-FITC uptake at 4°C and 37°C. (b) The 
cell surface binding measured at 4°C was subtracted from the percentage of DF positive cells 
at 37°C and (c) the same for the MFI. Cell surface binding and uptake were similar between 
DCs untreated or treated with leptin. Pool of at least three experiments. Data were analysed 
using t-test. 
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2.5. Optimisation of lymphocytes transmigration across HUVEC in low serum 
conditions 
 Measurement of lymphocyte adhesion and transmigration was previously conducted in 
media containing 20% of FCS (McGettrick et al., 2009). In these conditions, adhesion and 
transmigration of lymphocytes across HUVEC treated with TNF-α and IFN-γ for 24 hours 
was observed. Because leptin and adiponectin are present in bovine serum and are 
biologically cross-reactive with human cells, it was thought expedient to set up the assay in 
low serum media to remove the confounding actions of bovine adipokines (Wang et al., 
2004). When we compared the adhesion of migration in low serum conditions (2%) or our 
normal 20% serum conditions, total adhesion, firm adhesion on the top of the endothelium 
and transmigration of lymphocytes across the endothelium were not significantly affected 
(Figure 4-17). 
2.1. Leptin has limited effect on lymphocyte transmigration 
 Next, we investigated whether leptin could modulate lymphocyte transmigration. We 
know that PBL express LEPR, but expression has not been investigated in HUVEC. In order 
to determine through which cell type leptin was mediating its effects we measured LEPR on 
HUVEC. LEPR was highly expressed on HUVEC when assessed by flow cytometry; indeed 
levels appeared much higher than on PBMC (Figure 4-18).  
 To determine whether leptin was capable of stimulating endothelial cells so that they 
could recruit PBL, we treated unstimulated HUVEC with leptin. We observed no difference in 
total PBL adhesion compared to untreated HUVEC. However, the small proportion of PBL 
that did adhere to the EC could migrate with significantly greater efficiency when the 
HUVEC had been stimulated with leptin. The number of surface adherent PBL, which is the 
reciprocal of the transmigrated fraction showed the appropriate reduction associated with the 
more efficient transit of lymphocytes across the monolayer (Figure 4-19). 
Chapter 4-                                                  An examination of the effects of leptin on immunity 
125 
 
 We went on to determine whether leptin could regulate PBL recruitment on cytokine 
stimulated HUVEC. Importantly, stimulation of the HUVEC with cytokines caused a 
dramatic increase in total adhesion and transmigration of PBL compared to untreated cells 
(Figure 4-20). Under these conditions of cytokine stimulation, we treated either the HUVEC 
or PBL with 10nM of leptin (Figure 4-20). Treatment of HUVEC with leptin did not change 
the total number of PBL recruited. However, leptin did induce interesting variations in 
lymphocyte behaviour. Thus, there was a significant decrease of PBL transmigration along 
with the appropriate increase in the reciprocal measure of firm adhesion (Figure 4-20). 
Treatment of PBL with leptin had the same effect but the magnitude of the inhibitory response 
was more pronounced. 
  Finally, we tested whether the treatment of HUVEC with leptin could modulate the 
expressions of adhesion molecules such as ICAM-1, VCAM-1 and E-selectin. These changes 
were assayed by flow cytometry using unstimulated, TNF-α/IFN-γ stimulated, and TNF-
α/IFN-γ-leptin stimulated HUVEC. Leptin did not induce expression of adhesion receptors on 
unstimulated HUVEC. Importantly however and as expected, we saw up-regulation of 
VCAM-1 and ICAM-1 in response to cytokine treatment. E-selectin did not change at this 
time point (24h), but E-selectin expression is known to peak at approximately 6h and return to 
baseline within 24h (Figure 4-21). The treatment of cytokine stimulated HUVEC with leptin 
did not result in changes in adhesion receptor expression (Figure 4-21b) or surface expression 
(Figure 4-21c).  
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Figure 4-17: The effect of varying the concentration of serum on the adhesion and 
migration of PBL 
HUVEC were grown in 20% FCS complete medium and transferred to a 12 well plate in low 
serum medium (2%) or left in 20% FCS medium. HUVEC were stimulated with TNF-α and 
IFN-γ for 24 hours and the level of (a) total adhesion, (b) firm adhesion and (c) transmigration 
across the endothelium were assessed in static conditions. There was no significant effect on 
these parameters in low serum conditions. Pool of at least three independent experiments. 
Data were analysed using t-test. ns=non significant. 
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Figure 4-18: LEPR is expressed on HUVEC 
(a) The expression of LEPR on HUVEC was determined by flow cytometry. HUVEC were 
gated on their forward/side scatter profile and LEPR expression (green line) was determined 
using the isotype (solid grey) as negative control to set the LEPR gate. (b) Frequency of cells 
positive for LEPR and (c) surface expression of LEPR are higher for HUVEC than PBMC. 
Data are a pool of at least three independent experiments and were analysed using t-test. 
*p≤0.05, ***p≤0.001. 
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Figure 4-19: Treatment of unstimulated HUVEC with leptin increases PBL 
transmigration 
HUVEC were cultured in low serum media in presence or absence of 10nM leptin for 24 
hours. (a) Total adhesion, (b) firm adhesion on the top of the endothelium and (c) 
transmigration were measured in these conditions. Data are a pool of at least three 
independent experiments and were analysed using t-test. ***p≤0.001, ns=non significant. 
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Figure 4-20: Treatment of stimulated HUVEC and PBL with leptin decreases PBL 
transmigration 
Stimulated HUVEC and freshly isolated PBL were cultured in low serum media in presence 
or absence of 10nM leptin during 24 hours for the HUVEC and 1 hour for the PBL. (a) Total 
adhesion, (b) firm adhesion on the top of the endothelium and (c) transmigration were 
measured in these conditions. Data are a pool of at least three independent experiments and 
were analysed usingone-way ANOVA and Bonferroni’s multiple comparisons post-test. 
*p≤0.05; ***p≤0.001, ns=non significant. 
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Figure 4-21: Leptin does not affect adhesion molecules expression by HUVEC 
(a) ICAM-1, VCAM-1 and E-selectin expression on unstimulated (left panel) and stimulated 
with TNF-α/IFN-γ for 24 hours (right panel) HUVEC. HUVEC were cultured in absence or 
presence of leptin at 10nM and adhesion molecule expression was measured by flow 
cytometry. (b) No significant changes were observed with leptin treatment for ICAM-1, 
VCAM-1 and E-Selectin frequency and (c) surface expression. Data are a pool of at least two 
experiments and were analysed using one-way ANOVA and Bonferroni’s multiple 
comparisons post-test. ***p≤0.001. 
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3. Discussion 
 
 In this chapter, I demonstrate that leptin does not affect T cell proliferation, T cell 
production of intracellular cytokines, or antigen uptake by DCs. Whilst I was able to 
demonstrate leptin effect on the in-vitro generation of DCs from monocytes; I show that this 
is batch-dependent. Finally, I demonstrate that leptin is able to promote lymphocyte 
transmigration across the endothelium in absence of inflammation, but inhibits lymphocyte 
recruitment in presence of inflammatory signals. 
 
 Here, we first aimed to reproduce some of the data available in the literature, which 
describe the effect of leptin on T cell responses and DCs phenotype and function using serum-
free conditions in order to understand the potential functional significance of the differences 
in LEPR expression in T1D.  
 However, we found no differences in CD3+ T cell proliferation in presence of leptin in 
whole PBMC or sorted CD4+CD25-T cells plus monocytes assays. Measurement of antigen-
specific T cell proliferation is critical for our eventual goal of understanding cellular 
immunity against the pancreatic islet. We did not observe an effect of leptin on antigen-
specific T cell proliferation. We then chose to measure cytokine expression using intracellular 
staining. This technique was preferred instead of the classically used ELISA quantification 
because it allows co-staining with other T cell markers. We found no major differences in the 
expression of IFN-γ, IL-2, IL-21 and IL-10 in presence of leptin in response to polyclonal 
activation. 
 We then developed a system in which monocytes are efficiently differentiated to 
imDCs in serum-free conditions. The serum-free generated imDC demonstrated expression of 
the classical phenotypic markers of DC such as CD80, CD86, CD83, HLA-DR and DC-
SIGN, at similar levels to DCs generated in presence of serum. This is in agreement with 
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published observations using the same CellGroDC media (Napoletano et al., 2007). The only 
noticeable exception was a slightly lower frequency of CD1a+cells in serum-free conditions. 
Although, CD1a is a classic marker of DCs, not all DCs that can perform as APCs have CD1a 
(Gogolak et al., 2007). In addition, we obtained a satisfactory and similar T cell proliferation 
at a 1:10 DC to T cell ratio using DCs generated in serum-free and serum-containing media. 
We confirmed with the company (Cellgenix) the absence of leptin, insulin and other 
adipokines in the CellGrow media under confidential agreement. Therefore, we concluded 
that this media was optimal to study the effect of leptin on DCs phenotype and function. 
 When leptin was added during DC differentiation, we observed a slight significant rise 
in CD86 expression. ImDCs generated in presence of leptin displayed higher co-stimulation 
capacities. We found no differences in CD80, HLA-DR and DC-SIGN expression with leptin. 
Unfortunately, we failed to repeat these findings using a new batch of leptin from the same 
company. We tested a new source of leptin, added leptin at different times and different 
concentrations, but none of this modification altered CD86 expression. We concluded that the 
preliminary effect observed was caused by LPS contamination of leptin. Finally, we 
demonstrated that uptake of antigens by DCs in presence of leptin is not affected. 
 This work shows no effect of leptin on T cells responses and DC phenotype and 
function in contrast to published reports. However, we used a variety of techniques to 
investigate the effect of leptin and all were optimised in serum-free media contrary to 
previous studies, which used bovine serum in all their assays. We believed that investigating 
T cell responses in serum-free media would provide more accuracy as this would increase the 
sensitivity of cells to leptin.  
 We now believe that the lack of response to leptin may be caused by differential 
effects on naive and memory T cells. Indeed, studies have now shown that leptin up-regulates 
naive T cell proliferation but inhibits memory T cell stimulation by anti-CD3 and monocytes 
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(Lord et al., 2002). Therefore, unless we specifically select memory and naive T cells, we 
would not be able to pick up differences in whole PBMC or whole CD4+ T cells assays as any 
increase of proliferation would be blunt by any inhibition. 
 Another potential rationale behind the discrepancies that we observe compared to 
published results, would be a specific action of leptin on APC. Indeed, some reports show 
specific stimulation of monocytes but not T cells by leptin (Santos-Alvarez et al., 1999, 
Zarkesh-Esfahani et al., 2001). In addition, recent evidence has demonstrated that leptin 
increases cytokine and chemokine production such as IL-1β, IL-6, IL-12 and TNF-α and 
reduction of IL-10 by human imDCs in vitro (Mattioli et al., 2005 and 2008). These two 
studies have also determined that leptin increases imDCs motility by inducing actin filament 
polarisation and trigger higher T cells responses towards a Th1 phenotype. Leptin can also 
protect imDCs from apoptosis and these DCs are able to enhance strong CD8+ T cells 
responses (Mattioli et al., 2005 and 2008). Others have shown that absence of leptin receptors 
affects bone marrow derived DCs number and function in vivo (Lam et al., 2007). Indeed, 
db/db mice have lower number of DCs because of high rate of apoptosis. In addition, these 
DCs have reduced co-stimulatory molecules expression and a Th2 cytokine profile that 
reduced their capacity to stimulate T cells. However, we did not find any modulation of DCs 
phenotype and function by leptin. 
 
 Finally, we investigated the effect of leptin on PBL trans-endothelial migration. These 
assays were historically developed in medium containing 20% of bovine serum, optimal to 
HUVEC growth and maintenance. High levels of adipokines can be found in bovine serum 
and show biological activity (Wang et al., 2004). Therefore, a 20% supplementation of the 
media results in high levels of contaminating adipokines in the experimental assays. Hence, 
we optimised both static and flow assay with HUVEC cultured in low-serum medium (2%) 
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prior to the experiments. In these conditions, we found no difference in the capacity of low-
serum-cultured HUVEC to support recruitment, firm adhesion and transmigration compared 
to the classic method with 20% serum. In this chapter, we therefore worked using this low 
serum system in both static and flow conditions and this allowed us to study the full effect of 
the adipokines we considered. 
 
 Given the reported pro-inflammatory properties of leptin, we hypothesised that TNF-
α/IFN-γ-induced transmigration through endothelium would be increased in the presence of 
this adipokine. Interestingly, our data on LEPR indicated that leptin might have effects on 
either lymphocytes or HUVEC, as both have high expression of this receptor. Indeed there 
was the possibility that it might have differential effects on the different cells. Interestingly, 
we observed a significant effect of leptin on the transmigration of PBL when HUVEC 
unstimulated with cytokines were treated with leptin and used as the adhesive substrate. PBL 
transmigration was significantly increased with a concomitant decrease of firm adhesion. This 
observation is in agreement with previous studies showing that leptin was important for 
facilitating the migration of monocytes and macrophages (Gruen et al., 2007). We did not 
investigate the effect of leptin pre-treatment on PBL in unstimulated HUVEC conditions, 
although in the light of these observations, this would be worth examining as well. The fact 
that the EC were unstimulated by cytokines may indicate that leptin plays a role in the basal 
trafficking of PBL which occurs during immune surveillance, a process that occurs 
independently of inflammation.  
 Intriguingly, we found that when an inflammatory stimulus was utilised to stimulate 
the HUVEC (i.e. IFN-γ/TNF-α), the effects of leptin were “anti-inflammatory”, i.e. 
transmigration was significantly reduced. Moreover, this effect was evident whether HUVEC 
or PBL were treated with leptin. The effects of leptin in this assay were not dependent upon 
Chapter 4-                                                  An examination of the effects of leptin on immunity 
135 
 
regulation of endothelial cell adhesion receptors, as we did not see any changes in the levels 
of VCAM-1, ICAM-1 or E-selectin after treatment of HUVEC with this agent. The anti-
inflammatory effects of leptin are not unprecedented, as others have shown similar effects on 
proliferation of T cells when naive T cells were studied (Okamoto et al., 2000; Lord et al., 
2002). 
 We believe that more stringent studies are merited to understand the effects of leptin 
on lymphocyte trafficking. These experiments could involve manipulation of the cytokine 
stimulatory regimen, as it is possible that leptin may induce differential responses in HUVEC 
activated through different routes. Should the pattern of lymphocyte trafficking observed here 
be confirmed this may indicate a physiological role for leptin in immune surveillance as well 
as a role in regulating lymphocyte traffic in inflammation. Indeed, under physiological 
conditions, lymphocytes are recruited into tissues to patrol for antigens, thus allowing 
immune surveillance. Trafficking is highly increased during inflammation, however, the 
lymphocyte subsets recruited may not be the same and their effector functions in these two 
scenarios are likely to be divergent in order to match the needs of process being supported. A 
good example of this is in the liver where lymphocytes continuously patrol in the absence of 
inflammation and different populations can be rapidly expanded in response to infection or 
injury by recruiting lymphocytes from the blood (Lalor et al., 2002). In this work, we show 
that leptin may be able to regulate both of these aspects of lymphocyte trafficking, promoting 
basal immune surveillance, while providing a check to the magnitude of the inflammatory 
response. 
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 Conclusions 
 I do not find that leptin modulates T cell responses or APC phenotype and function to 
the degree described in published literature. Ideally, it would have been interesting to further 
test the effect of leptin on other DCs characteristics such as secretion of cytokines and 
morphological changes that are crucial to DCs function (Mattioli et al., 2005, Al-Awan et al., 
2001). It would have also been relevant to test the rate of apoptosis in presence of leptin as 
studies have shown that leptin has anti-apoptotic effects (Mattioli et al., 2009). Finally, leptin 
is able to modulate lymphocyte trafficking depending on the inflammatory status of the 
endothelium. 
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1. Introduction 
 
 Lymphocytes play a key role in the development of T1D (Imagawa et al., 1999, 
Hanafusa et al., 2008). Lymphocytes traffic to the islets through the pancreatic network of 
capillaries. However, to infiltrate the islets, lymphocytes must first cross the endothelial cells 
which line the vessels. Whilst immunotherapies have focused on depleting autoreactive cells, 
blockade of their trans-endothelial migration could also represent a therapeutic target. 
Emerging evidence of the immunomodulatory role of adipokines imply their therapeutic 
potential in this regard. 
 We were therefore interested in how adipokines influence the migration of 
lymphocytes across inflamed endothelium. Here, we have examined the effect of the 
adipokine adiponectin.  
 Adiponectin is the most abundant circulating adipokine, being present at 
concentrations of 3-30µg/ml in the blood plasma (Arita et al., 1999). In addition, adiponectin 
has previously been associated with an anti-inflammatory role in the immune system 
(Chapter 1-section 3.2.3). Data generated in our group by Dr Terence Pang have shown that 
the expression of adiponectin receptors on PBMC from patients with T1D is decreased, while 
no changes were observed for circulating adiponectin levels. Moreover, adiponectin is 
associated with inhibition of leukocyte migration (Cao et al., 2009, Ouedraogo et al., 2007). 
Mice lacking adiponectin exhibit a 2-fold increase of leukocyte rolling and a 5-fold rise in 
leukocyte adhesion on endothelium in peri-intestinal venules when assessed using intravital 
microscopy. Adiponectin had similar effects on adhesion of leukocytes in the isolated aortas 
of adiponectin knock-out mice (Ouedraogo et al., 2007). This study and others have shown 
that adiponectin may regulate leukocyte migration by altering endothelial expression of 
VCAM-1 and E-selectin (Ouedraogo et al., 2007; Ouchi et al., 1999; Cao et al., 2009). Whilst 
these in vivo studies using mice indicate a role for adiponectin in the control of leukocyte 
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migration, no data is available using human cells. Here, we report the first data on the role of 
adiponectin in regulating the trafficking of human leukocytes. We chose to use HUVEC as a 
model of endothelium for the reasons mentioned in the previous chapter. Furthermore, other 
studies have shown the expression of both adiponectin receptors in HUVEC (Hattori et al., 
2003; Lee et al., 2008; Zhang et al., 2008; Xu et al., 2010). It is therefore important to test 
adiponectin in migration assays using human endothelium and primary leukocytes. Here, we 
report some of the first assays of this type, in work conducted in collaboration with Drs Ed 
Rainger and Helen McGettrick. In these studies, we used the same conditions of HUVEC 
culture optimised in the assays with leptin i.e. low serum conditions and stimulation with 
TNF-α and IFN-γ. 
 
2. Results 
2.1. Adiponectin strongly inhibits lymphocytes transmigration 
2.1.1. Treatment of HUVEC with adiponectin affects lymphocyte transmigration 
 First, we aimed to confirm the expression of both adiponectin receptors AR1 and 2 on 
HUVEC using flow cytometry and qPCR. AR1 and AR2 expressions were found on 
HUVECs at both protein and mRNA level (Figure 5-1). AR2 expression was significantly 
higher than AR1 at mRNA level.  
 To determine whether adiponectin could influence lymphocyte migration, we 
measured lymphocyte recruitment on TNF-α/IFN-γ-stimulated HUVEC. In static conditions, 
treatment of HUVECs with 15μg/ml of adiponectin for 24 hours did not alter total adhesion of 
PBL (Figure 5-2a). However, there was a significant increase of firm adhesion of PBL on the 
endothelium and a concomitant reduction of PBL transmigration (Figure 5-2b, c).  
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Increasing dose of adiponectin (0.0001 to 15μg/ml) concentrations diminished the effect on 
PBL transmigration, thus indicating that the effect is dose-dependent (Figure 5-2d).  
 Next, we repeated these experiments in flow conditions, which more closely represent 
physiological conditions. Similarly to static assays, total adhesion is unchanged and 
transmigration is reduced on adiponectin-treated HUVEC (Figure 5-3). Interestingly, there is 
a trend to an increase in rolling with adiponectin treatment, suggesting an impairment of 
either chemokines-induced activation of leukocytes or changes in the counter receptors for 
leukocyte integrins. 
 We went on to verify whether the adiponectin inhibition of PBL transmigration was 
mediated via AR1 and AR2. AMPK is an important intermediate of AR1 and AR2 signalling 
that mediates the downstream effects of adiponectin binding to these receptors. Therefore, we 
used a common inhibitor of AMPK, referred as AMPK compound C, in order to block the 
adiponectin receptor signalling pathway. Whilst in previous experiments, HUVEC were 
treated with adiponectin for 24 hours, this degree of exposure to the AMPK compound C was 
cytotoxic. Therefore, the conditions were adjusted to a 30 minutes treatment of cytokine-
stimulated HUVEC with the AMPK compound C followed by one-hour treatment with 
adiponectin. Adiponectin significantly reduced PBL transmigration even after the brief 
treatment (Figure 5-4). Pre-treatment with AMPK compound C restored PBL transmigration 
to the control levels, indicating that effects of adiponectin on lymphocyte transmigration were 
mediated via AR1/AR2 receptors.  
 However, APMK is involved in numerous functions and signalling cascades 
(Reviewed in Hardie, 2011), and off-target effects are therefore possible in this experiment. In 
order to ensure the involvement of the receptors, we proceeded to knock-down AR1 and AR2 
expression in HUVEC using siRNA strategies. Transfection of a pool of four siRNA duplexes 
targeting the receptors led to an average of 95% and 88% knock-down of AR1 and AR2 
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respectively (Figure 5-5a). Co-transfection of both sets of siRNA duplexes slightly reduced 
the knock-down efficiency to an average of 87% and 72% for AR1 and AR2 respectively. 
Scramble siRNA duplexes were used as a negative control. After 48 hours of siRNA 
incorporation, HUVEC were stimulated with TNF-α and IFN-γ in presence or absence of 
adiponectin at 15µg/ml. Surprisingly, knock-down of both receptors at the same time did not 
reverse the effects of adiponectin (Figure 5-5b). We therefore proceeded to knock down each 
receptor individually. Preliminary data show that the effects of adiponectin are lost in the 
absence of AR2, indicating that the effects of adiponectin could be mediated by this receptor. 
However, the data are representative of a single experiment and should be reproduced in order 
to draw firm conclusions. 
 Finally, we tested whether the treatment of HUVEC with adiponectin could down-
regulate the expression of adhesion molecule and chemokines. These changes were assayed 
by flow cytometry using unstimulated, TNF-α/IFN-γ stimulated and TNF-α/IFN-
γ/adiponectin stimulated HUVEC. Adiponectin did not influence the frequency, surface 
expression and gene expression of VCAM-1, ICAM-1 or E-selection (Figure 5-6a, b). In 
addition, we observed no difference in gene expression of the IFN-γ-inducible chemokines in 
presence of adiponectin (CXCL9-11) (Figure 5-6c). 
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Figure 5-1: ARs are expressed on HUVEC 
The expression of ARs on HUVEC was determined by flow cytometry and qPCR. (a) 
HUVEC were gated on their forward/side scatter profile and AR1 (green line) and AR2 (blue 
line) expression were determined using the isotype (solid grey) as negative control to set the 
AR positive gate. (b) Number of cells positive for AR1 and AR2 and their surface expression 
are similar on HUVEC. (c) AR1 and AR2 gene expression was quantified using qPCR. Data 
are a pool of at least three experiments and were analysed by t-test.  **p≤0.01. 
a)
b)
c)
Isotype
AR1
AR2 
AR1         AR2 AR1         AR2
AR1         AR2
Chapter 5-          The effect of adiponectin on the trans-endothelial migration of lymphocytes 
143 
 
 
Figure 5-2: Treatment of HUVEC with adiponectin reduces PBL transmigration in 
static conditions 
HUVEC were cultured in low serum medium and stimulated with TNF-α/IFN-γ for 24 hours 
in absence or presence of increasing dose of adiponectin. (a) PBL adhesion was not affected 
by adiponectin and (b) firm adhesion is increased. (c) PBL transmigration was significantly 
reduced from 43% (top) to 17% (bottom) with adiponectin treatment at 15µg/ml and (d) this 
effect is dose dependent. Data are a pool of at least three experiments and were analysed using 
t-test and one-way ANOVA and Dunnett’s multiple comparisons post-test. **p≤0.01, 
***p≤0.001; ns=non-significant. 
 
TNF-α/IFN-γ- No adiponectin
TNF-α/IFN-γ- Adiponectin 15µg/ml
a) b)
c)
c) d)
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Figure 5-3: Treatment of HUVEC with adiponectin reduces PBL transmigration in flow 
conditions 
HUVEC were cultured in low serum medium in Ibidi slides and stimulated with TNF-α/IFN-γ 
for 24 hours in absence or presence of adiponectin at 15µg/ml. (a) Total PBL adhesion was 
unchanged and (b) there is a trend to increased rolling. (c) PBL transmigration was reduced 
with adiponectin treatment of HUVEC. Data are a pool of three experiments realised in 
duplicates and were analysed using t-test. ***p≤0.001. 
 
 
 
 
 
 
a) b)
c)
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Figure 5-4: AMPK inhibition restores normal level of transmigration 
HUVEC were cultured in low serum medium and stimulated with TNF-α/IFN-γ for 24 hours. 
AMPK compound C inhibitor was added at 1µg/ml for 30 minutes prior to addition of 
adiponectin at 15µg/ml for 1 hour. Adiponectin treatment induced a decrease of 
transmigration, which was restored to normal controls levels with AMPK inhibition. AMPK 
inhibitor on its own did not change transmigration. Data are a pool of three experiments and 
were analysed using one-way ANOVA and Bonferroni’s multiple comparisons post-test. 
**p≤0.01, ***p≤0.001. 
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Figure 5-5: Effect of AR1 and AR2 knock-down on HUVEC 
HUVEC were transfected with siRNA against AR1 (R1) and AR2 (R2) or scramble versions 
of the target siRNA. (a) Knock-down of both receptors was efficient in either single or double 
transfections, no decrease was observed with the control scrambled siRNA. (b) After 48 
hours, HUVEC were stimulated with TNF-α/IFN-γ and adiponectin and PBL transmigration 
was measured by phase contrast videomicroscopy. The data are a pool of three experiments 
except for migration experiments on single receptor knock-down, and were analysed using 
one-way ANOVA and Bonferroni’s multiple comparison post test. *p<0.05, **p<0.01, 
***p<0.001.  
 
AR1
AR2
a)
b)
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Figure 5-6: Adiponectin does not modulate expression of adhesion molecules and 
chemokines on HUVEC 
HUVEC were cultured in absence or presence of adiponectin at 15µg/ml and adhesion 
molecules expression was measured by flow cytometry. (a) No significant changes were 
observed with adiponectin treatment for ICAM-1, VCAM-1 and E-Selectin frequency and (b) 
surface expression. Significant differences were found for VCAM-1 frequencies between 
unstimulated and stimulated HUVEC. (c) mRNA was extracted from 
TNFα/INFγ/±adiponectin-treated HUVEC and adhesion molecules and chemokines 
expression was quantified by qPCR. Data are a pool of at least two experiments and were 
analysed using one-way ANOVA and Bonferroni’s multiple comparisons post-test. **p≤0.01. 
a)
b)
Untreated
Adiponectin-treated
c)
0      0      15     0       0     15      0      0     15
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2.1.2. Treatment of PBL with adiponectin inhibits lymphocyte transmigration 
 The PBL subset used in our ex-vivo assays includes memory and naive CD4+ and 
CD8+ T cells, B cells, NK cells, CD56high NK cells and NK T cells. Pang et al. have 
demonstrated that mainly B cells and NK cells express the adiponectin receptors in the 
lymphocytes pool. To further investigate the expression pattern of the receptor, we assessed 
AR1 and AR2 on memory (CD4+/CD8+CD45RO+) and naive (CD4+/CD8+CD45RO-) T cells, 
as well as B cells, NK cells (CD56+CD3-), CD56highNK cells (CD56highCD3-) and NK T cells 
(CD56+ CD3+) (Figure 5-7). Both receptors are expressed on B and NK cells (Figure 5-8). 
AR1 and 2 are also highly expressed on NK T cells and CD56high NK cells. On all other T 
cells subsets, AR1 and AR2 expression is low (or absent) and there are no major difference 
between the memory and naive subsets. 
 Next, we aimed to investigate the effect of treating PBL with adiponectin for one hour 
prior to migration on TNF-α/IFN-γ-stimulated HUVECs in static conditions. Under these 
conditions, adiponectin considerably reduced transmigration, and this effect is dose-dependent 
(Figure 5-9a, b). Adiponectin had an EC50 of 0.94µg/ml in these experiments, calculated 
using non linear regression analysis (Figure 5-9d). The R2of the curve fitting to the data is 
0.58, which indicates the goodness of the non linear regression fit is close to 1. The number of 
cells firmly adhered to the endothelium was reciprocally increased (Figure 5-9c) but no 
changes were observed on total adhesion or the velocity of lymphocyte migration underneath 
the endothelium (Figure 5-10). Similarly, adiponectin lowered PBL transmigration in flow 
conditions but no effect was observed on total levels of lymphocyte capture by the 
endothelium (Figure 5-11). Furthermore, there was a trend to elevated rolling for 
adiponectin-treated PBL.  
 We then checked whether the inhibition of PBL transmigration by adiponectin was 
mediated by AR1 and 2 signalling. PBL were pre-treated for 30 minutes with the AMPK 
Chapter 5-          The effect of adiponectin on the trans-endothelial migration of lymphocytes 
149 
 
inhibitor compound C, followed by adiponectin for an hour. AMPK compound C reversed the 
effects of adiponectin and restored PBL transmigration to levels comparable with those 
observed on cytokine-treated HUVEC (Figure 5-12). These results support the concept that 
AR1/AR2 in lymphocytes is also important for transmigration of these cells. However, as 
mentioned earlier, AMPK is involved in numerous functions and signalling cascades 
(reviewed in Hardie, 2011). Therefore, we attempted to knock down the AR1/AR2 receptors 
on PBL using siRNA. Transfection of lymphocytes is challenging, so we started by 
optimising the transfection efficiency using a random siRNA coupled to FITC, which allowed 
detection of transfected cells by flow cytometry. Using this method, we obtained a higher 
transfection efficiency using the Amaxa technology compared to lipid-mediated transfection 
(Lipofectamine) (Figure 5-13a). Transfection of a pool of four siRNA targeting both 
receptors led to an average of 63% and 74% knock-down of AR1 and AR2 respectively 
(Figure 5-13b). Scramble siRNA were used as a negative control and also induced AR1 and 
AR2 knock-down (57% and 72% respectively). After comprehensive analysis of AR1 and 
AR2 expression profile on untransfected compared to transfected PBL, we realised that the B 
cell and NK cells subsets were missing in the transfected conditions (Figure 5-14). It appears 
that neither transfection methods is suitable for treating B cells and NK cells which we 
assume are killed by this process. Because B cells and NK cells express the highest levels of 
AR1 and AR2 in the PBL population, the knock-down at first analysis appeared to be 
efficient. However, in reality the loss of these receptors simply reflected the death of the 
receptor bearing cells. Because of the technical difficulties encountered, we could not assay 
the effect of AR1/ AR2 knock-down on adiponectin-mediated inhibition of PBL 
transmigration. 
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Figure 5-7: AR expression on PBL subsets 
(a) Representative dots plots of AR1 and AR2 expression on PBL subsets. Viable cells were 
gated based on PI staining and PBL were gated on their forward/side scatter profile. B cells 
were identified with CD19 labelling, CD4+ and CD8+ T cells were gated and CD45RO allowed 
identifying the memory and naive subsets. (b) The different NKs populations were identified 
using CD3 and CD56. AR expression was determined based on the isotype control for each 
subset. Numbers represent the quadrants and gates frequencies. The data are representative of 
seven healthy controls. 
a)
b)
A
R
s
CD19
AR1 AR2
A
R
s
CD45RO
A
R
s
CD45RO
Gated on 
CD4+ T cells
Gated on 
CD8+ T cells
C
D
3
CD56
Isotype
NK T cells (CD3+ CD56+)
CD3-CD56high NK cells
CD3-CD56+ NK cells
Chapter 5-          The effect of adiponectin on the trans-endothelial migration of lymphocytes 
151 
 
 
Figure 5-8: ARs frequencies on PBL subsets 
Viable cells were gated based on PI staining and PBL were gated on their forward/side scatter 
profile. Each subset was gated based on their markers expression: CD19, CD56, CD3, CD4, 
CD8 and CD45RO. AR1 (a) and AR2 (b) expression was calculated by subtraction against the 
negative isotype control. The data are mean±SEM and are a pool of seven healthy controls. 
Data were analysed using one-way ANOVA and Bonferroni’s multiple comparisons post-test. 
***p≤0.001. 
 
 
 
a)
b)
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Figure 5-9: PBL treated with adiponectin have reduced transmigration capacities in 
static conditions 
HUVEC were cultured in low serum medium and stimulated with TNF-α/IFN-γ for 24 hours 
in absence of adiponectin. PBL were isolated and treated with adiponectin at 0.0001 to 
15µg/ml during one hour. (a) PBL transmigration was significantly reduced from 43% (top) to 
8.33% (bottom) with adiponectin treatment at 15µg/ml. (b) This effect is dose dependent and 
(c) firm adhesion of adiponectin-treated PBL is increased. Data are a pool of at least three 
experiments and were analysed using t-test and one-way ANOVA and Dunnett’s multiple 
comparisons post-test. *p≤0.05, **p≤0.01, ***p≤0.001. An EC50 of 0.94µg/ml was 
calculated using non linear regression analysis.  
 
TNF-α/IFN-γ- No adiponectin
a)
TNF-α/IFN-γ- Adiponectin 15µg/ml
b)
c)
d)
EC50= 0.94µg/ml
R2= 0.5805
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Figure 5-10: Adiponectin on PBL does not influence total recruitment and velocity 
HUVEC were cultured in low serum medium and stimulated with TNF-α/IFN-γ for 24 hours 
in absence adiponectin. There were no significant changes in (a) total adhesion and (b) 
velocity of the transmigrated cells after adiponectin treatment of PBL. Data are a pool of at 
least three experiments and were analysed using t-test and one-way ANOVA and Dunnett’s 
multiple comparisons post-test.  
 
 
 
 
 
a)
b)
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Figure 5-11: PBL treated with adiponectin have reduced transmigration capacities in 
flow conditions 
HUVEC were cultured in low serum medium in Ibidi slides and stimulated with TNF-α/IFN-γ 
for 24 hours in absence of adiponectin and PBL were pre-treated with adiponectin at 15µg/ml 
during one hour prior to migration. (a) There is no change in total adhesion and (b) a trend to 
increased rolling. (c) PBL transmigration was reduced from an average of 46% to 26% with 
adiponectin treatment. Data are a pool of three experiments realised in duplicates and were 
analysed using t-test. ***p≤0.001. 
 
 
 
 
 
a) b)
c)
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Figure 5-12: AMPK inhibition restores PBL transmigration 
HUVEC were cultured in low serum medium and stimulated with TNF-α/IFN-γ for 24 hours. 
AMPK compound C inhibitor was added at 10µg/ml for 30 minutes prior to addition of 
adiponectin at 15µg/ml for one hour. Adiponectin treatment induced a decrease of 
transmigration, which was restored to normal controls levels with AMPK inhibition. AMPK 
inhibitor on its own did not change transmigration. Data are a pool of three experiments and 
were analysed using one-way ANOVA and Dunnet’s multiple comparisons post-test. 
**p≤0.01, ***p≤0.001. 
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Figure 5-13: Transfection of PBL with siRNA targeting AR1 and AR2 
(a) PBL were transfected with siRNA-FITC using Amaxa or Lipofectamine techniques. 
Amaxa transfection leads to higher siRNA-FITC entry into the cells. (b) PI staining shows 
good viability of transfected cells and PBL were gated on forward/side scatter to determine 
ARs expression by setting the gate on the isotype control. (c) PBL were then transfected with 
a pool of four siRNA targeting AR1 or AR2 and both receptor expression was measured by 
flow cytometry. AR1 and AR2 expression are reduced on cells transfected with siRNA 
against AR1 or AR2, but the scramble negative control also induced ARs knock-down. The 
data are representative of at least three experiments. 
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Figure 5-14: AR knock-down reflects B and NK cell death 
Numbers represent gate frequencies. PBL were transfected with siRNA against AR1 using the 
Amaxa technology. The frequencies of CD19+ B cells and NK cells (CD3-CD19-) were 
reduced when cells were transfected with siRNA (right dot plot) compared to untransfected 
cells (left dot plot). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Untransfected Transfected siRNA-AR1
C
D
3
CD19
Chapter 5-          The effect of adiponectin on the trans-endothelial migration of lymphocytes 
158 
 
2.2. Adiponectin-mediated inhibition of transmigration is altered in T1D 
 Finally, we examined whether adiponectin could modulate transmigration of PBL 
from patients with T1D. Clinical parameters of healthy controls (HC) and T1D subjects are 
described in Table 5-1. Thirteen Caucasian or Asian age and BMI matched female and male 
subjects were recruited from the Diabetes Clinics of the Birmingham University Hospital 
along with twelve healthy laboratory colleagues. The cohort exhibited no significant 
differences for age and BMI between the HC and T1D groups. Most patients with T1D had 
established diabetes but two were newly diagnosed.  
 
 HC T1D 
N 12 13 
n Female/Male 6/6 5/8 
Age (years) 42.07 ± 14.98 46.77 ± 11.3 
BMI (kg.m2) 23.56 ±8.3 25.87 ± 4.53 
Duration of diabetes (years) NA 18.8 
Table 5-1: Clinical parameters of the patients included in the study 
Data are represented as Mean ± SD and analysed using non-parametric t-test. No significant 
differences for age and BMI were found between HC and T1D subjects.  
 
 
 First, we analysed the expression profile of AR1 and AR2 using flow cytometry on 
each PBL subsets in both groups. PBL were gated on PI, forward/side scatter and pulse width 
plots. The expression of both receptors was reduced on PBL from patients with T1D 
compared to “age matched” healthy controls (Figure 5-15).  The different PBL sub-
populations were identified by CD19 for B cells, CD3 for T cells, CD3+CD56+ for NK T 
cells, CD3-CD56+ for NK cells and CD3-CD56high for CD56high NK cells. Closer analysis of 
the expression of both receptors on B cells and T cells revealed no difference in AR1 and 
AR2 frequency between HC and T1D (Figure 5-16). In both groups however, the expression 
of AR1 and AR2 was very high on B cells compared to T cells, which confirms earlier 
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findings (Pang, Narendran, 2008). Interestingly, NK T cells exhibited a significantly lower 
expression of both receptors in T1D (Figure 5-17).  
 We went on to explore whether adiponectin modulates transmigration of PBL from 
patients with T1D at the same magnitude to healthy controls. The behaviour of PBL in 
response to adiponectin was consistent with previous results in the HC group (Figure 5-18). 
However, the adiponectin inhibition of transmigration was impaired with PBL from T1D 
patients (Figure 5-19).  
 Finally, as we observed a reduction in adiponectin receptors in T1D, we speculated 
whether this could be associated with the reduced effect of adiponectin observed on PBL 
transmigration. Indeed, the levels of both AR1 and AR2 are positively correlated with the 
percentage of inhibition of transmigration by adiponectin, to the point where the T1D and HC 
cohorts could be separated by plotting these parameters on separate axis (Figure 5-20). 
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Figure 5-15: PBL from patients with T1D express less adiponectin receptors 
(a) Representative histograms of AR1 and AR2 expression on PBL from healthy controls (top 
panel) and patients with T1D (bottom panel). (b) AR1 and (c) AR2 frequencies were 
determined for each subject by setting the gate on the isotype control and subtracting the 
isotype frequency from the AR staining. For example, the isotype frequency for HC (a, top 
panel) is 2.02% and AR1 is 25.5%. So the calculated AR1 expression is: 25.5%-2.02%= 
23.48%. Data are represented as mean±SEM and were analysed using t-test or Mann Whitney 
t-test when data did not pass the Kolmogorov-Smirnov normality test. *p≤0.05, **p≤0.01. 
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Figure 5-16: AR expression is not affected on B and T cells from patients with T1D 
Representative dot plots of (a) AR1 and (b) AR2 expression on B and T cells from healthy 
controls and patients with T1D. B cells were identified by their CD19 expression and T cells 
by CD3.  (c) AR1 and (d) AR2 frequencies were determined on both populations for each 
subject by setting the gate on the isotype control and subtracting the isotype frequency from 
the AR staining. No significant differences were found between the patients with T1D and the 
healthy controls. Data are represented as mean±SEM and were analysed using t-test. Data are 
a pool of seven subjects for both groups. 
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Figure 5-17: AR1 and AR2 expression is reduced on CD56high NK cells 
Representative dot plots of (a) AR1 and (b) AR2 expression on NK cell subsets from healthy 
controls and patients with T1D. NK cells, CD56highNK cells and NK T cells were identified 
by their expression of CD3 and CD56 as described earlier. (c) AR1 and (d) AR2 frequencies 
were determined on the three populations for each subject by setting the gate on the isotype 
control and subtracting the isotype frequency from the AR staining. Data are represented as 
mean±SEM and were analysed using t-test. Data are a pool of seven subjects for both groups. 
***p≤0.001. 
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Figure 5-18: PBL from T1D patients are released from the inhibitory effect of 
adiponectin on lymphocyte transmigration 
HUVEC were cultured in low serum medium and stimulated with TNF-α/IFN-γ for 24 hours 
in absence of adiponectin. PBL were isolated and treated with adiponectin at 15µg/ml for one 
hour. (a) PBL transmigration was significantly higher in patients with T1D: 31% of cells 
transmigrate (bottom) compared to 18% in HC (top) with adiponectin treatment at 15µg/ml. 
(b) This indicates that adiponectin-mediated inhibition of PBL transmigration is reduced in 
T1D. (c) The percentage of inhibition was calculated by dividing the percentage of 
transmigration with adiponectin treatment by the percentage of transmigration of untreated 
PBL. n= 13 for HC group and n=12 for T1D group. Data were analysed using t-test and one-
way ANOVA and Bonferroni’s multiple comparisons post-test. ***p≤0.001. 
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Figure 5-19: Total PBL adhesion is unchanged in T1D 
HUVEC were cultured in low serum medium and stimulated with TNF-α/IFN-γ for 24 hours 
in absence adiponectin. There were no significant changes in total adhesion between HC and 
T1D with or without adiponectin. Data are a pool of at least three experiments and were 
analysed using non-parametric one-way ANOVA and Bonferroni’s multiple comparisons 
post-test.  
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Figure 5-20: Levels of adiponectin receptors correlate with the capacity of adiponectin 
to inhibit PBL transmigration 
Correlations between frequency of (a) AR1 and (b) AR2 with the percentage of adiponectin 
inhibition of PBL transmigration were determined using linear regression analysis.  
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3. Discussion 
 
 We studied the effect of adiponectin on transmigration in order to examine the 
functional relevance of the different expression levels of adipokine receptors in T1D. Using 
an established model of lymphocyte migration, we show that adiponectin can strongly inhibit 
PBL transmigration by direct action on HUVEC and also on PBL. Additionally, we 
demonstrated that adiponectin-mediated inhibition of PBL transmigration is altered in T1D 
and this was significantly correlated with the level of adiponectin receptors expressed on 
PBL.  
 
 Measurement of PBL transmigration in vitro 
 Migration of PBL through endothelial cells has previously been studied using 
HUVEC, in both static and flow-based assays. HUVEC are well characterised, relatively easy 
to acquire and express the relevant adhesion molecules and chemokines required for efficient 
PBL recruitment. In static assays, PBL are allowed to settle on HUVEC monolayers in the 
absence of physical forces (Oppenheimer et al., 1990; McGettrick et al., 2007 and 2009). 
Static assays are relatively easy and quick to set up on clear plastic and require stimulation of 
HUVEC with both TNF-α and IFN-γ to support efficient recruitment of PBL (McGettrick et 
al., 2009). Under these conditions, adhesion and transmigration are observable as early as 6-8 
minutes after addition, using phase-contrast videomicroscopy. This is in comparison with 
widely used transwell systems in which PBL only migrate efficiently across endothelium and 
transwell membrane after about 18 hours (McGettrick et al., 2009). Indeed, the transwell 
system is not very physiological as it is unlikely that PBL takes so long to cross the 
endothelium in vivo. The only disadvantage of static assays on clear plastic is that it is not 
possible to analyse dynamic capture process as capture from flow and rolling cannot be 
distinguished. That is why we also confirmed our findings in flow assays. In this system, PBL 
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are perfused on the HUVEC monolayer at a specific shear stress (0.1Pa) (Luscinskas et al., 
1995; Bahra et al., 1998; McGettrick et al., 2009). This allows the quantification of total 
capture, rolling, firm adhesion and transmigration in a more physiological context. 
 Many studies have used T cell lines or stimulated T cells in migration assays. In our 
study, we studied migration of unstimulated PBL because evidences suggest that PBL can 
directly be recruited from the circulation during inflammation in vivo (Cose et al., 2007). In 
addition, TNF-α and IFN-γ stimulation provides the appropriate signals supporting PBL 
migration as it would in an inflammatory context. Indeed, HUVEC stimulation induces up-
regulation of ICAM-1, VCAM-1 and E-selectin expression as well as presentation of 
chemokines such as CXCL9, 10 and 11, required for efficient lymphocyte migration (Piali et 
al., 1998; Mazanet et al., 2000, McGettrick et al., 2009). 
 
 Effect of adiponectin on PBL transmigration 
 Previous studies in the adiponectin knock-out mouse model have demonstrated a role 
for adiponectin in regulating leukocyte migration. In this section, stimulated endothelium was 
treated with adiponectin for 24 hours or PBL were treated with adiponectin for one hour, 
before the adhesion assay. In both conditions, transmigration was drastically reduced, but the 
magnitude of the inhibition was more pronounced when the PBL were pre-treated with 
adiponectin.  
 Previous studies have linked the protective effect of adiponectin on vascular health to 
its capacity to preserve endothelial cell function. Indeed, low levels of adiponectin correlate 
with cardiovascular disease (Goldstein et al., 2007; Zhu et al., 2008) by causing impairment 
of endothelial-dependent vasodilatation in vivo (Ouchi et al., 2003; Shimabukur et al., 2003; 
Tan et al., 2004; Maruyoshi et al., 2005). These effects have been associated with regulation 
of endothelial cell derived nitric oxide production by adiponectin.  Indeed, aortic rings from 
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the adiponectin knock-out mouse show lower capacity to produce NO (Cao et al., 2009). Such 
effects have also been reported in bovine endothelial cells treated with adiponectin (Chen et 
al., 2003). Particularly relevant to our study, Ouedraogo et al, have reported elevated rolling 
and adhesion in the adiponectin knock-out mouse model. This was shown both in vivo, using 
intravital microscopy and ex-vivo using isolated mouse aorta. In the aortic preparations, 
monocytes adhesion was significantly increased in the knock-out tissue compared to wild-
type controls, and addition of adiponectin restored normal levels of rolling and adhesion in 
this assay and in the intravital model. In addition, this study linked the adiponectin-mediated 
regulation of leukocyte recruitment to the control of NO levels. The authors implied an effect 
of this pathway on E-selectin and VCAM-1 expression by the endothelium. This was also 
shown using human endothelial cells when adhesion of THP-1 monocytic cell line was the 
functional readout (Ouchi et al., 2003). To our knowledge the role of adiponectin in the 
regulation of lymphocyte trafficking has not been investigated with the exception of one study 
where lymphocytes were co-incubated with adiponectin and motility was observed in collagen 
gels (Lang et al., 2009). In these conditions, motility was not changed for CD8+ T cells. 
 In our system, we show for the first time that adiponectin inhibits lymphocyte 
transmigration across HUVEC. In this case, we pre-treated the HUVEC for 24 hours, 
similarly to previous studies (Ouchi et al., 2003). In this static assay, we observed a 
concomitant increase of firmly adhered PBL but no changes on total adhesion or migration 
velocities underneath the endothelium. These observations were reproduced in a flow based 
assay, which also showed modest changes in the levels of rolling cells. In addition, we found 
that inhibition of AMPK, a crucial intermediate of the adiponectin signalling cascade, inhibits 
the effects of adiponectin on lymphocyte transmigration. Although blockade of AMPK has 
widely been used to show a link between adiponectin and its receptors signalling (Son et al., 
2008), this is not an optimal test, as AMPK is involved in many other cellular functions, e.g 
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metabolism, regulation of mitochondrial biogenesis and disposal, cell polarity, cell growth 
and cell differentiation (Hardie et al., 2011). As no receptor antagonist is available, we aimed 
to knock-down the adiponectin receptors on HUVEC using siRNA as we have shown high 
expression on these cells. Knock-down of the receptors was efficient and we showed that the 
effect on HUVEC seem to be mediated by AR2. However, this experiment was only 
performed once due to the scarcity of HUVEC at this time.  
 Conversely to previous studies, we did not discern a modulation of E-selectin, ICAM-
1, VCAM-1, or the IFN-γ inducible chemokines, CXCL9, 10 and 11 on the endothelium in 
response to adiponectin, suggesting that another mechanism exists for regulating lymphocyte 
trafficking. We have not yet understood the mechanism of action of adiponectin on HUVEC, 
but we believe that adiponectin is altering either the firm adhesion of lymphocytes on the 
endothelium or the lipid signalling leading to trans-endothelial migration. The levels of 
adhesion per se, and the fraction of cells rolling are not altered, suggesting that the function of 
E-selectin is unaltered. Firm adhesion is only possible if the right chemokines signals activate 
LFA-1 (αLβ2) and VLA-4 (α4β1) integrins (Springer, 1994) so that they bind their endothelial 
cell borne receptors VCAM-1 and ICAM-1. However, in the absence of any discernable 
changes in chemokine expression we anticipate that adiponectin might be acting on the 
signalling process that modulates integrin function in lymphocytes.  
 
 Recruitment of lymphocytes is critical for the pathophysiology of vascular diseases 
(Joussen et al., 2004; Krieglstein et al., 2001). However, in physiological conditions, the 
recruitment of lymphocytes is minimal. Upon inflammation, adhesion molecules, selectins 
and chemokines are up-regulated at the surface of the endothelium with a concomitant 
increase of integrins expression on the circulating lymphocytes (Carlos et al., 1994). In 
conditions such as obesity, the perturbation of the physiology of adipose tissue causes up-
Chapter 5-          The effect of adiponectin on the trans-endothelial migration of lymphocytes 
170 
 
regulation of pro-inflammatory molecules and a decrease in secretion of anti-inflammatory 
mediators such as adiponectin (Festa et al., 2001). Consequently, prolonged exposure of the 
endothelium to these pro-inflammatory markers induces perturbations of endothelium 
homeostasis. Obesity is clearly associated with lower levels of adiponectin compared to 
healthy controls, which might contribute to the loss of control of leukocytes migration (Arita 
et al., 1999; Hotta et al., 2000; Pang et al., submitted). Inflammation is consequently 
maintained and can cause long-term complications. In our study, we were interested in T1D. 
Interestingly, this condition is not associated with changes in circulating adiponectin levels 
compared to healthy controls (Pang et al., submitted). However, T1D is also a chronic 
inflammatory disease. Here, we did not assess whether adiponectin could modulate the 
transmigration of patient PBL across endothelial cells treated with adiponectin. However, this 
would be worth investigating in the future. In addition, it would be interesting to test 
adiponectin on islet endothelium as these differ from our macrovascular model (Vajkoczy et 
al., 1995; Olsson et al., 2006). 
 In T1D, we found that expression of the adiponectin receptors on lymphocytes is 
lower compared to healthy controls. We have shown that lower levels of both receptors are 
negatively correlated to the capacity of adiponectin to inhibit lymphocyte transmigration. In 
other terms, low levels of adiponectin receptors reduce the sensitivity of lymphocytes to 
adiponectin. Although this is novel in the field of leukocytes recruitment to the endothelium, 
this was observed in our group before, when the co-stimulatory capacities of DCs were 
assayed (Pang et al., submitted). In this section, we also show for the first time that 
adiponectin can strongly inhibit lymphocyte trans-endothelial migration by action on the PBL 
themselves. These findings were also reproduced in flow conditions and inhibition of AMPK 
signalling rescued PBL transmigration from the adiponectin inhibition. We also transfected 
PBL with siRNA duplexes against the adiponectin receptors. However, expression of PBL 
Chapter 5-          The effect of adiponectin on the trans-endothelial migration of lymphocytes 
171 
 
sub-populations revealed that transfection caused a dramatic reduction in the number B 
lymphocytes and NK cells, which were probably killed by this process. We accept this as a 
limitation in this study, as we have not definitively confirmed that the effect of adiponectin on 
PBL is mediated by AR1 and/or AR2. This would be worth confirming in the future 
especially since studies have revealed that other receptors to adiponectin, such as T-cadherin, 
exist (Hug et al., 2004). Recent evidence shows that T-cadherin signals through AMPK to 
mediate the cardioprotective effects of adiponectin (Denzel et al., 2010). Indeed, levels of 
adiponectin dramatically increase in absence of T-cadherin, and studies have reported 
mutations on the T-cadherin gene that affects adiponectin levels are associated with risk of 
metabolic syndrome, T2D and stroke in the Chinese, Korean and Philipino populations 
(Chung et al., 2011; Wu et al., 2010; Jee et al., 2010). This suggests that in our system, T-
cadherin could also mediate the adiponectin-mediated inhibition of lymphocyte 
transmigration. However, we have failed to detect T-cadherin gene expression on whole 
PBMC or sorted T cells (data not shown). However, HUVEC exhibited high levels of T-
cadherin (dissertation Aled Benbow- Intercalating BMedSc student). We believe that T-
cadherin might be relevant for the effects of adiponectin observed by treating endothelium 
with this adipokine. As a matter of fact, some believe that T-cadherin and adiponectin 
receptors act in synergy to mediate vascular protection. This view is based on the evidences 
that absence of both AR1 and T-cadherin independently cause vascular problems because of 
the lack of adiponectin signalling (Denzel et al., 2010; Iwabu et al., 2010). 
 Although T cadherin may play a role on endothelial cells, our study shows that the 
capacity of adiponectin to inhibit PBL transmigration positively correlates with adiponectin 
receptor levels on PBL. This corroborates the involvement of these receptors in mediating 
adiponectin effects in our system. However, we acknowledge some limitations in the study of 
AR1/2 levels in T1D compared to HC. First, although we managed to match healthy controls 
Chapter 5-          The effect of adiponectin on the trans-endothelial migration of lymphocytes 
172 
 
to the patients with T1D for BMI and age, the subjects were not matched for gender and 
ethnicity. Gender and ethnicity induce variations in adiponectin levels and may affect the 
receptor levels (Barnes et al., 2008; Mente et al., 2010). Another limitation of this study is the 
absence of adiponectin receptors surface expression measured by MFI. At the time of sample 
processing, we faced equipment problems and we had to use a different flow cytometer to 
acquire the data. This consequently changed the MFI as this varies between machines 
depending on the lasers intensities and the parameters used. Therefore, we cannot compare 
surface expressions between the different subjects. We could also expect that adiponectin 
receptors expression would be lower on B cells from patients with T1D, therefore lowering 
the response of B cells to adiponectin. But this was not observed in our small cohort of 
patients. However, we found a significant decrease of adiponectin receptors expression on B 
cells in T1D compared to healthy controls in the subsequent cohort of patients that we used 
for the LEPR study (Pang PhD, data not shown). Indeed this cohort recruited more patients 
and controls, which were matched for gender, age and ethnicity. This level of control lacked 
in our cohort and this might have introduced bias in the receptor levels (Barnes et al., 2008; 
Mente et al., 2010). 
 
 Finally, it is worth indicating that in this study we used a human recombinant 
adiponectin kindly donated by Soren Tullin (NovoNordisk). This source of high molecular 
weight adiponectin has exceptionally low contents of endotoxins (0.6-3.21EU/mg) compared 
to commercially available sources (≥40EU/mg) (Turner et al., 2009). Indeed, it is crucial to 
use such a clean source of adiponectin as LPS contents of the commercially available sources 
have been associated with some contradictory data (Turner et al., 2009).  
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 Conclusions 
 We demonstrate that adiponectin prevents lymphocyte trans-endothelial migration in 
both HUVEC and PBL treatment conditions. This effect was dose-dependent in both 
circumstances and was reversed by AMPK inhibition. The adiponectin effect on PBL was lost 
in patients with T1D where adiponectin receptors expression is lower. This is consistent with 
our hypothesis that levels of adiponectin receptors determine the sensitivity of immune cells 
to adiponectin. The mechanism of adiponectin effect remains unclear, and will be explored in 
the next chapter. 
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1. Introduction 
 
 In agreement with previous data from our group, we found that AR1 and AR2 are 
mainly expressed on B cells, NK cells and NK T cells (Pang, Narendran, 2008). Surface 
expression of both receptors is absent from memory or naive CD4+ or CD8+ T cells. We 
therefore speculated that treatment of adiponectin was not directly acting on T cells to 
mediate their migration. Instead, we hypothesised that the effects of adiponectin on T cells 
were mediated through one of these subsets (i.e. B cells; NK cells or NK T cells)  
 
 In this chapter, we aimed to identify the mechanism of action underlying the inhibition 
of T cell trans-endothelial migration by adiponectin, in particular we examine the potential 
involvement of B and NK cells in this process. 
 
2. Results 
2.1. Adiponectin does not modulate integrins expression on PBL or their capacity to 
migrate towards chemokines 
 Here we aimed to understand how adiponectin modulated PBL transmigration. First, 
we checked that the inhibition of PBL transmigration by adiponectin was not simply a 
reflection of cell death or apoptosis induced by this agent. This was assessed using propidium 
iodide (PI) exclusion assay, which stains dead cells, as it can only enter the cell through 
permeabilised membranes. We observed no difference in frequency of PI positive cells in 
presence of adiponectin compared to the untreated PBL (Figure 6-1a). We went on to 
measure the expression of Caspase-3 in PBL in order to verify the effects of adiponectin 
treatment were through induction of PBL apoptosis. Neutrophils (as positive control) were 
cultured overnight, a process which induces a high rate of apoptosis. Active caspase-3 
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expression was detected in almost all neutrophils, indicating the high rate of apoptosis. In 
contrast, we did not detect the expression of active caspase-3 in freshly isolated PBL and we 
observed no effects of adiponectin treatment (Figure 6-1b). 
 Next we investigated whether adiponectin could modulate the expression of integrins 
and chemokine receptors on PBL, based on the supposition that these might modify the rate of 
PBL migration. We measured levels of αLβ2 (LFA-1), α4β1 (VLA-4), CXCR3 (receptor to 
CXCL9, 10, 11) and DP-2 (receptor to prostaglandin-D2) by flow cytometry after one hour 
treatment with adiponectin. We did not identify any significant changes in the frequencies of 
αLβ2, α4β1, CXCR3 and DP-2 positive cells, nor in the surface expression of these molecules 
on PBL treated with adiponectin compared to the untreated controls (Figure 6-2). 
 As no differences were found in the expression levels of CXCR3 and DP-2 receptors, 
we decided to analyse the migration of PBL treated with adiponectin towards their counter 
ligands, CXCL10 and PGD2, which are specifically involved in the transmigration process of 
PBL (Ahmed et al., 2011) For this purpose we set-up a chemotaxis assay using the Boyden 
chamber. The system is composed of two chambers separated by a filter with 8µm pores. The 
chemotactic agents are added to the bottom chamber and the PBL are placed in the top 
chamber. The number of cells that migrated through the filter was counted by acquisition of 
cell counts from the whole well volume on the flow cytometer. This assay revealed a strong 
migration of PBL towards SDF-1α, used as a positive control. Chemotaxis of PBL towards 
CXCL10 and PGD2 was significantly lower in comparison to the positive control. 
Importantly, we found no significant differences in chemotaxis towards SDF, CXCL10 or 
PGD-2 when cells were treated with adiponectin (Figure 6-3). 
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Figure 6-1: Adiponectin treatment does not cause PBL apoptosis and death 
PBL and neutrophils were isolated from blood, (a) stained with PI to measure cell death and 
for (b) Caspase-3 to quantify cell apoptosis. Neutrophils were cultured over night at 37ºC and 
stained the day after for Caspase-3. This induced high level of caspase-3 staining (left 
histograms) as expected. This was not observed for PBL treated with adiponectin for one hour 
(right histograms). The data are representative of three independent experiments for the PI 
staining and two for the Caspase-3 labelling. 
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Figure 6-2: Expression of integrins and chemokine receptors is not altered by 
adiponectin treatment 
PBL were isolated from the blood, stained for CXCR3, DP-2, α4β1 (VLA-4) and αLβ2 (LFA-1) 
and analysed by flow cytometry. (a) Representative dots plots for the expression of each 
molecule are shown. Gates were set on the isotype controls and there is no difference in 
absence or presence of treatment with adiponectin for one hour on (b) frequency and (c) 
surface expression. Data are shown as mean±SEM and are a pool of three independent 
experiments. Data were analysed using one-way ANOVA and Bonferroni’s multiple 
comparisons post-test. No significant differences were found. 
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Figure 6-3: Adiponectin does not influence PBL chemotaxis 
PBL were isolated from peripheral blood and incubated for one hour in presence or absence of 
adiponectin at 15µg/ml. After washes PBL were added to the top of the Boyden chamber. The 
bottom well contained media with SDF-1α (250ng/ml), CXCL10 (20ng/ml), PGD2 (1nM) or 
nothing.  After 4 hours at 37ºC, the total volume of the bottom well was acquired by flow 
cytometry to count the number of PBL that have migrated towards the chemokines. Data are 
shown as mean±SEM and are a pool of six donors. No significant differences were found 
between adiponectin treated and untreated PBL using one-way ANOVA and Bonferroni’s 
multiple comparisons post-test. 
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2.2. Adiponectin-mediated inhibition of PBL transmigration is lost upon 
depletion of B cells. 
 We and others have observed that T cells do not express AR1 and AR2 expression on 
the cell surface (Pang, Narendran, 2008). Thus we assumed that the effects of adiponection on 
T cell migration were mediated through another subset of PBL which did bare the receptors. 
We selectively removed B cells from the PBL population and analysed the effect of 
adiponectin under these conditions. We also looked at the effect of adiponectin on NK cells as 
they also express high levels of the receptors. 
 B cells were selectively removed from the PBL using anti-CD19 microbeads. This 
technique led to almost complete removal of B cells in the PBL pool, with on average only 
0.7% of B cells remaining in the B cell negative PBL (Bs-ve PBL) (Figure 6-4b). B cells 
were also negatively sorted for the assay, where B cells were treated for one hour with 
adiponectin and added back to the B cell depleted PBL preparations (Bs reconstitution). This 
technique of magnetic depletion yielded B cells with an average purity of 98% (Figure 6-4c). 
Similarly, NK cells were positively purified using anti-CD56 microbeads. This also achieved 
high purity (91%) (Figure 6-4d). We chose not to sort T cells using anti-CD3 microbeads, 
because in our hands this induced T cell activation and consequently modified T cell 
behaviour in our assays (Figure 6-5). Indeed, anti-CD3 positively selected T cells aggregate 
and do not transmigrate efficiently across the endothelium. 
 Using these tools we investigated the effect of removing B cells from the PBL. Bs-ve 
PBL fraction was treated with adiponectin for one hour and transmigration of the remaining 
cells was assayed in the usual fashion. We found that eliminating B cells from the PBL 
abrogated the adiponectin-mediated inhibition of PBL transmigration (Figure 6-6a). The 
addition of adiponectin stimulated B cells back into the B cell depleted preparations (1:10 
ratio) restored the inhibition of PBL transmigration by adiponectin (Figure 6-6a).  
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 Finally, we checked whether adiponectin could also affect NK cells. The whole 
population of CD56+ NK cells were positively sorted and treated with adiponectin for one 
hour. This population includes the three subsets of NK cells (identified in Chapter V). NK 
cells exhibited efficient migration across the endothelium but adiponectin was not able to 
reduce their transmigration (Figure 6-6b). Similarly, B cells treated with adiponectin and 
added to the NK cells fraction (Bs+ NKs) at 1:10 ratio did not induce inhibition of NK cell 
transmigration. These results indicate that the effect of B cells is specific for T cells. 
Moreover it transpires that the effects on T cells are probably specific to B cells, as NK cells 
treated with adiponectin and reconstituted with T cells (1:10), did not reduce T cell migration.  
 All together, these results indicate that the inhibition of PBL transmigration by 
adiponectin is mediated by B cells. These studies were also repeated under flow conditions 
(Figure 6-7). The Bs reconstitution data in these conditions did not reach significance, but the 
p-value is very close to 0.05 which suggests a trend to restoration of the adiponectin effect 
when B cells are added back to Bs-ve PBL. 
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Figure 6-4: Representative dot plots of B cell depletion and NK cells selection 
(a) Whole PBL were isolated from peripheral blood stained for B cell, T cell and NK cells 
markers. (b) PBL were depleted for B cells by anti-CD19 positive selection which removed 
almost all B cells giving the Bs-ve PBL fraction. (c) B cells were also negatively purified with 
99.2% purity and used for reconstitution of Bs-ve PBL fraction referred as Bs reconstitution 
fraction. (d) NK cells were positively selected for CD56 leading to 91.9% purity. The data are 
representative of at least four independent experiments 
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Figure 6-5: Anti-CD3 positive selection of T cells triggers cell activation and changesin 
the ability to migrate across endothelial cells 
CD3+ T cells were isolated from peripheral blood using anti-CD3 magnetic selection. (a) This 
technique led to 97.7% purity (left) but caused T cell activation as observed by the increase in 
granularity and size on the forward/side scatter dot plot (right). (b) Stimulation of T cells by 
anti-CD3 prompt T cells to form small aggregates on the top on the endothelium, which is 
typical of T cell stimulation in vitro. This alters the transmigration capacity of this population 
and therefore ruled out anti-CD3 positive selection for the future experiments. The data are 
representative of two independent experiments. 
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Figure 6-6:  B cells mediate the adiponectin-induced inhibition of PBL transmigration 
(a) PBL were isolated from peripheral blood and transmigration assays were performed using 
TNF-α/IFN-γ stimulated HUVEC and adiponectin pre-treated whole PBL, B cell depleted 
PBL (Bs-ve PBL), or B cell depleted PBL to which B cells had been re-constituted (Bs 
reconstitution) at 1 to 10 ratio. (b) Transmigration was also measured for NK cells (NKs), NK 
cells reconstituted with adiponectin-treated B cells (Bs+NKs) at 1 to 10 ratio, and for T cells 
reconstituted with adiponectin-treated NK cells (NKs+Ts) at 1 to 10 ratio. Data are shown as 
mean±SEM and are a pool of at least three independent experiments. Data were analysed 
using one-way ANOVA and Bonferroni’s multiple comparisons post-test. **p≤0.01, 
***p≤0.001. 
a)
b)
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Figure 6-7: B cells mediate the adiponectin-induced inhibition of PBL transmigration in 
flow conditions 
PBL were isolated from peripheral blood and transmigration assays in flow conditions were 
performed using TNF-α/IFN-γ stimulated HUVEC and adiponectin pre-treated B cell depleted 
PBL (Bs-ve PBL), or B cell depleted PBL to which B cells had been re-constituted (Bs 
reconstitution) at 1 to 10 ratio. No significant differences between adiponectin treated and 
untreated cells were found, but a trend was observed when B cells were added back to the 
PBL fraction. Data are shown as mean±SEM and are a pool of two independent experiments. 
Data were analysed using one-way ANOVA and Bonferroni’s multiple comparisons post-test. 
***p≤0.001. 
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2.3. B cells are recruited to the endothelium surface but do not transmigrate 
 Previous findings using transwell system show that the predominant subsets of PBL 
that migrate across the endothelium are CD4+ memory T cells followed by CD8+ memory T 
cells (McGettrick et al., 2009). However, there are no data available on the behaviour of PBL 
subpopulations in our in vitro system, especially on B cells and NK cells.  
 Here we aimed to identify the phenotype of PBL subsets that are firmly adhered to the 
endothelium (phase bright) and that have migrated across the HUVEC (phase dark). PBL 
were added to HUVEC that had been cultured in low serum media and stimulated with TNF-
α/IFN-γ for 24 hours. After removal of none-adherent cells, firmly adherent cells were 
harvested from the surface of the endothelium with EDTA and gentle agitation. Migrated cells 
were harvested along with the HUVEC monolayer using accutase treatment for 30 seconds. 
Both fractions were labelled for the B cells, CD4/CD8 memory/naive T cells, NK T cells, NK 
cells and CD56high NK cells subsets and analysed by flow cytometry. Under these conditions, 
we observed preferential recruitment of CD4+ memory T cells in both the firmly adherent and 
transmigrated populations (Figure 6-8 and 9). On the top of the endothelium, the percentage 
of CD4+ memory T cells was the highest followed by CD8+ memory T cells (Figure 6-9a). 
There was also recruitment of B cells, NK cells and CD56high NK cells. The main subsets that 
had transmigrated were CD4+ memory T cells, closely followed by NK T cells, naive CD8+ T 
cells and NK cells (Figure 6-9b). Very few B cells, CD4+ naive T cells and CD56highNK cells 
were found underneath the endothelium. 
 We then calculated the enrichment ratio on the surface and underneath the 
endothelium by dividing the number of cells firmly adhered or migrated for each subset by the 
number of cells added (based on whole PBL staining). This analysis generated slightly 
different results. On the top of the endothelium, we found enrichment for B cells, memory 
CD4+ and CD8+ T cells, followed by CD56high NK cells, NK T cells and naive CD8+ T cells. 
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Enrichment for naive CD4+ and NK cells was low on the endothelium surface (Figure 6-9c). 
Enrichment of different subsets in the transmigrated pool showed that NK cells were most 
efficiently enriched, closely followed by NK T cells, CD4+ memory T cells and slightly less 
memory and naive CD8+ T cells and CD56high NK cells (Figure 6-9d). As before, there is 
negligible migration of B cells and naive CD4+ T cells. 
 These experiments were repeated in flow conditions. Using the flow-based assay, 
firmly adhered PBL were removed by perfusing EDTA across the HUVEC and collecting 
them in a plastic syringe on the Harvard pump. Transmigrated PBL were again collected by 
accutase treatment. Whole PBL (blood) and both firmly adhered and transmigrated fractions 
were analysed for PBL subpopulations by flow cytometry (Figure 6-10a-d). Using this 
approach, we obtained similar data to those found under static conditions with the exceptions 
that there was a higher percentage of naive CD8+T cells and NK cells and fewer CD8+ 
memory T cells (Figure 6-10e, g). If we consider enrichment ratio for the top fraction, there 
are no major differences between all the PBL subpopulations compared to static adhesion 
assays. The enrichment ratio for the transmigrated cells also shows a similar profile to static 
conditions (Figure 6-10f, h). In conclusion, these data indicate an ability of B cells to bind to 
the cytokine stimulated endothelium; however, in the conditions we used, B cells were not 
able to transmigrate efficiently. Therefore, it is important to understand which signals allow 
their surface adhesion.  
 We went on to examine the functional basis of B cell adhesion. Antibodies against 
α4β1 (Max68P), αLβ2 (IB4) and VCAM-1 (4B2+GH12) were used to block adhesion. We 
observed a strong inhibition of B cell adhesion when α4β1 (VLA-4) and VCAM-1 were 
blocked (Figure 6-11). Furthermore, we looked at blockade of chemokine receptor signalling 
using pertussin toxin (PTx). However, inhibition of GPCR signalling using this agent did not 
cause a loss of B cell adhesion. These results indicates that B cell adhesion is mediated by 
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α4β1 (VLA-4)/VCAM-1 interaction, although the activating stimulus which stabilises B cell 
adhesion on the surface remains unknown. 
 Finally, we sought to determine which subsets of B cells are preferentially recruited to 
the endothelium. Indeed, multiple B cells subpopulations exist, and to our knowledge, no 
study has explored which B cell subsets are preferentially recruited to cytokine stimulated 
endothelium. We used the same technique previously described to harvest the PBL from the 
endothelium surface and labelled the cells with CD19, CD38, IgD, IgM and CD27. This 
staining allowed us to differentiate between naive (mature) B cells (1) (identified as 
CD38+IgD+IgM+), memory B cells (2) (CD38-IgD-IgM-CD27+), plasma cells (3) 
(CD38+++IgD-IgM-CD27-), intermediate B cells (4) (CD38++IgD+IgM+) and transitional B 
cells (5) (CD38+++IgD+IgM+) (Figure 6-12a, b). We calculated the enrichment ratio as 
previously described by dividing the percentage of each B cell subset on the endothelium 
surface by the percentage of each B cell subpopulations in whole blood. Using this method of 
analysis, we found a trend towards enrichment of plasma cells and a modest enrichment of 
memory B cells (Figure 6-12c). These two B cell subsets constitute the effector B cell 
populations, as they are generated after encounter with an antigen.  
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Figure 6-8: Representative dot plots of transmigrated and firmly adhered PBL subsets 
on the endothelium in static conditions 
PBL were isolated from peripheral blood and static transmigration assays were performed 
using TNF-α/IFN-γ stimulated HUVEC as previously described. After acquisition, PBL 
firmly adhered to endothelium were removed using EDTA and gentle agitation. The HUVEC 
and the migrated PBL were collected using accutase. Whole PBL treated with accutase were 
used to determine the proportion of each subset added. Whole accutase treated PBL, firmly 
adhered and transmigrated fractions were stained and analysed by flow cytometry for (a) B 
cells, (b) CD4 memory and naive T cells, (c) CD8 memory and naive T cells and (d) NK cells 
subsets. The data are representative of at least three independent experiments. 
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Figure 6-9: Behaviour of firmly adhered and migrated PBL subsets in static conditions 
PBL were isolated from peripheral blood and static transmigration assays were performed 
using TNF-α/IFN-γ stimulated HUVEC and cells were stained as previously described on 
Figure 6.9. (a) The percentages of each subset on the top of HUVEC and (b) transmigrated 
were determined by flow cytometry. The enrichment ratio for each subset was calculated by 
dividing the percentage of (c) cells firmly adhered or (d) transmigrated by the percentage of 
each subset added determined on the whole accutase treated PBL fraction. Data are shown as 
mean±SEM and are representative of at least three independent experiments. Data were 
analysed using one-way ANOVA and Bonferroni’s multiple comparisons post-test. *p≤0.05, 
**p≤0.01. 
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Figure 6-10: Behaviour of firmly adhered and migrated PBL subsets in flow conditions 
PBL were isolated from peripheral blood and transmigration flow assays were performed 
using TNF-α/IFN-γ stimulated HUVEC as previously described. After acquisition, PBL 
firmly adhered to endothelium were removed using EDTA under flow conditions. The 
HUVEC and the migrated PBL were collected using accutase. Whole accutase treated PBL, 
firmly adhered and transmigrated fractions were stained and analysed by flow cytometry for 
(a) B cells, (b) CD4+ memory and naive T cells, (c) CD8 memory and naive T cells and (d) 
NK cell subsets. (e) The percentage of each subset on the top of HUVEC and (g) 
transmigrated were determined by flow cytometry. The data are representative of at least three 
independent experiments. The enrichment ratio for each subset was calculated by dividing the 
percentage of (f) cells firmly adhered or (h) transmigrated by the percentage of each subset 
added determined on the whole accutase treated PBL fraction. Data are shown as mean±SEM 
and are representative of at least three independent experiments. Data were analysed using 
one-way ANOVA and Bonferroni’s multiple comparisons post-test. 
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Figure 6-11: B cell adhesion is mediated by VLA-4 (α4β1) -VCAM interaction 
B cells were negatively selected and recruitment was measured on HUVEC stimulated with 
TNF-α and IFN-γ. B cells were pre-treated with antibodies selectively blocking α4β1 
(Max68P) and αLβ2 (IB4) integrins binding to their respective VCAM-1 and ICAM-1 
adhesion molecules. HUVEC were treated with 4B2 and GH12 to inhibit VCAM-1 
interactions. In addition GPCR signalling blockade was realised using Pertussin toxin (PTx) 
known to stop transmigration mediated by chemokines receptors signalling. Data are 
represented as mean±SEM and represent three independent experiments. Data were analysed 
using one-way ANOVA and Dunnet’s multiple comparisons post-test. ***p≤0.001. Courtesy 
of Dr Helen McGettrick. 
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Figure 6-12: Preferential recruitment of effector B cells at the surface of the 
endothelium 
PBL were isolated from peripheral blood and transmigration flow assays were performed 
using TNF-α/IFN-γ stimulated HUVEC as previously described. (a) After acquisition, PBL 
firmly adhered to endothelium were removed using EDTA plus gentle agitation and labelled 
for the different B cell subpopulations. (b) Naive (mature) B cells (1) were identified as 
CD38+ IgD+ IgM+, memory B cells (2) as CD38-IgD-IgM-CD27+, plasma cells (3) as 
CD38+++IgD-IgM-CD27-, intermediate B cells (4) as CD38++IgD+IgM+ and transitional B cells 
(5) as CD38+++IgD+IgM+. (c) The enrichment ratio on the endothelial surface was calculated 
by dividing the percentage of each subset recruited on HUVEC by the percentage of each 
subset added from the whole PBL (blood) staining. Data are shown as mean±SEM and are 
representative of three donors. Data were analysed using one-way ANOVA and Bonferroni’s 
multiple comparisons post-test. 
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2.4. Peritoneal infiltration of lymphocytes is higher in B cell knock-out mice 
 We demonstrate that adiponectin-stimulated B cells modulate T cell migration in vitro. 
Here, we aimed to validate this effect in vivo. In collaboration with Prof. Chris Buckley and 
Dr Francesca Barone, we used a peritoneal mouse model of acute inflammation to study the 
effect of B cells on T cell migration in vivo. Peritoneal inflammation was induced by injection 
of 1 mg of zymozan A into the peritoneum of wild-type (wt) mice or B cell knock-out (KO) 
mice (Jh-/-), both on a  BALB/c  background. After 48 hours, peritoneal cells were isolated 
and counted by flow cytometry using CD3 expression for T cells, CD4+ and CD8+ T cells and 
their naive (CD62L+CD44-), central memory (CD62L+CD44+) and effector memory (CD62L-
CD44+) subsets. We also, stained for CD11c+DCs and F4/80/podoplanin positive 
macrophages. The whole volume of each tube was acquired on the flow cytometer to allow 
accurate counting. Peritoneal and circulating leukocytes were gated based on forward/side 
scatter profile and pulse-width to exclude duplets of cells (Figure 6-13).  
 Interestingly, absence of B cells resulted in a significantly larger number of CD3+T 
cell in the inflamed peritoneum compared to the wt (Figure 6-14). The number of T cells was 
slightly higher in the peritoneum of B cell KO mice treated with PBS compared to the wt, but 
this difference was not significant. Injection of zymosan also induced a slight increase of T 
cell number in the peritoneum of the wt, but not as high as in the B cell KO. Further analysis 
of T cell sub-populations revealed that the high recruitment of T cells in the peritoneum of B 
cells KO mice is mainly composed of CD4+ T cells (Figure 6-15). Indeed the absolute 
number of CD4+ T cells was significantly higher in the inflamed peritoneum of B cell KO 
mice compared to the inflamed wt and to the B cell KO treated with PBS.  
 We went on to analyse the specific recruitment of CD4+ naive, central memory and 
effector memory T cells in the peritoneum. We observed a significantly higher recruitment of 
CD4+ effector memory T cells in the inflamed peritoneum of B cell KO mice compared to 
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non-inflamed conditions. However, there was not a significant difference when compared 
with the inflamed wt (Figure 6-16). Regarding CD8+T cells subsets, no significant 
differences were found for effector memory T cells, however, there was a significant increase 
of naive CD8+ T cells number in the inflamed peritoneum of B cell KO mice compared to the 
inflamed wt (Figure 6-17). We also counted the number of macrophages and dendritic cells 
(DCs) in the peritoneum. This analysis revealed no significant differences between the 
inflamed or non-inflamed wt and B cell KO mice for both macrophages (Figure 6-18) and 
DCs (Figure 6-19).  
 Finally, the same staining protocols were conducted on circulating leukocytes. CD3+ T 
cells and B cells were found in the blood of wt with or without zymosan. CD3+ T cells but no 
B cells were found in the blood B cell KO mice (Figure 6-20). Additionally and as expected, 
we found very few macrophages and DCs in either wt or B cell KO with or without zymosan. 
This is in agreement with the usual tissue/lymphoid organs location of these cell types. CD4+ 
and CD8+ T cells were found in both wt and B cell KO mice, however, in both strains of 
mice, and with or without zymosan, naive T cells were predominantly found in the circulation 
(Figure 6-21). Very few central memory and effector memory CD4+ or CD8+ T cells were 
detected in the blood of these mice. 
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Figure 6-13: Gating strategy for leukocytes in the peritoneum and in the blood 
Peritoneal lavage and cardiac puncture allowed collection of leukocytes present in the 
peritoneum and the blood respectively of wt and Bs KO mice with or without inflammation. 
After labelling cells were acquired by flow cytometry. (a) The whole peritonela leukocyte 
population was gated based on forward/side scatter dot plots and (b) duplets of cells were 
excluded by gating on forward side scatter and pulse width. 
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Figure 6-14: Absolute T cell number is higher in the inflamed peritoneum of B cell 
knock-out mice compared to the wt mice 
Leukocytes were collected from the peritoneum after 48 hours without any injection (wt 0), 
with PBS injection (wt PBS, Bs KO PBS) and with zymosan injection (wt zymosan, Bs KO 
zymosan) in (a) wt and (b) Bs KO mice. T cells were identified by expression of CD3 and B 
cells using CD19 and B220. (c) Data for each mouse groups were pooled, represented as 
mean and were analysed using one-way ANOVA and Bonferroni’s multiple comparisons 
post-test.*p≤0.05. 
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Figure 6-15: Absolute number of CD4+ T cells is higher in the inflamed peritoneum of B 
cell knock-out mice compared to the wt mice 
Leukocytes were collected from the peritoneum after 48 hours without any injection (wt 0), 
with PBS injection (wt PBS, Bs KO PBS) and with zymosan injection (wt zymosan, Bs KO 
zymosan) in (a) wt and (b) Bs KO mice. CD4+ and CD8+ T cells were identified by gating on 
CD3 first and by the expression of CD4 and CD8. (c) Data for each mouse groups were 
pooled, represented as mean and were analysed using one-way ANOVA and Bonferroni’s 
multiple comparisons post-test. *p≤0.05. 
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Figure 6-16: Absolute number of effector memory CD4+ T cells is slightly higher in the 
inflamed peritoneum of B cell knock-out mice compared to the wt mice 
Leukocytes were collected from the peritoneum after 48 hours without any injection (wt 0), 
with PBS injection (wt PBS, Bs KO PBS) and with zymosan injection (wt zymosan, Bs KO 
zymosan) in (a) wt and (b) Bs KO mice. CD3+ and CD4+ T cells were first gated and naive, 
central memory and effector memory T cells were identified by the expression of CD44 and 
CD62L. Naive CD4 are CD62L+CD44-, central memory T cells are CD62L+CD44+ and 
effector memory T cells are CD62L-CD44+. (c) Data for each mouse groups were pooled, 
represented as mean and were analysed using one-way ANOVA and Bonferroni’s multiple 
comparisons post-test. *p≤0.05. 
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Figure 6-17: Absolute number of naive CD8+ T cells is slightly higher in the inflamed 
peritoneum of B cell knock-out mice compared to the wt mice 
Leukocytes were collected from the peritoneum after 48 hours without any injection (wt 0), 
with PBS injection (wt PBS, Bs KO PBS) and with zymosan injection (wt zymosan, Bs KO 
zymosan) in (a) wt and (b) Bs KO mice. CD3+ and CD8+ T cells were first gated and naive, 
central memory and effector memory T cells were identified by the expression of CD44 and 
CD62L. Naive CD4 are CD62L+CD44-, central memory T cells are CD62L+CD44+ and 
effector memory T cells are CD62L-CD44+. (c) Data for each mouse groups were pooled, 
represented as mean and were analysed using one-way ANOVA and Bonferroni’s multiple 
comparisons post-test. *p≤0.05. 
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Figure 6-18: Absolute number of macrophages in the inflamed peritoneum of wt mice 
compared to B cell knock-out mice 
Leukocytes were collected from the peritoneum after 48 hours without any injection (wt 0), 
with PBS injection (wt PBS, Bs KO PBS) and with zymosan injection (wt zymosan, Bs KO 
zymosan) in (a) wt and (b) Bs KO mice. Macrophages were identified by the expression of 
F4/80 and podoplanin (gp38) after gating on CD45+ cells and gating out CD3+ T cells and 
CD11c+ dendritic cells. (c) Data for each mouse groups were pooled, represented as mean and 
were analysed using one-way ANOVA and Bonferroni’s multiple comparisons post-test. No 
significant differences were found. 
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Figure 6-19: Absolute number of dendritic cells in the peritoneum is higher in inflamed 
conditions in both wt and B cell knock-out 
Leukocytes were collected from the peritoneum after 48 hours without any injection (wt 0), 
with PBS injection (wt PBS, Bs KO PBS) and with zymosan injection (wt zymosan, Bs KO 
zymosan) in (a) wt and (b) Bs KO mice. DCs were identified by the expression of CD11c and 
after gating on CD45+ cells and gating out CD3+ T cells and F4/80+/podoplanin+ 
macrophages. (c) Data for each mouse groups were pooled, represented as mean and were 
analysed using one-way ANOVA and Bonferroni’s multiple comparisons post-test. No 
significant differences were found. 
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Figure 6-20: Representative dots plots of B cells, CD3+ T cells and macrophages in the 
blood 
Blood was collected by cardiac puncture, red blood cells were lysed and leukocytes were 
labelled for flow cytometry. (a, b) B and T cells were identified with CD3 and CD19 in mice 
without any injection (wt 0), with PBS injection (wt PBS, Bs KO PBS) and with zymosan 
injection (wt zymosan, Bs KO zymosan) in wt and Bs KO mice. (c, d) Macrophages were 
identified by the expression of F4/80 and podoplanin (gp38) after gating on CD45+ cells and 
gating out CD3+ T cells and CD11c+ dendritic cells in the same mice. 
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Figure 6-21: Representative dots plots of CD4 and CD8 T cells subsets in the blood 
Blood was collected by cardiac puncture, red blood cells were lysed and leukocytes were 
labelled for flow cytometry. CD4 and CD8 T cells were gated and naive, central memory and 
effector memory T cells were identified by the expression of CD44 and CD62L. Naive CD4 
are CD62L+CD44-, central memory T cells are CD62L+CD44+ and effector memory T cells 
are CD62L-CD44+ in (a) wt mice without any injection, (b) wt with PBS injection, (c) wt with 
zymosan injection,  (d) Bs KO with PBS and (e) Bs KO with zymosan. 
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3. Discussion 
 
 In this chapter, we demonstrate a novel mechanism of action of adiponectin which 
mediates inhibition of lymphocyte trans-endothelial migration. We show that under 
conditions of adiponectin stimulation, B cells affect T cell transmigration. In this assay, B cell 
do not transmigrate and mainly plasma cells and memory B cells are recruited to the 
endothelium. In addition, we found that B cell adhesion is mediated via α4β1 (VLA-
4)/VCAM-1 interaction.We have confirmed these findings in vivo in the B cell knock-out 
mouse using a peritoneal model of inflammation. 
 
 Adiponectin is not modulating PBL transmigration in a classic manner 
 A number of studies have revealed that adiponectin has pro-apoptotic effects for 
lymphocytes and cell lines (Pang PhD; Yokota et al., 2000; Dieudonne et al., 2006; Cong et 
al., 2007; Brakenhielm et al., 2004). Although, this effect is not fully understood, we sought 
to confirm that the inhibition of PBL transmigration we observed was not the consequence of 
lymphocyte apoptosis. In our system, PI staining did not reveal cell death in the presence of 
adiponectin and levels of the apoptotic marker, Caspase-3, were normal.  
 Integrins are crucial in supporting lymphocyte recruitment and modulation of their 
expression at the cell surface changes the capacity of lymphocytes to transmigrate through 
endothelium (Springer, 1994). When PBL were treated with adiponectin for one hour, there 
were no changes in the cell surface expression of integrins LFA-1 (αLβ2) or VLA-4 (α4β1). 
Furthermore, CXCR3 signalling is essential for activation of integrins that stabilise 
attachment and initiate transmigration in this TNF-α/IFN-γ driven system (McGettrick et al., 
2009; Piali et al., 1998). In addition T cell transmigration in this model also requires a PGD2 
signal downstream of chemokine stimulation to achieve efficient transmigration (Ahmed et 
al., 2011). Indeed, in this study, PGD2 blockade reduced T cell transmigration but not the 
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levels of T cell adhesion to the endothelial cells. This suggests that signalling through the 
PGD2 receptor; DP2 is initiated after chemokine signalling and regulates migration and 
diapedesis rather than attachment (Ahmed et al., 2011). This could be relevant to our data, as 
we only see changes in transmigration rather than in total adhesion. However, we found no 
differences in the expression of both CXCR3 and DP-2 on PBL after adiponectin treatment. 
In addition, we used a chemotaxis assay to check the functionality of both CXCR3 and DP-2 
receptors. This assay consisted in measuring the capacity of adiponectin treated PBL 
(compared to untreated cells) to transmigrate through a filter towards CXCL10 or PGD2, 
ligands for CXCR3 and DP-2 respectively. We observed no changes in the chemotaxis of 
PBL towards either stimulus after treatment with adiponectin. These findings suggest that 
adiponectin is not modulating PBL transmigration by modulation of integrins or chemokines 
receptors expressions, or by changing signalling capacities of CXCR3 and DP-2.  
 
 Role of B cells in the mechanism of action of adiponectin 
 We and others have observed an almost complete absence of the classical adiponectin 
receptors, AR1 and AR2, on T cells. Paradoxically however, adiponectin can regulate T cell 
proliferation (Wilk et al., 2011). This has now been attributed to an indirect effect of 
adiponectin on APC such as monocytes and DCs, which do express high levels of adiponectin 
receptors, rather than a direct effect on T cells through an unknown receptor (Pang et al., 
submitted). This data is compelling, as it indicates that for adiponectin to modulate T cell 
responses, the presence of accessory cells that express adiponectin receptor(s) is necessary. In 
our system, PBL subsets with such characteristic are the B lymphocytes and NK cells (Pang, 
Narendran, 2008; chapter 5). The former and not the later were shown to be the key 
regulatory cells in our new paradigm (discussed in detail below).  
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 Interestingly, previous studies have determined that the lymphocyte recruited across 
unstimulated or cytokine activated endothelium are predominantly memory CD4+ T cells and 
naive and memory CD8+ T cells (Lichtman et al., 1997; McGettrick et al., 2009; Pietschmann 
et al., 1992; Brezinschek et al., 1995)). In agreement with these studies we found preferential 
migration of CD4+ and CD8+ memory T cells as well as CD8+ naive T cells in both our static 
and flow assays. In both systems, naive CD4+ T cells did not efficiently transmigrate. These 
subsets were also enriched on the top of the endothelium. In addition, we found that NK cells, 
NK T cells and CD56highNK cells migrated very efficiently across the endothelium. Indeed, 
the transmigration of NK cells was the most efficient of any lymphocyte population. This data 
concurs with previous studies showing high migratory capacities of NK cells across 
endothelium monolayers (Allavena et al., 1996). Interestingly, migration of NK cells is 
mediated by β2 integrin activation upon ligation of PECAM at least for NK cells and 
CD56highNK cells (Berman et al., 1996). NK T cell adhesion and transmigration may utilise a 
different pathway and is reported to involve β1 integrins (Franitza et al., 2004). This study 
also shows that NK T cells preferentially respond to CXCR4 ligands such as CXCL12 on the 
endothelium. 
 Interestingly, B cells themselves did not transmigrate after becoming firmly adherent 
to the endothelium in our assay. In agreement with published data performed in flow-based 
assays (Yago et al., 1997), we found that B cell adhesion relied on VLA-4 (α4β1) -VCAM 
interaction in our static assay. One limitation of this observation is that B cells are clearly able 
to cross the endothelium in vivo, and our observations may be an artefact. For example, we 
have detected B cells in the lower wells of transwell experiments, where 24h was allowed for 
endothelial cell transmigration (unpublished observations). In addition, B cells were found in 
the peritoneum of wild type mice treated with zymosan, which suggest they possess an 
intrinsic capacity to migrate across microvascular endothelium and that lack of B cell 
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migration in our current assay reflects the dynamics of migration of this lymphocyte subset. 
Moreover, B cells migrate efficiently across HEV (Ebisuno et al., 2003), although this type of 
endothelium is different from that in the periphery and is highly specialised for immune cell 
recruitment and lymphocyte trafficking (Miyasaka et al., 2004). Thus, it would be worth 
measuring transmigration of B cells in this assay over a longer time course and to compare B 
and T cells kinetics. In a physiological context, it seems probable that B cells adhere to the 
endothelium before or at the same time as T cells. This way B cells are able to control 
transmigration of T cells under the influence of circulating adiponectin. We speculate that 
after some undefined period, B cells eventually migrate across the EC.  These speculations are 
supported to some extent by studies in the mouse model of zymosan driven peritoneal 
inflammation. In these conditions, B cell numbers are low in the peritoneal exudates over the 
first 48 hours after zymosan administration and dramatically increase after 72 hours 
(Rajakariar et al., 2008). In addition, studies have shown different patterns of recruitment in 
inflamed tissues between B and T cells. Rather than migrating and diffusing within the site of 
inflammation, B cells are present as clusters of tightly packed cells at restricted stromal sites 
(Meeusen et al., 1991).  
 We also determined that stimulated endothelium preferentially recruited memory B 
cells and plasma cells form the available pool of circulating B cells. Because these subtypes 
are enriched at the surface of the endothelium and because the effect we observe is rapid, we 
believe that memory B cells and plasma cells could be the B cell subtype responsible for the 
effect on T cell migration, although this requires confirmation. In addition, plasma cells are 
highly specialised for secretion of soluble molecules so such a role would be logical. 
However, it was brought to our attention that plasma cells may not express CD19. Therefore, 
when we selectively remove B cells based on CD19 expression, we would still have the 
plasma cells in the assay. This would strongly mitigate against such a role for plasma cell in 
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our assay. However, CD19 expression by plasma cells is a subject of some controversy. 
Recent evidence shows circulating plasma cells are infrequently encountered in the blood. 
Thus, plasma cells are generated in the germinal centres of secondary lymphoid organs. Upon 
antigen stimulation B cells proliferate and become memory B cells or plasmablasts. 
Plasmablasts start secreting antibodies in the medullary cord but not as efficiently as plasma 
cells because they are still proliferating. The plasmablasts eventually become plasma cells, 
secreting large amount of antibodies, and then most plasma cells die rapidly. However a small 
proportion of plasma cells leave the SLOs through the circulation to enter the bone marrow 
where they can survive for long periods (reviewed in Shapiro-Shelef, Calame, 2005). These 
long-lived circulating plasma cells in blood express CD19 at low levels (Medina et al., 2002; 
Arce et al., 2004; Horst et al., 2002; Harada et al., 1996). In addition, they express integrins 
such as VLA-4 (α4β1) which we found allows their adhesion onto EC (Medina et al., 2002). 
They differ from plasma cells found in tonsils and their phenotype changes once they enter 
the bone marrow (Medina et al., 2002; Arce et al., 2004). In addition, the number of 
circulating plasma cells increases following inflammation as well as vaccination (Harada et 
al., 1996; Shapiro-Shelef, Calame, 2005). Whether this population is substantial enough to be 
recruited in sufficient numbers during inflammation to regulate T cell migration is unclear, 
and an area requiring clarification. However, we should also acknowledge the limitations of 
the antibody panel we used to identify B cell subsets. This leaves some ambiguity in our 
attributions of subset identity and it would be worth getting a fuller panel of markers to 
identify all the different transitional B cells and the different memory B cells as well as 
plasma cells more accurately. 
 In conclusion, B cell depletion removes the majority of CD19+ B cells and we believe 
it also includes plasma cells. This is sufficient to show that without B cells the adiponectin-
mediated inhibition of PBL transmigration is lost. However, it would be worth checking on 
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sorted B cells subsets as well. Indeed, it is possible to sort for plasma cells and memory B 
cells and perform similar transmigration assays. For instance, it would be interesting to see if 
the effect is lost in absence of plasma cells and with reconstitution, as well as using the 
supernatant and Brefeldin A.  
 
 In vivo confirmation 
 Here we have used a zymosan driven model of acute peritoneal inflammation in mice 
to define the involvement of B cells in the regulation of T cell migration in vivo. Zymosan is a 
purified polysaccharide fraction of the yeast cell wall which induces inflammation in vivo by 
activation of complement (Fearon et al., 1977), induction of histamine from mast cells and 
basophils, induction of oxygen-free radicals and lysosomal enzymes (Bonney et al., 1978), 
generation of free fatty acids and eicosanoids in peritoneal inflammation (Doherty et al., 
1987; Lundy et al., 1990) and induction of pro-inflammatory cytokines by monocytes and 
macrophages (Sanguedolce et al., 1992). Zymosan-induced inflammation is therefore a 
comprehensive model to study inflammation as it induces many relevant pathways.  
 Peritoneal inflammation has been used before to study kinetics of leukocytes 
recruitment during inflammation (McLoughlin et al., 2005; Takada et al., 1993; Rajakariar et 
al., 2008). It can be induced by different compounds such as zymosan and or bacteria such as 
E.coli or Staphylococcus (Takada et al., 1993; McLoughlin et al., 2005). We chose zymosan 
induced peritonitis because of the availability of data on the kinetics of leukocyte recruitment 
in this model (Rajakariar et al., 2008). When used at the appropriate concentration, zymosan 
induces a resolving acute inflammation in which neutrophils first invade the peritoneum 
followed by macrophages after a few hours. T lymphocytes occupying the naive peritoneum 
and are lost upon induction of inflammation, exiting via the draining lymphatics by action of 
PGD2 on the DP-1 receptor (Rajakariar et al., 2008). However, after six hours, T cells start 
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repopulating the inflamed peritoneum and numbers significantly increase above baseline 
levels over time. It is slightly different for B cells, as they only start to repopulate the 
inflamed peritoneum after 48 hours. Meanwhile, neutrophil counts decrease after 48 hours. 
These reports identify two phases during this inflammatory response. The first phase is 
characterised by innate immune-mediated inflammation and the second is more of a resolving 
phase involving lymphocytes. There is also a rise of NK cells, gamma/delta T cells and Treg 
number during the resolving phase. This has been associated with their involvement in 
resolution but also protection against a secondonary infection. Finally, the peritoneum is 
restored to ‘naivety’ after seven days. If this is not the case, e.g. if using higher concentrations 
of zymosan, then the model becomes chronic and inflammation causes death.  
 Although this model is convenient and easy to set up, it has a few disadvantages. 
Analysis of the whole peritoneal exudate by flow cytometry shows a profile of cells 
containing a lot of debris and red blood cells. Thus, to be able to compare results between 
mice and determine the absolute number of cells, it was important to gate on the whole 
leukocyte populations in a similar manner for each mouse. We excluded red blood cells and 
debris based on the forward/side scatter profile and then excluded duplets of cells, which 
allowed us to get a cleaner profile. After optimisation of the staining, we managed to easily 
identify CD3+ T cells and their subsets, as well as DCs and macrophages.  
 In addition, this is a cavity based model and therefore does not involve tissue specific 
responses. Another way to look at inflammation in tissues would be to use the canulation 
technique. Using this method, inflammation could be induced in salivary glands for instance, 
and this would allow us to look at specific recruitment into tissues in the B cell KO model. 
Although, zymosan is well characterised as an inducer of inflammation in the peritoneum, 
other stimuli have been used and may be worth consideration. In summary, although this 
model provides good evidence for a role of B cells during T cell recruitment in an 
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inflammatory response, it would be interesting to analyse this in other models. In fact, we 
have utilised B cell knock-out mice on the C57BL/6 background in a model of Salmonella 
typhimurium induced hepatic inflammation (in collaboration with Dr Adam Cunningham, 
University of Birmingham). We found that the number of T cells per infection loci in the liver 
was higher in B cell-deficient mice compared to wt (data not shown). Although, this is a 
model of infection, inflammation is also a part of the infectious processes. These data 
consolidate our findings in another model of inflammation but also in another mouse strain. 
 Finally, we did not investigate adiponectin levels in the mice included in the study. 
Serum samples were collected and it would be worth measuring adiponectin levels in these 
mice. It has been shown that circulating adiponectin levels decrease during zymosan-induced 
inflammation but no changes was observed in the peritoneal exudates (Pini et al., 2008). It 
would be interesting to confirm this in our mice. 
 
 Conclusions 
To summarize, we provide evidence for a novel role for B cells in regulating T cell 
recruitment in the presence of adiponectin. These effects were validated in vivo, using a 
model of inflammation in the B cell knock-out mice. 
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1. Introduction 
 
 We clearly show that B cells modulate T cell migration in vitro and in vivo. In this 
chapter, we aimed to understand how B cells modulate T cell migration. We therefore 
investigated whether the B cells act on the T cells by secreting an agent or by cell to cell 
contact. We then aimed to identify potential soluble candidates secreted by B cells and we 
tested their biological activity in our model of PBL transmigration. 
 
2. Results 
2.1. B cells modulate T cell migration through a secreted agent X 
 Here, to test whether B cells secrete an agent that modulates T cell transmigration, B 
cells were isolated as previously described and incubated with adiponectin for one hour. The 
supernatant of B cells was then added to the Bs-ve PBL for 30 minutes and transmigration 
was measured as previously described. Additionally, B cells were treated with Brefeldin A 
(BrefA), an inhibitor of protein transport from the endoplasmic reticulum to the Golgi which 
essentially inhibits secretion in B cells. After three hours incubation with BrefA, adiponectin 
was added to the B cells for one hour and the BrefA B cells were used to reconstitute the Bs-
ve PBL (Bref A Bs PBL). As previously described, we found that B cell depletion resulted in 
loss of the inhibition of transmigration mediated by adiponectin (Figure 7-1). Adding the 
supernatant of B cells treated with adiponectin to the Bs-ve PBL restored the inhibition of 
transmigration. Importantly, the blockade of protein secretion with BrefA ablated the B cell- 
mediated inhibition of PBL transmigration. These results indicate that inhibition of PBL 
trans-endothelial migration by adiponectin is mediated by an agent secreted by B cells. 
 However, supernatant of B cells added to the Bs-ve PBL fraction, contains adiponectin 
which cannot be removed from the supernatant before treatment. As indicated earlier, 
Chapter 7-           A novel adiponectin-induced, B cell-derived peptide, PEPITEM, inhibits the 
migration of T cells 
215 
 
HUVEC express the adiponectin receptors (Chapter 5) and treatment of HUVEC with 
adiponectin also reduces PBL transmigration. To check that adiponectin is not directly acting 
on the HUVEC in the B cell supernatant experiment, we went on to knock down both 
adiponectin receptors on HUVEC. We achieved an average of 90% knock-down for AR1 and 
80% for AR2 (Figure 7-2a). Under these conditions, the supernatant of B cells treated with 
adiponectin still inhibited PBL transmigration (Figure 7-2b). These data therefore confirm 
that in experiments using B cell supernatants, it is a secreted agent and not adiponectin which 
inhibits T cell transmigration. 
 
 
Figure 7-1: B cells modulate PBL transmigration through a secreted agent X 
B cells were isolated and incubated in presence or absence of adiponectin at 15µg/ml. 
Supernatant was taken after one hour and added to Bs-ve PBL which significantly restored the 
adiponectin inhibition of PBL transmigration. For some conditions, B cells were treated with 
Brefeldin A for four hours and adiponectin after 3 hours and added back to Bs-ve PBL. This 
induced loss of the adiponectin effect. Data are shown as mean±SEM, are a pool of three 
independent experiments and analysed using one-way ANOVA and Bonferroni’s multiple 
comparison post test. ***p<0.001, ns=non significant. 
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Figure 7-2: Knock-down of adiponectin receptors on HUVEC does not affect inhibition 
of transmigration by the secreted Agent X 
(a) HUVEC were transfected with siRNA against AR1 and AR2 or scrambled versions of the 
target siRNA. (b) After 48 hours, HUVEC were stimulated with TNF-α/IFN-γ and PBL 
transmigration was measured on Bs-ve PBL reconstituted with B cell supernatant with or 
without adiponectin. In these conditions, inhibition of PBL transmigration by Agent X 
contained in B cell supernatant was not affected by the absence of AR1/2 on the endothelium. 
Data are shown as mean±SEM, are a pool of three experiments and were analysed using one-
way ANOVA and Bonferroni’s multiple comparison post test. *p<0.05, **p<0.01, 
***p<0.001. 
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2.2. Adiponectin-mediated inhibition of PBL trans-endothelial migration is mediated by 
S1P 
 Next, we aimed to identify the B cell-secreted Agent X. Our first candidate was 
sphingosine-1-phosphate (S1P), because of its well-described role in the control of T cell 
migration. Studies have shown that S1P binds to two GPCR receptors on T cells, S1P receptor 
1 and 4 (S1P1, S1P4) in mice and humans (Matloubian et al., 2004; Graeler, Goetzl, 2002). 
These receptors have been detected only at an RNA level or by western blot in human T cells, 
but never using flow cytometry. We purchased rabbit primary antibodies against the receptors 
and optimised the staining of both S1P1 and 4, which allowed us to quantify each receptor, 
either on the surface or intracellularly, on T cells using flow cytometry. We found that both 
S1P1 and 4 were minimally expressed at the cell surface (Figure 7-3a). Interestingly 
however, the frequency of S1P1 positive cells, but not S1P4 positive cells was significantly 
increased on PBL that have transmigrated (Figure 7-3b, c). Further analysis revealed that 
both receptors are highly expressed intracellularly (Figure 7-4a). We observed no significant 
differences in the frequency of positively staining cells, or the MFI when comparing whole 
PBL, firmly adhered cells, and migrated cells. However, significantly higher MFI were found 
for intracellular S1P4 in all conditions analysed (Figure 7-4b, c). 
In summary, whole PBL express both S1P1 and S1P4 at the surface at low levels and at high 
levels intracellularly. 
  In order to show the involvement of S1P in the adiponectin effect on PBL 
transmigration, we aimed to block the S1P receptors using a specific antagonist. Thus, whole 
PBL or Bs-ve PBL were treated for 30 minutes with the S1P1/4 antagonist, W146. Cells were 
then washed and PBL were treated with adiponectin for an additional hour and subjected to 
transmigration on TNF-α/IFN-γ stimulated HUVEC. Bs-ve PBL were reconstituted with B 
cells treated with adiponectin for one hour. For both conditions, pre-treatment with the S1P 
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receptor antagonist reversed the adiponectin-mediated inhibition of PBL transmigration 
(Figure 7-5). This suggests that the adiponectin effect is mediated via the S1P receptors on T 
cells.  
 We went on to investigate the direct action of S1P on transmigration in Bs-ve PBL 
preparations. As these B cell depleted PBL lack a response to adiponectin, we might expect a 
restoration of inhibition of PBL transmigration by S1P, if S1P is the B cell-secreted agent. Bs-
ve PBL were treated with S1P at 0.0001 to 100µM for 30 minutes. Interestingly, S1P induced 
a significant dose-dependent inhibition of transmigration, which was as potent as the 
adiponectin effect and at high concentrations (Figure 7-6a). 
 In parallel, we looked at the time course of inhibition of migration in these 
experiments. This analysis revealed that S1P-induced inhibition of PBL transmigration was 
lost over time, as was the effect of adiponectin (Figure 7-6b, c), interestingly with very 
similar kinetics. In addition, we ensured that PBL treated with S1P were alive. This was 
confirmed by the absence of PI staining after S1P treatment (Figure 7-7). In conclusion, as 
we reveal a loss of the effects of adiponectin after antagonising S1P receptors, and as 
exogenous S1P can reconstitute the effects of adiponectin treatment, it is possible that this 
molecule is the agent secreted by B cells in response to adiponectin. 
 However, production of S1P by B cells requires expression of the sphingosine kinases 
1 and/or 2 (SPHK1, SPHK2). Indeed, these enzymes are essential for the phosphorylation of 
sphingosine leading to S1P production. Thus, we analysed the mRNA expression of both 
enzymes in B cells and HUVEC. Surprisingly, B cells did not express SPHK1 and SPHK2. 
However, SPHKs, especially SPHK1, were expressed at high levels in HUVEC (Figure 7-
8a). Interestingly, stimulation of HUVEC with TNF-α/IFN-γ induced a slight but not 
significant up-regulation of SPHK1 mRNA expression (Figure 7-8b). Therefore we had to 
modify our model. It now appears that S1P was not the B cell-secreted agent, although S1P, 
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probably derived from endothelial cells was responsible for inhibiting T cell migration. Thus, 
it would appear that S1P is released from the endothelium upon stimulation by another agent 
released form adiponectin-stimulated B cells 
 To verify this paradigm, we aimed to confirm that the production of S1P by HUVEC 
was responsible for the adiponectin-mediated inhibition of PBL transmigration. Thus, we 
depleted HUVEC for SPHK1/2 using siRNA duplexes. However, we could only obtain low 
knock-down efficiency for SPHK1 (≈40%) (Figure 7-9a). Knock-down of SPHK2 was more 
efficient (≈82%) Even a double transfection protocol for SPHK1 did not deliver efficient 
knock-down. Consequently, adiponectin-mediated inhibition of PBL transmigration was not 
reversed on HUVEC with SPHK1 and/or SPHK2 knock-down (Figure 7-9b). Due to the poor 
efficiency of knock-down it is not possible to draw firm conclusions from these experiments. 
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Figure 7-3: Surface expression of S1P1 and 4 on whole PBL 
(a) S1P1 and 4 surface expression was measured by flow cytometry on whole PBL (blue), 
firmly adhered PBL to the endothelium (orange) and transmigrated PBL (red). Histograms for 
both receptors show little surface expression. (b) The frequency of PBL expressing S1P1 is 
significantly increased on transmigrated PBL but no significant differences were found for 
S1P4 and for (c) the surface expression of both receptors expressed as MFI. However, there 
was generally a trend to an increase of S1P1 and 4 expressions on transmigrated PBL. Data 
are shown as mean±SEM, are a pool of three donors and were analysed using one-way 
ANOVA and Bonferroni’s multiple comparison post test. *p≤0.05. 
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Figure 7-4: Intracellular expression of S1P1 and 4 on whole PBL 
(a) S1P1 and 4 intracellular expression was measured by flow cytometry on whole PBL 
(blue), firmly adhered PBL to the endothelium (orange) and transmigrated PBL (red). 
Histograms for both receptors show high intracellular expression. (b) The frequency of PBL 
expressing S1P1 and 4 and (c) the expression (MFI) were not significantly different between 
whole PBL, firmly adhered or migrated conditions. However, significantly higher MFI of 
S1P4 was found. Data are shown as mean±SEM, are a pool of three donors and were analysed 
using one-way ANOVA and Bonferroni’s multiple comparison post test. *p≤0.05, **p≤0.01, 
***p≤0.001. 
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Figure 7-5: Blockade of S1P receptor abrogates adiponectin-mediated inhibition of PBL 
transmigration 
PBL or B cells were pre-incubated with S1PR antagonist W146 at 1µM for 40 minutes, 
followed by one hour treatment with adiponectin (AQ) in some conditions. Bs-ve PBL were 
then reconstituted as described before with the antagonist±adiponectin treated B cells. 
Transmigration was measured by phase contrast videomicroscopy on TNF-α/IFN-γ stimulated 
HUVEC. Data are shown as mean±SEM, are a pool of three independent experiments and 
were analysed using one-way ANOVA and Bonferroni’s multiple comparison post test. 
*p≤0.05. 
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Figure 7-6: S1P inhibits transmigration of PBL depleted for B cells 
(a) PBL were depleted for B cells (Bs-ve PBL) and treated with S1P at 0.0001 to 100µM for 
30 minutes. Transmigration on TNF-α/IFN-γ stimulated HUVEC was measured using phase 
contrast videomicroscopy. (b) PBL were treated with adiponectin (AQ) for one hour as 
previously described. Transmigration of PBL with or without adiponectin and (c) of Bs-ve 
PBL with or without S1P  was measured over time starting at the usual 8-10 minutes time 
point and every 15 minutes until one hour. In these conditions S1P induced inhibition of 
transmigration which was lost over time as drastically as the adiponectin mediated inhibition. 
Data are shown as mean±SEM, are pool of at least three independent experiments and were 
analysed using one-way ANOVA and Bonferroni’s multiple comparison post test. *p≤0.05, 
**p≤0.01, ***p≤0.001. 
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Figure 7-7: S1P treatment is not cytotoxic 
PBL depleted for B cells (Bs-ve PBL) were treated with S1P at 1 and 10µM and the buffer 
used to resuspend the stock solution of S1P. After washes, cells were stained with propidium 
iodide (PI) a marker of dead cells and analysed by flow cytometry. No differences were 
observed in presence or absence of S1P. Data are representative of two independent 
experiments. 
 
Figure 7-8: HUVEC express high levels of SPHK1 
mRNA of unstimulated and TNF-α/IFN-γ stimulated HUVEC and B cells was collected and 
converted into cDNA. (a) Real-time PCR for sphingosine kinase 1 and 2 (SPHK1 and 2) were 
analysed as relative expression of SPHK1 and 2 to the endogenous control. (b) Fold change to 
the unstimulated control HUVEC was also calculated compared to stimulated conditions. 
Data are shown as mean±SEM, are a pool of at least 2 independent experiments and were 
analysed using one-way ANOVA and Bonferroni’s multiple comparison post test. *p≤0.05. 
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Figure 7-9: Effect of SPHK1/2 knock-down on PBL transmigration 
(a) HUVEC were transfected with siRNA against SPHK1 and SPHK2 or scramble versions of 
the target siRNA. After 24 hours, HUVEC were re-transfected with the relevant siRNA pool 
and were stimulated with TNF-α/IFN-γ. PBL transmigration was measured by phase-contrast 
videomicroscopy in presence or absence of adiponectin. SPHK1 knock-down was not as 
effective as SPHK2. (b) Therefore PBL transmigration in SPHK1/2 knock-down HUVEC in 
presence of adiponectin was unchanged compared to the untransfected control. Data are 
shown as mean±SEM, are a pool of three independent experiments and were analysed using 
one-way ANOVA and Bonferroni’s multiple comparison post test. *p≤0.05, **p≤0.01, 
***p≤0.001. 
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2.3. Identification of the secreted Agent X by mass spectrometry 
 We established that S1P is not the B cell-secreted agent. Instead, under adiponectin 
stimulation B cell seem to be able to produce an unidentified agent that triggers S1P 
production by HUVEC, and that in turn inhibits PBL transmigration. In collaboration with Dr 
Ashley Martin, we used a proteomics approach to identify this agent.  
 Proteomics is the large scale study of proteins and peptides contained in a complex 
biological mixture. It allows identification of proteins, determination of their structure and the 
presence of post-translational modifications. Protein mixtures are analysed using mass 
spectrometry analysis (principle of the method used are described in Chapter 2-section 2.8.2). 
Identification of proteins in a biological sample is usually achieved by fragmentation of the 
proteins into peptides using trypsin. The specific profile of fragmentation acquired upon mass 
spectrometery is analysed by a software attached to a sequence database which allows 
identification of the consequent proteins based on their fragmentation profiles. Identification 
of peptides into a biological sample does not require use of trypsin and this method therefore 
represented a logical first approach to identify the B cell-derived agent. 
 B cells were incubated with or without adiponectin for one hour and the supernatants 
were collected. The supernatants as well as similar volume and concentration of recombinant 
adiponectin were then purified on a C18 column to remove potential contaminants and large 
size proteins. Samples were analysed by LC-MS/MS using a gradient of 2 to 36% acetonitrile 
on the HPLC column. Data were analysed using the Mascot search engine for the SwissProt 
protein database. This generated the three lists: Table 7-1 for B cell supernatant with 
adiponectin, Table 7-2 for B cells supernatant without adiponectin and Table 7-3 for the 
recombinant adiponectin control. These lists archive the peptides originating from these 
samples and associate them with parent proteins. Mascot performs mass spectrometry analysis 
through a statistical evaluation of matches between observed and projected fragments from 
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primary sequences databases. It therefore calculates a score that indicates the quality of the 
match between the mass of the peptide from the mass spectrometry analysis and the real mass 
in the database, the higher the score, the closer match. Scores above 30 for individual peptides 
represent stringent statistical matches (as advised by the software manufacturer). However, in 
these tables the scores are the sum of each peptide identified for a given protein. The list of 
proteins is organised in descending order of score, and because of space constraints, we only 
provided the first 10 hits with the highest scores. To identify a potential candidate in the B 
cell supernatant with adiponectin treatment, we also applied a subtractive data analysis 
method. Hits from the adiponectin stimulated sample were compared to the B cell supernatant 
without adiponectin and recombinant adiponectin controls and common analytes were 
discarded. Proteins with high peptide scores after subtractive analysis are listed in Table 7-4. 
Only one high scoring peptide was identified with this method (highlighted in red in Table 
7-1). 
 The 14 amino acid peptide belongs to the 14-3-3 zeta/delta protein with a matching 
score of 63.1. It was eluted at 13.2 minutes and was absent from the base peak chromatogram 
(BPC) of the B cell supernatant without adiponectin (Figure 7-10). The parent ion for the 
identified peptide has an m/z (mass/charge ratio) of 774.88 (Figure 7-11). This m/z parent ion 
peak is absent from the B cell supernatant without adiponectin, confirming specificity (Figure 
7-12). MS/MS of the m/z 774.88 parent ion was only possible by collision induced 
dissociation (CID) and not by electron transfer dissociation (ETD) (Figure 7-13). The 
MS/MS gave a specific profile of fragmentation that allowed identification of the peptide 
sequence: SVTEQGAELSNEER (Figure 7-14). We acquired a synthesised version of the 
peptide, referred to as standard. BPC analysis revealed that the synthetic reagent was very 
pure and importantly, found the same m/z of 774.88 for the parent ion (Figure 7-15). The 
elution time was slightly different as the compound was eluted at 15.7 minutes but this was 
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explained by slight changes in the acetonitrile elution gradient used in this particular 
experiment. Finally, comparison of the MS/MS for the identified peptide and the standard 
revealed an almost complete match between the two fragmentation profiles (Figure 7-16). 
 Taken together, these data allowed identification of a 14 amino acid peptide as the 
candidate agent released from adiponectin stimulated B cells. This peptide was not found in 
the relevant controls. The peptide sequence was confirmed using the synthesised standard that 
had an identical m/z, similar time of elution and matching MS/MS fragmentation profile. The 
peptide will now be referred as PEPITEM. 
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Table 7-1: Results of the Mascot database search on B cell supernatant with adiponectin 
Data representative of the nine highest score detected after Mascot human protein database 
search which resulted in 264 hits. Protein hits are classed by descendant scores and only 
scores higher than 30 were considered. Potential candidates were identified by comparison 
with supernatant without adiponectin and recombinant adiponectin control. Proteins found in 
these samples were excluded (colour) as well as proteins with low score even if not present in 
the controls (black). Only hit number 5 was unique to this sample with a high score of 63.1 
and 1 peptide hit.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7-2: Results of the Mascot database search on B cell supernatant with adiponectin 
Data representative of the eight highest score detected after Mascot human protein database 
search which resulted in 303 hits. Proteins found in the adiponectin supernatant are 
represented in colour. At the bottom of the table, the hits found in the adiponectin supernatant 
but did not come with high score here were added. This sample did not contain hit number 5 
found in the adiponectin supernatant and most of the proteins identified were also found in the 
recombinant adiponectin and adiponectin supernatant samples. 
 
 
Hit 
Nb 
Accession Protein 
MW 
[kDa] 
Similar 
Proteins 
Scores Peptides 
RMS90 
[ppm] 
1 TITIN_HUMAN Titin 3813.8 5 
128.4 
(M:128.4) 
7 580.66 
2 LRP1_HUMAN 
Prolow-density lipoprotein 
receptor-related protein 1 
504.2 1 
116.9 
(M:116.9) 
6 169.37 
3 MUC6_HUMAN Mucin-6 252.0 1 
96.0 
(M:96.0) 
5 1087.98 
4 LAMA2_HUMAN Laminin subunit alpha-2 343.7 1 
65.0 
(M:65.0) 
3 171.98 
5 1433Z_HUMAN 14-3-3 protein zeta/delta 27.7 1 
63.1 
(M:63.1) 
1 25.23 
6 CO1A2_HUMAN Collagen alpha-2(I) chain 129.2 1 
61.5 
(M:61.5) 
2 993.21 
7 KDM6B_HUMAN Lysine-specific demethylase 6B 180.3 1 
60.1 
(M:60.1) 
2 533.71 
8 WNK2_HUMAN 
Serine/threonine-protein kinase 
WNK2 
242.5 1 
59.9 
(M:59.9) 
2 121.81 
9 PGBM_HUMAN 
Basement membrane-specific 
heparan sulfate proteoglycan 
core protein 
468.5 6 
55.4 
(M:55.4) 
3 339.06 
Hit 
Nb 
Accession Protein 
MW 
[kDa] 
Similar 
Proteins 
Scores Peptides 
RMS90 
[ppm] 
1 MUC16_HUMAN Mucin-16 2353.1 1 
91.9 
(M:91.9) 
5 692.07 
2 LDH6A_HUMAN 
L-lactate dehydrogenase A-like 
6A 
36.5 4 
57.6 
(M:57.6) 
2 185.09 
3 LRP1_HUMAN 
Prolow-density lipoprotein 
receptor-related protein 1 
504.2 1 
55.5 
(M:55.5) 
3 404.48 
4 CSMD3_HUMAN 
CUB and sushi domain-containing 
protein 3 
405.7 1 
55.1 
(M:55.1) 
3 204.18 
5 KRA55_HUMAN Keratin-associated protein 5-5 21.4 6 
52.9 
(M:52.9) 
3 190.77 
6 PPRC1_HUMAN 
Peroxisome proliferator-activated 
receptor gamma coactivator-
related protein 1 
177.4 4 
52.7 
(M:52.7) 
3 1297.58 
53 MUC6_HUMAN Mucin-6 252.0 1 
36.5 
(M:36.5) 
2 996.31 
246 PGBM_HUMAN 
Basement membrane-specific 
heparan sulfate proteoglycan core 
protein 
468.5 1 
16.3 
(M:16.3) 
1 284.62 
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Table 7-3: Results of the Mascot database search on the recombinant adiponectin 
control 
Data representative of the 11 of the highest scores detected after Mascot human protein 
database search which resulted in 264 hits. Proteins found in the adiponectin supernatant are 
represented in colour. At the bottom of the table, the hits found in the adiponectin supernatant 
but did not come with high score here were added. This sample did not contain hit number 5 
found the adiponectin supernatant and most of the proteins identified were also found in the 
supernatants with and without adiponectin. 
 
 
m/z 
Elution 
time 
(min) 
Score Modification Type 
Association 
protein 
Sequence 
774.88 13.2 63.1 NA CID 
14-3-3 
zeta/delta 
SVTEQGAELSNEER 
 
Table 7-4: Candidate peptide for Agent X 
Protein database search on the ions detected in the Bs supernatant with adiponectin sample 
revealed the presence of the peptide presented in the table. This peptide originates from the 
14-3-3 zeta/delta protein and will now be referred as PEPITEM. 
 
 
 
 
 
Hit 
Nb 
Accession Protein MW [kDa] 
Similar 
Proteins 
Scores Peptides 
RMS90 
[ppm] 
1 MEG11_HUMAN 
Multiple epidermal growth 
factor-like domains 11 
110.8 2 
102.7 
(M:102.7) 
5 518.82 
2 SYNE2_HUMAN Nesprin-2 795.9 1 
67.9 
(M:67.9) 
4 641.57 
3 MUC16_HUMAN Mucin-16 2353.1 16 
65.0 
(M:65.0) 
4 827.47 
4 PI3R5_HUMAN 
Phosphoinositide 3-kinase 
regulatory subunit 5 
97.3 1 
52.9 
(M:52.9) 
1 1081.17 
8 CO7A1_HUMAN Collagen alpha-1(VII) chain 295.0 1 
49.0 
(M:49.0) 
2 368.63 
18 KDM6B_HUMAN 
Lysine-specific demethylase 
6B 
180.3 9 
41.0 
(M:41.0) 
2 517.29 
19 CO4A1_HUMAN Collagen alpha-1(IV) chain 160.5 1 
40.7 
(M:40.7) 
2 333.15 
20 TITIN_HUMAN Titin 3813.8 4 
40.5 
(M:40.5) 
1 1663.60 
60 LAMA1_HUMAN Laminin subunit alpha-1 336.9 1 
33.9 
(M:33.9) 
1 1158.36 
101 WNK1_HUMAN 
Serine/threonine-protein 
kinase WNK1 (95% 
homology WNK2) 
250.6 1 
21.9 
(M:21.9) 
1 74.32 
29 LTBP1_HUMAN 
Latent-transforming growth 
factor beta-binding protein 1 
186.7 1 
39.0 
(M:39.0) 
1 202 
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Figure 7-10: Comparison of the base peak chromatogram of B cell supernatant with or 
without adiponectin 
Base peak chromatograms for the mass spectrometry analysis of the B cell supernatants with 
(top) or without (bottom) adiponectin. The chromatograms show high intensities peaks 
starting from about 14 minutes to 26 minutes that are likely to be contaminations. The large 
peak at the end shows the acetonitrile wash-up followed by re-equilibration of the column. 
Similar elution profiles are observed for both conditions. 
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Bs Supernatant No Adiponectin
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Figure 7-11: Base peak chromatogram of Bs supernatant with adiponectin and MS 
spectrum profile at 13.2 minutes 
Protein database search identified the Agent X candidate at 13.2 min elution time on the base 
peak chromatogram (top). MS spectrum of the 13.2 min elution time point contains the parent 
ion of Agent X candidate with m/z=774.88 (bottom).  
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Figure7-12: Comparison of MS spectra from supernatant with or without adiponectin 
Comparison of the MS spectra from B cell supernatant with (top) or without (bottom) 
adiponectin at 13.2 min revealed that the parent ion for Agent X candidate at m/z=774.88 is 
only present in the supernatant of B cells treated with adiponectin. 
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Figure 7-13: MS/MS of the Agent X candidate parent ion 774.88 
MS/MS of the parent ion 774.88 was only possible by collision induced dissociation (CID) 
and not by electron transfer dissociation (ETD).  
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Figure 7-14: Determination of parent ion 774.88 sequence 
The MS/MS spectrum is composed of b (fragmentation from N-terminal) and y 
(fragmentation from C-terminal) ions, which allow reconstituting the peptide sequence. 
Sequence of the standard was the same as the peptide identified in the supernatant of B cells 
treated with adiponectin.  
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Figure 7-15: Base peak chromatogram and MS spectra (15.7 min) of the synthesised 
standard for the Agent X candidate 
The Agent X candidate peptide was acquired and analysed by mass spectrometry. The base 
peak chromatogram shows high purity of the reagent as the elution one single high elution 
peak was found (top). The elution time of the standard is 15.7 minutes. This differs from the 
previous samples because of acetonitrile gradient changes in the analysis. In these conditions, 
the parent ion for the standard was identified at m/z=774.88, which is the same as the Agent 
X candidate in the B cell supernatant with adiponectin. 
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Figure 7-16: Comparison MS/MS parent ion m/z 774.88 from Bs supernatant with 
adiponectin to the synthesised peptide standard 
MS/MS of the parent ion m/z 774.88 for the synthesised standard revealed the same 
fragments profile as the one in the B cell supernatant with adiponectin sample. This confirms 
that the sequence identified in the first analysis is correct. 
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2.4. Testing the biological function of PEPITEM 
 We wished to determine whether PEPITEM shows biological activity in our in vitro 
transmigration assay. We arranged for a synthesised peptide and scramble control to be 
synthesised by Alta Bioscience, University of Birmingham. Mass spectrometry of the peptide 
revealed high level of purity (section 2.3). PBL were isolated from peripheral blood and 
PEPITEM was added to the PBL at 0.001 to 10ng/ml just before addition of the PBL on the 
TNF-α/IFN-γ stimulated HUVEC. We observed a dose-dependent inhibition of PBL 
transmigration across the endothelium in presence of PEPITEM (Figure 7-17a). Importantly, 
treatment of PBL with the scramble control or tetanus toxoid and pro-insulin peptides did not 
inhibit PBL transmigration. These results indicate the specificity of PEPITEM. The peptide 
had an EC50 of 18.6pM in these experiments, calculated using non linear regression analysis 
(Figure 7-17b). The R2of the curve fitting to the data is 0.77, which indicates the goodness of 
the non linear regression fit is close to 1. 
 Finally, we investigated the biological activity of PEPITEM in vivo using the B cell 
KO model of peritoneal inflammation. B cells KO mice were intravenously injected with 
100µg PEPITEM or the scramble control four hours before intraperitoneal injection of 
zymosan which also contained 100µg of the relevant peptide. After 24 hours, a final 
intravenous injection of 100μg of peptide was given. Thus the mice received a total of 300µg 
of the PEPITEM or scramble peptides. Both peptides were synthesised with an additional 
amide group on C-terminal. The amide group provides protection of the peptide from 
proteolytic cleavage that might occur in vivo. After 48 hours, peritoneal leukocytes were 
collected and counted by flow cytometry. We detected a significant reduction of CD3+ T cells 
recruitment in the inflamed peritoneum of B cell KO mice treated with PEPITEM (Figure 7-
18a). Importantly, this was not observed with the scramble peptide treatment confirming the 
specificity of the peptide. In addition, analysis of T cell subsets revealed less recruitment of 
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CD4+ T cells (Figure 7-18b), especially of the effector memory subset, which was the major 
subset recruited in the B cell KO without peptide treatment (Figure 7-18c). 
 In conclusion, the peptide identified as the B cell-secreted-Agent X inhibits 
lymphocytes transmigration both in vitro and in vivo. These data strongly support a biological 
role for Agent X, henceforth referred to as PEPtide Inhibitor of Trans-Endothelial 
Migration (PEPITEM). 
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Figure 7-17: Agent X inhibits PBL transmigration 
(a) PBL were isolated from peripheral blood and transmigration assays were performed using 
TNF-α/IFN-γ stimulated HUVEC and adiponectin pre-treated whole PBL, whole PBL 
containing Agent X at 0.001 to 10ng/ml, whole PBL containing 10ng/ml of Agent X 
scramble, PBL with tetanus toxoid peptide (TTp) at 10ng/ml and PBL with pro-insulin (PI) at 
10ng/ml. PBL transmigration was dose-dependently reduced in presence of Agent X but not 
with the scramble, TTp and PI controls. Data are a pool of three independent experiments and 
were analysed using one-way ANOVA and Bonferroni’s multiple comparison post test. 
*p≤0.05, **p≤0.01, ***p≤0.001. (b) An EC50 of 18.6pM was calculated using non linear 
regression analysis.  
EC50=18.6pM
R2= 0.77
a)
b)
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Figure 7-18: PEPITEM reduces T cell recruitment in vivo 
Leukocytes were collected from the peritoneum after 48 hours with zymosan injection in the 
wt or B cell knock-out. T cells were identified by expression of CD3 (a). CD4+ and CD8+ T 
cells were identified by gating on CD3 first and by the expression of CD4 and CD8 (b). CD3+ 
and CD4+ (c) or CD8+ (d) T cells were first gated and naive (N), central memory (CM) and 
effector memory (EM) T cells were identified by the expression of CD44 and CD62L. Naive 
CD4 are CD62L+CD44-, central memory T cells are CD62L+CD44+ and effector memory T 
cells are CD62L-CD44+. Data for each mouse groups were pooled, represented as mean and 
were analysed using one-way ANOVA and Bonferroni’s multiple comparisons post-test. 
*p≤0.05. 
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3. Discussion 
 
 In this chapter, we demonstrate a novel mechanism of action of adiponectin which 
mediates inhibition of lymphocyte trans-endothelial migration. We show that under 
conditions of adiponectin stimulation, B cells generate a newly identified soluble peptide 
referred to as PEPITEM, which is able to promote release of S1P by the endothelium, thus 
affecting T cell transmigration (Figure 7-19). We have confirmed these findings in vivo in the 
B cell knock-out mouse using a peritoneal model of inflammation. 
 
 
 
 
Figure 7-19: Mechanism of action of adiponectin-mediated inhibition of lymphocyte 
trans-endothelial migration 
Adiponectin stimulates production of PEPITEM by B cells. PEPITEM triggers the secretion 
of S1P by the endothelium, theoretically by interaction with its receptor on the endothelium. 
S1P interaction with its receptor on the T cells inhibits their transmigration. S1PR signalling 
and downstream effects on migration are unknown in this context.  
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 Involvement of S1P in the mechanism of action of adiponectin 
 Here, we have determined that B cell modulate T cell migration through a secreted 
agent under adiponectin stimulation. In addition, we demonstrate that S1P inhibits T cell 
migration through macrovascular endothelium. Although S1P has been widely associated 
with inducing T cell egress from secondary lymphoid organs into efferent lymphatics, recent 
reports reveal a capacity for S1P to inhibit T cell migration from tissues to afferent lymphatics 
(Legerwood et al., 2008). This is mediated by high S1P levels in tissues during inflammation 
(Legerwood et al., 2008; Roviezzo et al., 2011). These studies show the importance of S1P 
and S1PR signalling during an inflammatory response and highlight localised effects which 
differ in lymph nodes and in the periphery. Functions in the periphery are believed to help T 
cells accomplish their functions at the site of injury, as they cannot migrate to the lymph 
nodes and are retained in tissues. Here we report for the first time a role for S1P in regulating 
T cell migration in the vascular compartment. We believe that this data is consistent with 
observations of S1P mediated regulation in other compartments, indeed previous reports of 
S1P function in regard of T cell migration made this an obvious candidate for regulating T 
cell function in our assays and it is therefore not surprising that we observe a S1P-induced 
inhibition of T cell migration in our model. Interestingly, the functional range of 
concentrations in our experiments is in agreement with published efficacy of this agent to 
modulate T cell function (Legerwood et al., 2008; Roviezzo et al., 2011). We used in the 
order of 0.1μM to induce an inhibition of lymphocyte transmigration. However, the data 
measuring S1P concentrations ex vivo and in vivo show variations between tissue 
compartments and some differences between studies. In human serum, S1P levels range from 
0.4 to 1.1µM (Caligan et al., 2000; Berdyshev et al., 2005). In plasma, circulating 
concentrations of S1P have been reported between 0.2 to 0.9µM with the majority bound to 
albumin and lipoproteins (Murata et al., 2000). Notably however, S1P bound to lipoproteins 
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is still active (Nofer et al., 2004). S1P concentrations are lower in the lymph (80nM) and in 
the lymph nodes and other tissues (5-20nM) (Cyster, 2005). In mice, some studies show high 
circulating S1P levels of about 1 to 10µM and about 100nM in the lymph (Pappu et al., 2007). 
Although we used a “high” concentration of S1P to observe an effect on T cell migration, this 
was still close to the circulating levels, suggesting these concentrations were appropriate in 
the vascular compartment. It is also possible that S1P levels become high locally. This would 
mean that higher global S1P levels would be required to see an effect. Indeed, we believe that 
B cells that adhere on the endothelium and secrete PEPITEM will induce a localised rise in 
S1P release by the endothelium.  
  
 Interestingly, we observed that the inhibitory effects of exogenous and endogenous 
S1P were lost over time. We associated this with the short half-life of S1P in plasma, which 
has been reported at 15 minutes (Venkataraman et al., 2008). Gratifyingly, the dynamics of 
S1P mediated inhibition of T cell migration were the same whether S1P was induced through 
addition of adiponectin, or was added as a synthetic exogenous agent. We believe that these 
similar profiles are indicative of the close relationship between adiponectin signalling and 
S1P production and therefore confirm our hypothesis that S1P is involved in the adiponectin-
mediated inhibition of lymphocyte trans-endothelial migration. In addition, when we used a 
S1PR antagonist, we lost the inhibitory effect of adiponectin. Collectively, these data show 
the involvement of S1P in the adiponectin mediated inhibition of T cell migration 
 It should be noted that S1P was such an obvious choice of agent for regulating T cell 
migration that initially we thought it might have been generated by B cells in response to 
adiponectin stimulation. However, experiments measuring SPHK1 and 2 in B cells, which 
lacked these kinases, refuted this hypothesis. These observations are in conflict with one other 
study which found expression of SPHK in B lymphoblastoid cells (Pi et al., 2006). However, 
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in this study they did not compare the gene expression to other positive controls and used an 
immortalised cell line which is likely to have different transcriptional characteristics 
compared to primary B cells.  SPHKs are essential for S1P synthesis. Indeed, SPHK-deficient 
mice have no detectable S1P in the plasma or lymph (Pappu et al., 2007). We observed high 
expression of both SPHKs in HUVEC. High expression of SPHKs has been reported before in 
HEV, but to our knowledge, the current literature does not report their expression in other 
vascular beds (Pham et al., 2010). This finding led us to the hypothesis that S1P was 
synthesised by the HUVEC in our system, under the influence of a B cell-secreted agent that 
we have now identified as PEPITEM. 
 We sought to link the S1P mediated effects of adiponectin to HUVEC by depleting 
SPHKs in these cells using siRNA. However, SPHK1 was highly up-regulated upon TNF-α 
and IFN-γ stimulation of HUVEC and we had great difficulty in achieving suitable levels of 
depletion. This was still the case after multiple transfections of the siRNA duplexes. 
Therefore, we attributed the lack of effect of siRNA to this suboptimal knock-down and not to 
the fact that the kinases were irrelevant to our system. Although the antagonist data confirm 
the involvement of S1PR and therefore S1P in the actions of adiponectin, this still needs to be 
confirmed with more stringent experimental approaches. It would be relevant to use lentiviral 
particles expressing siRNA against SPHKs, as this would provide a more efficient and 
permanent knock-down. An easier way would be to inhibit SPHKs activity using chemical 
compounds such as L-cycloserine or DL-threo-dihydrosphingosine (DTD) (Roviezzo et al., 
2011). Additionally, a S1P blocking antibody, referred as sphingomab, exists (Takabe et al., 
2008). The other alternative would be to measure S1P levels in the media after stimulation 
with PEPITEM using mass spectrometry (Caligan et al., 2000; Berdyshev et al., 2005) and 
relate these to function. In the future a combination of these strategies would need to be used 
to deliver a concrete proof of hypothesis. 
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 In agreement with the literature, we found very low levels of S1PR receptor 
expression on the extracellular membranes of T cell (Cyster, 2005). It may seem unusual that 
antagonism of a small quantity of receptors is enough to ablate S1P signalling in these cells, 
however, we did not investigate the biology of the receptors in presence of the antagonist, 
S1P, adiponectin or PEPITEM. It would be interesting to study the expression profile on the T 
cell surface in presence of these, and moreover on the firmly adhered or transmigrated PBL, 
as we have only conducted analysis on freshly isolated cells in suspension. Indeed, we do not 
know if in our model the receptor signalling is regulating migration, for example by 
modifying integrin function, or if S1P is causing receptors internalisation and therefore 
blocking a signal essential for trans-endothelial migration.  
 Finally, it would be interesting to treat the endothelium with S1P and see if the effect 
is still observed, as evidences is available showing that EC express S1P receptors for S1P and 
these can be internalised upon agonist binding. Functions for S1P in EC include regulation of 
EC-EC junctions (Singer et al., 2005) and this may be relevant to the mechanism of action of 
adiponectin in our assay as most lymphocytes migrate between the endothelial cells. Indeed, 
this is an important experiment as those conducted to date do not discriminate between the 
effects of S1P on T cells and HUVEC. 
 Regarding a mechanism of action for S1P on T cell transmigration, it has been shown 
that in secondary lymphoid organs, S1P induces S1PR1 signalling that overcomes CCR7-
mediated retention of T cells, thereby allowing egress into the circulation (Pham et al., 2008). 
In the periphery, no mechanism for the function of S1P has so far been identified. We propose 
a potential involvement of cyclic AMP (cAMP) in our model. cAMP has inhibitory effects on 
leukocytes trans-endothelial migration (Lorenowicz et al., 2007). The mechanism of cAMP 
action on lymphocyte transmigration is still unknown but cAMP can also block adhesion by 
reducing the activation of VLA-4 (α4β1) (Lorenowicz et al., 2007). We believe that action on 
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integrin activation could be a potential mechanism by which S1P could modulate T cell 
transmigration. In addition, studies have now shown that S1P is able to stimulate cAMP 
production by muscle cells, and that adiponectin is able to induce its production in endothelial 
cells (Damirin et al., 2005; Ouchi et al., 2000). 
 
 Identification of PEPITEM 
 Proteomics is a widely used technique to identify active compounds in supernatants. 
However, mass spectrometry analysis detects a considerable amount of proteins/peptides, 
especially when using a non-tryptic approach. Indeed a lot of the peptides found using this 
approach are either false positives or the result of contamination. Problems with 
contaminations are a recurrent issue in mass spectrometry especially when using complex 
biological samples. To prevent this, the columns are intensively washed in between samples 
and no sample will be processed until the system is clean. To eliminate false positives, it is 
essential to have the right negative controls. In our case, we compared supernatants from B 
cells stimulated with adiponectin with supernatants from untreated cells. Moreover these 
supernatants were generated in serum/protein free medium to reduce the complexity of the 
mixtures being analysed. Using this strategy, contamination and false positives can be 
excluded by simple comparison between the conditions. To further improve our samples 
purity, we pre-purified them on a C18 column. The conditions of washes and elution allowed 
us to enrich the samples for small molecules such as peptides and to exclude large proteins 
that irreversibly bind to the column.  
 Using this technique, we identified PEPITEM, a 14 amino acids peptide belonging to 
the 14-3-3 zeta/delta protein. The identification resulted in a very high score indicating the 
accuracy of the match between the peptide in the sample and the peptide in the databases. In 
addition, the peptide was specific to the adiponectin-stimulated B cell supernatant and the 
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peptide in this sample has similar profile of MS and MS/MS to the synthetic standard that we 
had manufactured. Together these allow us to have great confidence in the identity and 
specificity of PEPITEM.  
 14-3-3 proteins are found in all eukaryotic organisms with high evolutionary 
conservation (Figure 7-20), often in multiple isoforms, from 2 in yeast, nematode and 
drosophila to 13 in plants and regulate a whole range of biological processes. In the tomato, 
14-3-3 proteins regulate MAP kinases pathway, ion channels and lypoxygenases that are 
important for mechanisms of defence (Oh et al., 2010). In yeast, 14-3-3 proteins have a major 
role in the subcellular localization of proteins. For instance, Yak1 protein kinase, involved in 
glucose-sensing, associates with cytoplasmic 14-3-3 proteins in the absence of glucose, 
whereas in the presence of glucose it is mainly present in the nucleus (van Heusden, 
Steensman, 2006). Interestingly 14-3-3 proteins regulate the life span of Caenorhabditis 
elegans (nematode) by cooperating with important transcription factors such as SIR-2.1 and 
DAF-16/FOXO (Wang et al., 2006). 
 In mammals,  the 14-3-3 proteins are a family of seven highly homologous and 
conserved isoforms named β (beta), ε (epsilon), γ (gamma), η (eta), σ (sigma), τ (tau), ζ (zeta) 
depending on their elution profiles. The 14-3-3 proteins named α (alpha) and δ (delta) are the 
phosphorylated versions of β and ζ respectively (reviewed in Fu et al., 2000). The proteins are 
expressed in almost all tissues (Celis et al., 1990). 14-3-3 proteins have been reported to bind 
to and modulate the function of a wide number of intracellular proteins (Fu et al., 2000). 
Binding to their partners results in inhibition or stimulation of the partner protein. Therefore, 
these proteins are involved in the regulation of diverse biological processes such as 
metabolism, cell cycle regulation, apoptosis and protein trafficking (Fu et al., 2000; Bridges 
et al., 2005; Dougherty et al., 2004). 14-3-3 proteins essentially interact with their partners 
through a phosphorylated serine motif (Muslin et al., 1996). Binding of 14-3-3 proteins 
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mediates changes in signalling capacities of their multiple ligands (examples in Figure 7-21). 
For instance, binding of 14.3.3ζ to Raf-1 modulates its conformation, while binding of 
14.3.3β to lip35 allows exit of MHC class II from the endoplasmic reticulum, as a final 
example, interaction of 14-3-3τ with PKCµ inhibits its kinase activity (Morrison et al., 1997; 
Kuwana et al., 1998; Hausser et al., 1999). Disruption of the expression and/or function of 
14-3-3 proteins can therefore cause clinical disorders. Although, 14-3-3 proteins have not 
been associated with a specific disease, they have been connected with various pathological 
processes. For instance, many of the 14-3-3 partner proteins are products of oncogenes, which 
suggest an involvement of 14-3-3 proteins in cancer (Lodygin et al., 2005). In addition, 14-3-
3 proteins are also highly expressed in the brain and aberrant regulation of expression or 
function is implicated in neurological disorders (Layfield et al., 1996).  
 To our knowledge, none of the seven 14-3-3 isoforms have been directly linked to the 
regulation of leukocyte trafficking in vitro or in vivo. However, some reports show 
involvement of 14-3-3 beta and zeta/delta in regulation of cell spreading (reviewed in 
Mhawech, 2005). It seems that binding of 14-3-3 beta to β1 integrin helps cell spreading and 
migration (Han et al., 2001; Rodriguez, Guan, 2005). 14-3-3 zeta/delta acts on integrin 
signalling by binding to Cas, an integrin signalling adaptor (Garcia-Guzman et al., 1999). 
These observations were reported in fibroblast cell lines as well as in T cells (Nurmi et al., 
2006). In addition, 14-3-3 proteins were found to interact with apelin-13 in HUVEC causing 
an increase of monocytes adhesion (Li et al., 2010). However, this study has limitations as the 
authors used the THP-1 monocytic cell line which might not behave like freshly isolated 
primary monocytes and also measured adhesion on ECV304 endothelial cells, which are not 
considered HUVEC anymore. The data in this area is therefore limited and need more 
investigations. 
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 Interestingly, although 14-3-3 zeta/delta expression has been measured in almost all 
leukocytes subsets (i.e. monocytes, CD4+ and CD8+ T cells, B cells and NK cells (BioGPS), 
14-3-3 proteins have not been closely associated to the function of the immune system. The 
only reports potentially involving 14-3-3 proteins in the immune function, describe their 
binding capacity to mediators of T cell activation. Binding of 14-3-3 proteins to different 
intermediate in the T cell stimulation pathway induces stimulation or inhibition of T cells 
activation (Di Bartolo et al., 2007; Liu et al., 1996; Meller et al., 1996). For instance, the 
interaction of 14-3-3τ with Cbl and phosphatidylinositol 3-kinase triggers T cell activation 
(Liu et al., 1996). In addition, 14-3-3ε and ζ cooperates with SPL-76 to tune T cell activation 
(Di Bartolo et al., 2007). On the other hand, binding of 14-3-3τ with PKC inhibits T cell 
activation (Meller et al., 1996). However, the data available on this topic is limited and 
sometimes controversial. Certainly there is no indication that active peptides of these proteins 
play an integral role in regulation of immune function. 
 PEPITEM is specific to 14-3-3 zeta/delta as evidenced by a comprehensive protein 
blast (NCBI) search. Indeed, although other 14-3-3 proteins have similar sequences, none is 
an absolute match for PEPITEM. However and very interestingly, the PEPITEM sequence in 
14-3-3 zeta/delta is highly conserved between species. It is found in a majority of mammals, 
i.e. mice, rats, panda and horse but also birds (chicken), at 100% sequence homology (Figure 
7-22). Moreover a highly conserved sequence (92-93% homology) is present in fish and 
amphibians. Remarkably, a sequence recognisable as PEPITEM is also present in nematodes 
(92% homology). Two types of 14-3-3 are also found in Saccharomyces cerevisae (yeast) and 
include a sequence close to PEPITEM but with more differences compared to other species 
(78% homology) and lack some of the sequence and similarly for insects and plants (73% 
homology). 
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 PEPITEM is located from residue 28 to 41 in the 14-3-3 zeta/delta protein. Several 
studies have determined the crystal structure of 14-3-3 zeta/delta on its own, in dimers or 
interacting with its ligands (Liu et al., 1995; Ottmann et al., 2007). A 14-3-3 zeta/delta 
monomer is composed of nine anti-parallel α-helices forming the limit of the amphiphile 
groove allowing interaction with its partners (Liu et al., 1995). This structure is conserved 
between vertebrates, yeast and even plants (Liu et al., 1995).  We positioned PEPITEM on the 
14-3-3 zeta/delta crystal structure and it is located between α-helice2 and α-helice3, with 
some residues forming the start of each helix (Figure 7-22). In addition, we noticed that 
PEPITEM is not cryptic, instead it is quite accessible and exposed at the protein outer surface. 
We assume that this essential for proteolytic cleavage from the parent molecule. 
 This peptide has never been identified before except as a tryptic peptide for the 
recognition of the 14-3-3zeta/delta protein. The only other occurrence of PEPITEM in the 
literature, involves the same sequence as a peptide presented by HLA-DQ8 in the NOD mice 
(Suri et al., 2005). But in this reference there is no indication of a physiological role for the 
peptide.  
 Finally, we confirmed the capacity of PEPITEM to inhibit T cell migration in our in 
vitro assay but also in vivo. The peritoneal model of inflammation previously allowed us to 
show that absence of B cell during acute inflammation promotes higher recruitment of T cells 
in the peritoneum. And this can be partially reversed when PEPITEM is administrated to the 
B cell KO mice. For this experiment, we acquired PEPITEM with an additional amide group 
on C-terminal, as this is known to protect against proteolytic cleavage. As we have not yet 
investigated the pharamokinetics of PEPITEM in vivo, we had no indication of dose of 
peptide to administer. We believe that this explains the suboptimal effects of PEPITEM 
administration in the peritonitis model (i.e. about 40% of maximal effect was induced by our 
protocol). It would be interesting to investigate PEPITEM in models of T cell-mediated 
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disease, such as T1D, atherosclerosis, rheumatoid arthritis, Crohn’s disease and other auto-
immune and/or chronic inflammatory diseases. However, it is essential to conduct 
pharmacokinetic studies on the peptide first in order to optimise appropriate doses in the 
animal models. 
 
 
 Conclusions 
 To summarize, we provide evidences for a novel role for B cells in regulating T cell 
recruitment in the presence of adiponectin. We identified a unique peptide secreted by B cells 
under adiponectin stimulation. We demonstrate that this peptide is regulating T cell migration 
by stimulating S1P release from the endothelium (Figure 7-19). These effects were validated 
in vivo, using a model of inflammation in the B cell knock-out mice. This small peptide is an 
interesting potential therapeutic agent in T cell-mediated diseases. Whilst this work is 
innovative, it leads to a number of important mechanistic and therapeutic investigations that 
need to be explored.  
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Homo sapiens   MDKNELVQKAKLAEQAERYDDMAACMKSVTEQGAELSNEERNLLSVAYKNVVGARRSSWRVV 
Mus musculus   MDKNELVQKAKLAEQAERYDDMAACMKSVTEQGAELSNEERNLLSVAYKNVVGARRSSWRVV 
Gallus gallus  MDKNELVQKAKLAEQAERYDDMASCMKSVTEQGAELSNEERNLLSVAYKNVVGARRSSWRVV 
Danio rerio    MDKLELIQKAKLAEQAERYDDMAACMKQVTEQGEELSNEERNLLSVAYKNVVGARRSAWRVI 
Xenopus laevis MDKNELVQKAKLAEQAERYDDMAACMKRVTEEGGELSNEERNLLSVAYKNVVGARRSSWRVV 
Drosophila     VDKEELVQKAKLAEQSERYDDMAQAMKSVTETGVELSNEERNLLSVAYKNVVGARRSSWRVI 
A. thaliana      RDEFVYMAKLAEQAERYEEMVEFMEKVAKAVDKDELTVEERNLLSVAYKNVIGARRASWR 
C.elegans        KEELVNRAKLAEQAERYDDMAASMKKVTELGAELSNEERNLLSVAYKNVVGARRSSWRVI 
S.cerevisae               AKLAEQAERYEEMVENMKAVASSGQELSVEERNLLSVAYKNVIGARRASWRIV 
 
Homo sapiens   SSIEQKTEGAEKKQQMAREYREKIETELRDICNDVLSLLEKFLIPNASQAESKVFYLKMKGD 
Mus musculus   SSIEQKTEGAEKKQQMAREYREKIETELRDICNDVLSLLEKFLIPNASQPESKVFYLKMKGD 
Gallus gallus  SSIEQKTEGAEKKQQMAREYREKIETELRDICNDVLSLLEKFLIPNASQAESKVFYLKMKGD 
Danio rerio    SSIEQKTEGNDKKLQMVKEYREKVEGELRDICNEVLTLLGKYLIKNSTNSESKVFYLKMKGD 
Xenopus laevis SSIEQKTEGAEKKQEMSREYREKIEAELREICNDVLNLLDKFLIANATQPESKVFYLKMKGD 
Drosophila    SSIEQKTEASARKQQLAREYRERVEKELREICYEVLGLLDKYLIPKASNPESKVFYLKMKGD 
A. thaliana  SSIEQKEESRGNDDHVSLIRDYRSKIETELSDICDGILKLLDTILVPAAASGDSKVFYLKMKGD 
C.elegans      SSIEQKTEGSEKKQQMAKEYREKVEKELRDICQDVLNLLDKFLIPKAGAAESKVFYLKMKGD 
S.cerevisae  SSIEQKEESKEKSEHQVELIRSYRSKIETELTKISDDILSVLDSHLIPSATTGESKVFYYKMKGD 
 
Homo sapiens   YYRYLAEVAAGDDKKGIVDQSQQAYQEAFEISKKEMQPTHPIRLGLALNFSVFYYEILNSPE 
Mus musculus   YYRYLAEVAAGDDKKGIVDQSQQAYQEAFEISKKEMQPTHPIRLGLALNFSVFYYEILNSPE 
Gallus gallus  YYRYLAEVAAGDDKKGIVEQSQQAYQEAFEISKKEMQPTHPIRLGLALNFSVFYYEILNSPE 
Danio rerio    YYRYLAEVAAADDKMDTITNSQGAYQDAFEISKKDMQPTHPIRLGLALNFSVFYYEILNSPEQ 
Xenopus laevis YYRYLAEVAAGDAKSDIVGQSQKAYQDAFDISKTEMQPTHPIRLGLALNFSVFYYEILNCPD 
Drosophila     YYRYLAEVATGDARNTVVDDSQTAYQDAFDISKGKMQPTHPIRLGLALNFSVFYYEILNSPD 
A. thaliana    YHRYLAEFKSGQERKDAAEHTLTAYKAAQDIANSELAPTHPIRLGLALNFSVFYYEILNSPD 
C.elegans      YYRYLAEVASGDDRNSVVEKSQQSYQEAFDIAKDKMQPTHPIRLGLALNFSVFFYEILNAPD 
S.cerevisae   YHRYLAEFSSGDAREKATNSSLEAYKTASEIATTELPPTHPIRLGLALNFSVFYYEIQNSPD 
 
Homo sapiens  KACSLAKTAFDEAIAELDTLSEESYKDSTLIMQLLRDNLTLWTSDTQGDEAEAGEGGEN 
Mus musculus  KACSLAKTAFDEAIAELDTLSEESYKDSTLIMQLLRDNLTLWTSDTQGDEAEAGEGGEN 99% 
Gallus gallus KACSLAKTAFDEAIAELDTLSEESYKDSTLIMQLLRDNLTLWTSDTQGDEAEAGEGGEN 99% 
Danio rerio   ACSLAKQAFDEAIAELDTLNEDSYKDSTLIMQLLRDNLTLWTSD                84% 
Xenopus laevisKACSLAKTAFDEAIAELDTLSEESYKDSTLIMQLLRDNLTLWTSDTHGDEAEQGEGGEN 90% 
Drosophila    KACQLAKQAFDDAIAELDTLNEDSYKDSTLIMQLLRDNLTLWTSDTQGDEAEPQEGGDN 81% 
A. thaliana   RACNLAKQAFDEAIAELDTLGEESYKDSTLIMQLLRDNLTLWTSDMQDDVAD        65% 
C.elegans    DKACQLAKQAFDDAIAELDTLNEDSYKDSTLIMQLLRDNLTLWTSDAATDDTDANETEGG  81% 
S.cerevisae   KACHLAKQAFDDAIAELDTLSEESYKDSTLIMQLLRDNLTLWTSD                70% 
 
Figure 7-20: Aligment of the 14-3-3 zeta/delta proteins found in different species 
The sequence of 14-3-3 zeta/delta was aligned for mammals (Homo sapiens- human and Mus 
musculus- Mouse, birds (Gallus gallus- Chicken), fishes (Salmo salar- Salmon), amphibians 
(Xenopus laevis- Frog), insects (Drosophila melanogaster- Fly), plants (Arabidopsis 
thaliana), nematodes (C. elegans) and yeast (Saccharomyces cerevisae). Differences in the 
14-3-3 zeta/ delta or equivalents between the different species are highlighted in blue. 
PEPITEM or equivalents is shown in red on the sequence and differences between the 
different species on the PEPITEM sequence are highlighted in yellow. Green highlighted 
amino acids show differences in amino acids with similar biochemical properties to the amino 
acids of the human peptide sequence. We found 100% homology for PEPITEM for mice and 
chicken compared to human; 93% for fish, 92% for the frog, 86% for the fly, 71% for the 
plant, 92% for C.elegans and 78% for yeast.  
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Figure 7-21: 14-3-3 proteins regulate other protein localisation and signalling. 
Binding partners whose localisation and functions are regulated by 14-3-3 proteins are listed. 
(Adapted from Dougherty et al., 2004). 
 
 
Figure 7-22: Sequence and crystal structure modelling of 14-3-3 zeta/delta protein 
(a) 14-3-3 zeta/delta protein is composed of 245 amino acids. PEPITEM is located from 
amino acid 28 to 41 in the protein sequence. (b) This structure shows a 14-3-3 zeta dimer. 
Each monomer is composed of nice anti-parallel α-helices. This structure shows the binding 
of the exoenzyme S peptide in a hydrophobic manner (green and brown residues). Here we 
aimed to highlight the structural localisation of PEPITEM (yellow residues). The peptide is 
located in the loop between α-helices 2 and 3 and seems to be relatively exposed. (Structure 
from Ottmann et al., 2007). 
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 In this thesis, I demonstrate a potential role for the adipokines leptin and adiponectin 
in the pathophysiology of T1D.  
I found higher expression of LEPR on PBMC from T1D but was not able to determine a 
functional relevance for this difference. However, I was able to determine possible functional 
relevance for the lower levels of adiponectin receptors on PBMC that has previously been 
described in our laboratory. I have demonstrated that adiponectin decreases T cell migration 
across inflamed endothelium, and that the lower adiponectin receptor expression in T1D 
results in greater transmigration of T cells. I went on to show that adiponectin achieves its 
effects by stimulating the secretion of a newly identified peptide by B cells. The 14 amino 
acids peptide, PEPITEM originates from the 14-3-3 zeta/delta protein and induces release of 
S1P by the endothelium which in turn blocks the trans-endothelial migration of T cells. 
  
 These observations not only add to the knowledge of adiponectin involvement in the 
control of lymphocyte recruitment to the endothelium but also led to the discovery of 
PEPITEM. PEPITEM holds therapeutic potential for conditions resulting from inappropriate 
migration of T cells across inflamed endothelium. These would include T1D, rheumatoid 
arthritis, Crohn’s disease, and atherosclerosis. PEPITEM may offer greater therapeutic 
potential than adiponectin or S1P. Indeed, adiponectin regulates many homeostatic functions, 
such as lipid and glucose metabolism and insulin sensitivity and is already present at very 
high levels in the circulation (Arita et al., 1999; Kadowaki, Yamauchi, 2006). S1P regulates 
the egress of T cells from the SLOs and regulates trafficking of T cells within and into lymph 
nodes (Cyster, 2005). Use of either adiponectin or S1P as “anti-T cell” recruitment strategies 
is likely to have significant off-target effects on metabolic and immune function.     
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 Current immunotherapies for T1D aim to deplete populations such as T cells (anti-
CD3) and B cells (Rituximab). Despite the success of these therapies to preserve residual 
beta-cell function, these treatments are associated with undesirable adverse effects and appear 
to fail over a long-term period (Pescovitz et al., 2009; Chatenoud et al., 1994; Herold et al., 
2002; Keymeulen et al., 2005). In contrast to these therapies, we believe that PEPITEM may 
allow blockade of T cell recruitment in the islets without affecting antibody or T cell 
responses to pathogens.  
 Interestingly, Rituximab causes depletion of B cells and this is associated with 
preservation of beta-cells in T1D, therefore suggesting a negative role of B cells in the disease 
physiopathology (Pescovitz et al., 2009). In addition, studies have shown that the B1 B cells 
subset can specifically promote the infiltration of T cells in the pancreas of diabetic mice 
(Ryan et al., 2010). In contrast, we show that B cells are crucial to down-regulate T cell 
recruitment to the inflamed endothelium and might be beneficial to stop beta-cell destruction. 
These findings are not necessarily contradictory. First, it is unsure which B cells subsets are 
completely depleted with Rituximab (Browning, 2006). It is therefore essential to identify the 
subset of B cells capable of secreting PEPITEM. In addition, recent evidence refers to B cells 
as “not always the bad guys” (Fillatreau et al., 2008). Indeed, studies have identified a subset 
of B cells able to regulate autoimmune diseases by production of IL-10 and depletion of this 
subset worsens autoimmune diseases (Fillatreau et al., 2002; Wolf et al., 1996; DiLillo et al., 
2010). This subset is referred as regulatory B cells (Breg). Breg have been identified and 
characterised in mice but only a few studies have looked at Breg in human and the current 
literature does not provide specific markers to identify Breg in the circulation (DiLillo et al., 
2010). Although, we believe that effector B cells (long-life plasma cells and memory B cells) 
might be responsible for PEPITEM production, this has not been confirmed. In addition, our 
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panel of markers did not allow identification of Breg on the endothelium as the markers are 
not yet known. 
 The discovery of PEPITEM as an endogenous peptide belonging to the 14-3-3 
zeta/delta protein is intriguing as this family of proteins is barely involved in the control of 
lymphocyte transmigration. Indeed, the current literature in this area only demonstrates a role 
of 14-3-3s to regulate integrin activation in lymphocytes and fibroblasts by binding to their 
signalling partners (Nurmi et al., 2006). To our knowledge, none of these proteins have been 
associated with a control of S1P production that would influence T cell migration across the 
endothelium. 
 The results outlined in this thesis raise important issues that need further urgent 
investigation. In particular, we urgently need to assess the pathways linking adiponectin, SIP 
and PEPITEM, as well as test the therapeutic potential of this in animal studies. A more 
comprehensive list of experiments this work leads onto is listed following this discussion. 
 
 In summary, my work provides new insights in the role of adiponectin in modulating 
T cells recruitment across the endothelium and we identified an endogenous peptide capable 
of mediating this effect. These findings suggest an intricate communication between B and T 
cells, which are already known to interact in the course of immune responses. The ability of B 
cells to make the peptide may vary in autoimmune diseases and may contribute to the 
development of disease. Therefore, understanding PEPITEM biology and effect in murine 
models of autoimmune diseases is imperative.  I also show how adiponectin could be 
involved in the development of T1D, and how it may link the recognised epidemiological 
association between insulin resistance and the development of this disease. 
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Further experiments: 
Whilst the work outlined in this thesis is informative, it reveals areas that need further 
investigation. These are listed below:  
 
 Leptin: 
 Analyse the effect of leptin on the stimulation of naive versus memory T cells 
 Study the effect of leptin on the behaviour of monocytes on the endothelium as 
these express high levels of LEPR. 
 
 Adiponectin and S1P: 
 Confirm the involvement of the adiponectin receptors in the inhibition of 
lymphocyte transmigration by adiponectin. 
 Investigate the release of S1P by HUVEC under adiponectin or PEPITEM 
stimulation: mass spectrometry analysis, SPHKs inhibitors or lentiviral knock-
down. 
 Analyse the effect of S1P on T cell migration: integrins localisation and 
activation and cAMP levels. 
 Measure effect of S1P (under PEPITEM stimulation) on the recruitment of 
other leukocytes subsets that express S1P receptors. For instance, monocytes 
express S1P1, 2 and 4. Studies have shown that binding of monocytes to aortas 
from NOD mice, is increased compared to the wild-type and treatment of the 
aortas with S1P considerably reduced the adhesion of monocytes (Whetzel et 
al., 2006). Further studies show that S1P inhibits monocyte adhesion to the 
endothelium by shifting the apical localisation of integrins to the basal surface 
(Aoki et al., 2007). 
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 PEPITEM 
 Measure the pharmacology of PEPITEM: acquisition of a radio-labelled 
peptide and measure its binding affinity to stimulated HUVEC with classical 
methods of pharmacokinetics.  
 Analyse PEPITEM toxicity in vivo. 
 Follow T cell recruitment under PEPITEM treatment in the pancreas: in vivo 
imaging. 
 Identify the endothelial receptor for PEPITEM: biotin pull-dowm and mass 
spectrometry. 
 Analyse PEPITEM circulating levels in health and T1D or other autoimmune 
diseases: mass spectrometry. 
 Synthesis of antibodies raised against PEPITEM 
 Understand how PEPITEM is cleaved from the 14-3-3 zeta/delta protein: 
proteasome? 
 Test PEPITEM in animal model of autoimmune diseases (Collaboration with 
Dr Susan Wong): need to determine its pharmacokinetics for appropriate 
dosing. 
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Sabbatical at the Hagedorn Institute (Novo Nordisk) in Copenhagen 
From October to December 2010, I joined the Hagedorn Institute under Anette Sams 
supervision in the context of our collaboration with Novo Nordisk. During this sabbatical, I 
started the optimisation of a method for transfecting lymphocytes with siRNA (Appendix 
Figure 1). I also reproduced some of my in vitro data showing that adiponectin inhibits the 
trans-endothelial migration of lymphocytes, using a transwell assay with fluorescently 
labelled lymphocytes (Appendix Figure 2). 
 
 
 
Appendix Figure 1: Development of a method to transfect lymphocytes with siRNA 
(a) PBL were transfected with siRNA-FITC using Dharmafect 2 or Lipofectamine 2000, two 
lipid –mediated delivery methods. Transfection efficiency was measured by flow cytometry. 
(b) Viability was measured using a PI exclusion method. 
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Appendix Figure 2: Effect of adiponectin on PBL transmigration in a transwell system 
(a) Schematic representation of the transwell system. HUVEC were cultured in low-serum 
conditions and stimulated with TNF-α/IFN-γ/adiponectin (TI or TI AQ). PBL were isolated 
and in some conditions pre-treated with adiponectin for 1 hour and added on the endothelium 
(TI PBL AQ). The transwell plate is placed in a fluorescent reader kept at 37°C and 
fluorescence is measured only in the bottom chamber (only possible because the filter and top 
chamber are made of black plastic). (b) In both HUVEC and PBL treatment, adiponectin 
significantly reduced PBL transmigration in the bottom chamber over time. 
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